

WO 00/50639

Continued

8 of 12

stipiamide; fenalamid A1; phenalamide A1	Preclinical	[12R- [1(S*),2E,4E,6Z,8E,1 0E,12R*,13R*,14E,1 6S*]]-13-hydroxy-N- (2-hydroxy-1- methylethyl)- 2,10,12,14,16- pentamethyl-18- phenyl-2,4,6,8,10,14- octadecahexaenamide	cancer
SU 201	Discontinued		cancer
SU 65591	Preclinical		cancer
SUN 4599	Discontinued	2-alpha-L- arabinopyranosyl-9- hydroxy-5,11- dimethyl-6H- pyrido[4,3- b]carbazolium bromide	cancer
superfibronectin	Preclinical		cancer
suramin; CI 1003; METARET	Marketed	8,8'- [carbonylbis[imino- 3,1- phenylene]carbonylimi no(4-methyl-3,1- phenylene)carbonyli mino]]bis-1,3,5- naphthalenetrisulfonic acid	parasitic infection; cancer

swainsonine; (-)-swainsonine; swainsonine hydrochloride; GD 0039	Phase II	[[1S-(1alpha,2alpha,8beta,8beta)]-octahydro-1,2,8-indolizinetriol	cancer; viral infection
T4GEN	Phase I		HIV infection; cancer
TAC 903	Preclinical	chrome-8-acetic acid	cancer
tamoxifen methiodide; PA 50300	Preclinical		cancer
TBC 1635	Preclinical		retinopathy; cancer
tBCEU	Preclinical	4-tert-butyl-[3-(2-chloroethyl)ureido]benzene	cancer
TER 286	Preclinical	(2R)-L-gamma-glutamyl-3-[[2-[[bis(2-chloroethyl)amino]phosphoryl]oxy]ethyl]sulfonyl]-L-alanyl-2-phenyl-glycine	cancer

thaliblastine; thaliblastine; thalicarpine; (+)- thalicarpine; TBL; thalicarpin; NSC 68075	Phase III	[S-(R*,R*)]-9-[4,5-dimethoxy-2-[(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl]phenoxy]-5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-4H-dibenzo[de,g]quinoline	cancer
thrombopoietin mimetic, Axys	Discontinued		cancer; thrombocytopenia
TJ 14026	Discontinued		cancer
transforming growth factor beta receptor inhibitors, Affymax	Preclinical		cancer
triacycluridine	Phase I		cancer
tricitiribine; NSC 154020; TCN	Preclinical	1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene-3-amine	HIV infection; cancer
TRIFENS	Preclinical		diarrhea; gastrointestinal disorder; sickle cell anemia; cancer
TT 62	Discontinued	5-fluoro-2'-deoxyuridine 5'-tetradecylphosphate	cancer

tucarecol; BWA 589C; BW 589C80; BW 589C; 589C	Phase II	4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid	sickle cell anemia; viral infection; HIV infection; cancer; hepatitis
tumor suppressor genes, oncology, Onyx	Preclinical		cancer
tumor suppressor genes, Onyx	Preclinical		cancer
U 77863	Discontinued	trans-3-(2'-methylphenyl)-2-propene-1-carboxamide	cancer
UBC 10 inhibitors, cancer, ProScript	Preclinical		cancer
UK 21	Preclinical	N-(1-oxo-2-propylpentyl)glycine triester with 5-fluorouridine	cancer
V 489	Phase I		cancer
VA 5	Preclinical	6-(2,5-dimethoxyphenyl)-2,3-dihydroimidazo[2,1-b]thiazole	heart failure; cancer
variolin B	Discontinued		cancer; viral infection
VDacac	Preclinical		cancer; contraception
VDDTC	Preclinical		cancer; contraception
velaresol; BW 12C79; Suspended 12C	Suspended	5-(2-formyl-3-hydroxyphenoxy)-pentanoic acid	cancer; sickle cell anemia
VG 18563	Preclinical		anemia; cancer

Vitamin B12 growth blockers, Receptagen WIN 33377	Preclinical				cancer
	Discontinued	N-[[1-[[2-(diethylamino)ethyl]amino]-9-oxo-9H-thioxanthen-4-yl]methyl]-methanesulfonamide			cancer
XK 469	Preclinical				cancer
Y 25510	Discontinued	(+,-)-3-[4-[2-(dimethylamino)-1-methylethoxy]phenyl]-1H-pyrazolo[3,4-b]pyridine-1-acetic acid			cancer
YM.534	Phase I	6-[4-[[5-(1H-imidazol-1-yl)pentyl]oxy]phenoxy]-2,2-dimethylhexanoic acid ethyl ester monohydrochloride			cancer
YW 200	Preclinical				cancer
YW 213	Preclinical				cancer
ZD 2767P	Phase I	N-[[4-[bis(2-iodoethyl)amino]phenoxy]carbonyl]-L-glutamic acid			cancer
ZD 9063P	Preclinical				cancer
zilascorb; ZOXXOZ	Suspended	5,6-O-((RS)-benzylidene-alpha-L)-L-ascorbic acid			cancer

zinstatin stimalamer; drug delivery system, neocarzinostatin; neocarzinostatin delivery system; YM 881; SMANCS	Marketed	zinstatin stimalamer	cancer
ZK 119010	Preclinical	2-(4-hydroxyphenyl)-3-methyl-1-[6-(1-pyrrolidinyl)hexyl]-1H-indol-5-ol	cancer
ZYN 176	Suspended		cancer
ZYN-LINKER conjugated thiocolchicine analogues	Preclinical		cancer
epiristeride; SKF 105657; ONO 9302	Discontinued	17beta-[[[(1,1-dimethylethyl)amino]carbonyl]androsta-3,5-diene-3-carboxylic acid	benign prostate hypertrophy; cancer; alopecia; acne
finasteride; MK 906; MK 0906; YM 152; PROSCAR; FINASPROS; CHIBRO-PROSCAR; FINASTID; PROSTIDE; EUTIZ; PRODEL; PROPECIA	Marketed	(5alpha,17beta)-N-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide	cancer; benign prostate hypertrophy; alopecia; acne
123	Discontinued		cancer; acne; hirsutism

SD-144110.1

A 63162	Preclinical	N-hydroxy-N-[1-[4-(phenylmethoxy)phenyl]ethyl]acetamide	5 lipoxygenase inhibitor	cancer
masoprocol; CHX 100; ACTINEX	Marketed	(R*,S*)-4,4'-(2,3-dimethyl-1,4-butanediyl)bis-1,2-benzenediol	5 lipoxygenase inhibitor	skin disease; cancer; psoriasis
SC 41661A	Discontinued		5 lipoxygenase inhibitor	cancer
KBR 8498	Preclinical	(1 alpha,2 alpha,4 beta)-4-[[2-(1-piperazinyl)-4-quinazolinyl]oxy]-1,2-cyclopentanediol	5HT agonist	cancer
EF 7412	Preclinical	N-3-[4-[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]-1-piperazinyl]phenyl]ethanesulfonamide	5HT antagonist; 5HT1A antagonist; glutamate release inhibitor	neurodegeneration; depression; cancer
adecypenol; OM 3223	Preclinical	5-(7,8-dihydro-8-hydroxyimidazo[4,5-d][1,3]diazepin-3(4H)-yl)-3-(hydroxymethyl)-3-cyclopentene-1,2-diol	adenosine deaminase inhibitor	cancer

pentostatin; 2'-deoxycoformycin; cavidarabine; CI 825; NSC 218321; PD 81565; CL 67310465; YK 176; NIPENT; COFORIN	Marketed	(R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol	adenosine deaminase inhibitor	cancer
adenosine allosteric modulators, Medco	Preclinical		adenosine regulating agent	cardiovascular disease; cancer; stroke
OCT 1003	Preclinical	3-nitrosobenzamide	ADPRT ligand	cancer
OCT 1004	Preclinical	6-nitroso-1,2-benzopyrone	ADPRT ligand	cancer
forfenimex; forphenicicol; BF 121	Discontinued	(S)-alpha-amino-3-hydroxy-4-(hydroxymethyl)benzoic acid	alkaline phosphatase inhibitor; immunostimulant	bacterial infection; cancer
ambamustine; PTT 119; BLASTOP	Phase III	N-[3-[bis(2-chloroethyl)amino]-N-(4-fluoro-L-phenylalanyl)-L-phenylalanyl]-L-methionine, ethyl ester	alkylating agent	cancer
bistriazenes, NIH	Preclinical		alkylating agent	cancer
bizelesin; U 7779; NSC 615291	Phase I	[S-(R*,R*)]-6,6'-[carbonylbis(imino-1H-indole-5,2-diylcarbonyl)]bis[8-(chloromethyl)-3,6,7,8-tetrahydro-1-methylbenzo[1,2-b:4,3-b']dipyrrol-4-ol]	alkylating agent	cancer

carzelesin; U 80244	Phase II	N-[2-[[1-(chloromethyl)-1,6-dihydro-8-methyl-5-[[[(phenylamino)carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]-6-(diethylamino)-2-benzofurancarboxamide	alkylating agent	cancer
CBS 5	Discontinued	4-[3-(2-chloroethyl)-1-(benzyl)-2-triazenyl]-1,4-dioxobutyl-beta-alanyl-tryptophyl-methionyl-aspartyl-phenylalaninamide	alkylating agent	cancer
DABIS maleate; NSC 262666	Preclinical	1,4-bis(2-chloroethyl)-1,4-diazoniabicyclo[2.2.1]heptane ((Z)-2-butenedioate (1:2)	alkylating agent	cancer

drug delivery system, camustine biodegradable implant; drug delivery system, sustained release BCNU; BODEL BCNU implant; camustine delivery system; prolifeprasan 20, camustine implant; GLIADEL; GLIADEL WAFER	Marketed			alkylating agent	cancer
electrophilic alkylating agents, BioNumerik	Preclinical			alkylating agent	cancer
EO 9; NSC 382459	Phase II	(E)-5-(1-aziridiny)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione		alkylating agent	cancer
estramustine analogue	Phase II			alkylating agent	cancer
glufosfamide; D 19575	Phase I	1-[N,N'-bis(2-chloroethyl)phosphorodiamidate]-beta-D-glucopyranose		alkylating agent	cancer
glutathione S-transferase-activated toxins, Telik	Discontinued			alkylating agent	cancer
isopropyl pyrrolizine derivative; IPP	Discontinued			alkylating agent	cancer
KF 22678	Preclinical			alkylating agent	cancer

SD-144110.1

mafosfamide; mefosfamide; ASTA Z 7557; NSC 345842; ASTA Z 7654; Z 7557	Discontinued	cis-(+,-)-2-[[2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin-4-yl]thio]ethanesulfonic acid P-oxide	alkylating agent	cancer
melphalan + A-MSH; F1K	Discontinued		alkylating agent	cancer
melphalan + L-amino oxidase	Preclinical		alkylating agent	cancer
OCX 177; OCX 0177	Preclinical		alkylating agent	cancer
porfiromycin; porfiromycine; N- methylmitomycin C; ENT 50825; NSC 56410; U 14743; PROMYCIN	Phase III	[1aS-(1a.alpha.,8.beta.,8a.alpha.,8b.alpha.)]-6-amino-8-[[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-1,5-dimethyl-azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione	alkylating agent	cancer
SBR 11170; SBR 170	Preclinical		alkylating agent	cancer
temozolomide; methazolastone; SCH 52365; CCRG 81045; NSC 362856; M&B 39831; TEMODAL	Marketed	3,4-dihydro-3-methyl-1-imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide	alkylating agent	cancer
treosulfan; OVASTAT; TREOSULFAN	Marketed	L-threitol 1,4-dimethanesulfonate	alkylating agent	cancer

SD-144110.1

PNU 159548	Phase I	(7S-cis)-9-acetyl-7-[[[3-(1-aziridinyl)-2,3,6-trideoxy-4-O-(methylsulfonyl)-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione	alkylating agent; DNA intercalator	cancer
mitolactol; bromoalcohol; dibromodulcitol; DBD; NSC 104800; MITOLACTOL; METHOLACTOLE; ELOBROMOL	Marketed	1,6-dibromo-1,6-dideoxygalactitol	alkylating agent; peptide	cancer
bisaziridinylspermine; BAS	Preclinical	N,N'-bis[3-(1-aziridinylpropyl)]-1,4-butanediamine	alkylating agent; polyamine analogue	cancer
diarizidinylspermine; DASPM	Preclinical	N,N'-bis[3-(1-aziridinylpropyl)]-1,4-butanediamine	alkylating agent; polyamine analogue	cancer
O6-benzylguanine	Phase I		alkyltransferase inhibitor; chemosensitizer	cancer
samarium 153 Sm lexidronam; Sm 153-EDTMP; samarium 153-EDTMP; samarium EDTMP; CYT 424; QUADRAMET	Marketed	(OC-6-21)-[[[1,2-ethanediy]bis[nitri]bis[phosphonato]](8-)-N,N',OP,OP',OP'',OP''']-samarate(5-)-153Sm	analgesic; NSAID; radiotherapeutic	cancer; pain; rheumatoid arthritis

abiraterone; piraterone; CB 7630; CB 7598	Phase I	(3beta)-17-(3-pyridinyl)-androsta-5,16-dien-3-ol	androgen synthesis inhibitor	cancer
cancer therapy, Institute of Cancer Research	Preclinical		androgen synthesis inhibitor	cancer
cancer therapy, Saarbrücken University	Preclinical		androgen synthesis inhibitor	cancer
GI 111924	Suspended		androgen synthesis inhibitor	cancer
VN 851	Preclinical		androgen synthesis inhibitor	cancer
VN 871	Preclinical		androgen synthesis inhibitor	cancer
YM 116	Phase I	2-(1H-imidazol-4-ylmethyl)-9H-carbazole	androgen synthesis inhibitor	cancer
YM 53789	Preclinical	2-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-9H-carbazole	androgen synthesis inhibitor	cancer
YM 55208	Preclinical	2-[1-(1H-imidazol-1-yl)ethyl]-9H-carbazole	androgen synthesis inhibitor	cancer
gene therapy, cancer, Genetix	Preclinical		angiogenesis inducer; biotechnology; gene therapy	cancer
2-methyl-2-phthalimidino-glutaric acid	Preclinical		angiogenesis inhibitor	cancer

9alpha-fluoromethoxyprogesterone acetate; FMPA	Preclinical	(6-alpha)-17-(acetyloxy)-9-fluoro-6-methyl-pregn-4-ene-3,20-dione	angiogenesis inhibitor	cancer
ANG 453; ZD 6126	Preclinical		angiogenesis inhibitor	cancer
angiogenesis inhibitor, Boston Life Sciences	Preclinical		angiogenesis inhibitor	cancer
angiogenesis inhibitor, Merck KGaA; EMD 121974	Phase I		angiogenesis inhibitor	cancer
angiogenesis inhibitors, AstraZeneca	Preclinical		angiogenesis inhibitor	cancer
angiogenesis inhibitors, Nanodesign	Preclinical		angiogenesis inhibitor	cancer
angiogenesis inhibitors, Novartis/Schering AG	Preclinical		angiogenesis inhibitor	cancer
angiogenesis inhibitors, Repligen	Preclinical		angiogenesis inhibitor	cancer; retinopathy
CT 3577	Discontinued		angiogenesis inhibitor	cancer

FCE 26644; PNU 151484	Preclinical	7,7'-[carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diy)]carbonylimino(1-methyl-1H-pyrrole-4,2-diy)]carbonylimino]]bis-1,3-naphthalenedisulfonic acid tetrasodium salt	angiogenesis inhibitor	cancer
FCE 27164; PNU 165897	Preclinical	7,7'-[carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diy)]carbonylimino(1-methyl-1H-pyrrole-4,2-diy)]carbonylimino]]bis-1,3,5-naphthalenetrisulfonic acid hexasodium salt	angiogenesis inhibitor	cancer
gene discovery, tumor epithelium	Preclinical		angiogenesis inhibitor	cancer
greenstatin	Preclinical		angiogenesis inhibitor	cancer
irsogladine; irsogladine maleate; isaglidole; MN 1695; GASLON; GASLON-N	Marketed	2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine	angiogenesis inhibitor	cancer gastrointestinal ulcer; cancer
RG 8803; RG 8803B11; RG 1009	Preclinical		angiogenesis inhibitor	cancer

squalamine	Phase I	(3beta,5alpha,7alpha,24R)-3-[[3-[(4-aminobutyl)amino]propyl]amino]cholestan-7-24-diol 24-(hydrogen sulfate)	angiogenesis inhibitor	viral infection; cancer; retinopathy
SR 25989	Discontinued		angiogenesis inhibitor	cancer
SU 301	Discontinued		angiogenesis inhibitor	cancer
SU 302	Discontinued		angiogenesis inhibitor	cancer
suradista	Phase I		angiogenesis inhibitor	cancer
TAN 1120	Preclinical	8-acetyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[octahydro-5-hydroxy-2-(2-hydroxypropyl)-4,10-dimethylpyrano[3,4-d]-1,3,6-dioxocin-8-yl]oxy]-5,12-naphthacenedione	angiogenesis inhibitor	cancer
TZ 93	Discontinued		angiogenesis inhibitor	cancer
VE-cadherin-2 antagonists, ImClone Systems	Preclinical		angiogenesis inhibitor	cancer
VEGF receptor modulators, Pharmacia	Preclinical		angiogenesis inhibitor	cancer
INGN 401	Preclinical		angiogenesis inhibitor; antiproliferative agent	cancer
soluble Tie-2	Preclinical		angiogenesis inhibitor; biotechnology	cancer

SD-144110.1

angiogenesis inhibitor, Bio-Technology General; plasminogen-related peptide Bio-Technology General	Preclinical		angiogenesis inhibitor; cancer biotechnology; peptide	cancer
SU 6668	Phase I		angiogenesis inhibitor; growth factor modulator	cancer
AE 941; NEOVASTAT; NEORETNA; PSOVASCAR; ARTHROVAS	Phase III		angiogenesis inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; eye disease; retinopathy
FR 111142; WF 2015A	Discontinued	4,5-dihydroxy-2-hexenoic acid 5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl ester	angiogenesis inhibitor; NSAID	cancer; rheumatoid arthritis; retinopathy
heparanase inhibitors, InSight	Preclinical		angiogenesis inhibitor; NSAID	cancer; inflammation
troponin I; cartilage derived inhibitor	Preclinical		angiogenesis inhibitor; NSAID; biotechnology	cancer; rheumatoid arthritis; eye disease
antiangiogenesis agent, Ixsys	Discontinued		angiogenesis inhibitor; peptide	cancer; restenosis
XMP 300	Preclinical		angiogenesis inhibitor; peptide	inflammation; cancer
ENDOSTATIN	Preclinical		angiogenesis inhibitor; peptide; biotechnology	cancer

thrombospondin 1 inhibitor, InKine; TSP-1 inhibitor, InKine	Preclinical		angiogenesis inhibitor; platelet antiaggregant; radiodiagnostic; contrast medium	cancer; diagnosis; thrombosis
tecogalan sodium; DS 4152; SP PG	Phase I	sulfated polysaccharide peptidoglycan	angiogenesis inhibitor; polysaccharide sulfate	cancer
SU 5416	Phase II	3-[(4,5-dimethyl-1H-pyrol-2-yl)methylene]-1,3-dihydro-2H-indol-2-one	angiogenesis inhibitor; tyrosine kinase inhibitor; signal transduction inhibitor	cancer
rubiginone B1	Discontinued		angucyclinone; antibiotic	cancer
aclarubicin; aclarubicin hydrochloride; aclacinomycin A; NSC 208734; MA 144A1; JACLACIN; ACLAPLASTIN; ACLACINOMYCIN; ACLACINON	Marketed	methyl(1R,2R,4S)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[[2R,6S)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-1-naphthacenecarboxylate	anthracycline; antibiotic; DNA intercalator	cancer

drug delivery system, Phase II liposome anthracycline; anthracycline liposome; AR 522; ANNAMYCIN			anthracycline; antibiotic; DNA intercalator	cancer
IT 62B	Discontinued		anthracycline; antibiotic; DNA intercalator	cancer; bacterial infection
SO 075R1	Preclinical		anthracycline; antibiotic; DNA intercalator	bacterial infection; cancer
bisantrone; bisantrene hydrochloride; CL 216942; NSC 337766; ADCA; CYABIN	Phase III	bis[(4,5-dihydro-1H- imidazol-2- yl)hydrazono]-9,10- anthracenedicarboxal dehyde	anthracycline; DNA intercalator; antibiotic	cancer
daunoform	Preclinical		anthracycline; DNA intercalator; antibiotic	cancer
doxoform	Preclinical		anthracycline; DNA intercalator; antibiotic	cancer
drug delivery system, micellar doxorubicin; doxorubicin micelles	Preclinical		anthracycline; DNA intercalator; antibiotic	cancer
epidoxoform	Preclinical		anthracycline; DNA intercalator; antibiotic	cancer

nemorubicin; FCE 23762	Phase II	[8S-[8alfa,10alfa(R*)]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-(2-methoxy-4-morpholinyl)-alfa-L-lyxohexopyranosyl]oxy]-5,12-naphthacenedione	anthracycline; DNA intercalator; antibiotic	cancer
ZYN 191	Suspended		anthracycline; DNA intercalator; antibiotic	cancer
D 26232; AN 207	Preclinical	(2S-cis)-6-[N6-[5-[2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-(2,3-dihydro-1H-pyrrol-1-yl)-alpha-L-lyxohexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethoxy]-1,5-dioxopentyl]-D-lysine]-luteinizing hormone-releasing factor (swine)	anthracycline; DNA intercalator; antibiotic; gonadorelin agonist; peptide	cancer
AN 1006	Discontinued		anthraquinone	cancer

anthraquinone prodrugs, De Montfort University	Discontinued		anthraquinone; radiosensitizer	cancer
antiandrogen, prostatic carcinoma	Discontinued		antiandrogen	cancer
bicalutamide; Zeneca 176334; ICI 176334; CASODEX	Marketed	(+)-N-[4-cyano-3- (trifluoromethyl)phen yl]-3-[(4- fluorophenyl)sulfony l]-2-hydroxy-2- methylpropanamide	antiandrogen	benign prostate hypertrophy; cancer
ICI 192779	Suspended		antiandrogen	cancer
LGD 1331	Preclinical		antiandrogen	cancer; benign prostate hypertrophy; acne; alopecia
nilutamide; RU 23908; RU 23908-10; ANANDRON; NILANDRON	Marketed	5,5-dimethyl-3-[4- nitro-3- (trifluoromethyl)phen yl]-2,4- imidazolidinedione	antiandrogen	cancer
osaterone; osaterone acetate; TZP 4238; HIPROS	Pre- registration	17-(acetyloxy)-6- chloro-2-oxapregna- 4,6-diene-3,20-dione	antiandrogen	benign prostate hypertrophy; cancer; osteoporosis
zanoterone; WIN 49596	Phase II	(5alpha,7alpha)-1'- (methylsulfonyl)-1H- pregn-20-yno[3,2- c]pyrazol-17-ol	antiandrogen	benign prostate hypertrophy; cancer
albaccarin; virenomyacin M, V	Discontinued		antibiotic	cancer

ankinomycin	Discontinued	2-(4,4-anhydro-1,6-dideoxy- α -L-sorbo-2,3-oxiranosyl)-1,1-hydroxy-5-methyl-10-[2,3,6-trideoxy-3-(dimethylamino)-3-C-methyl- α -L-lyxo-hexopyranosyl]-4H-anthra[1,2-b]pyran-4,7,12-trione	antibiotic	cancer
antibiotic, Sagami	Preclinical	(7S-cis)-7-[(2,6-dideoxy- α -L-lyxo-hexopyranosyl)oxy]-9-(fluoroacetyl)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione	antibiotic	cancer
anticancer, Chugai	Discontinued	3'-deoxytalopiericidin A1 (DTPA)	antibiotic	cancer
AT 2433A1	Discontinued	1-chloro-13-[6-O-[2,4-dideoxy-4-(methylamino)- α -D-threo-pentopyranosyl]-4-O-methyl-beta-D-glucopyranosyl]-12,13-dihydro-6-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione	antibiotic	cancer

azamitosenes	Preclinical	antibiotic	cancer
BE 12406A	Discontinued	antibiotic	cancer
betacilamycin B; BCMA	Preclinical	antibiotic	cancer
CC 1065	Discontinued	antibiotic	bacterial infection; cancer
collismycin A; SF 2738A	Discontinued	antibiotic	cancer

collismycin B; SF 2738B	Discontinued	(Z)-4-methoxy-5-(methylthio)-[2,2'-bipyridine]-6-carboxaldehyde oxime	antibiotic	cancer
collismycin C; SF 2738C	Discontinued		antibiotic	cancer
cypemycin	Discontinued	N,N-dimethyl-L-alanyl-(E)-2,3-didehydro-2-aminobutanoyl-L-propyl-L-alanyl-(E)-2,3-didehydro-2-aminobutanoyl-L-propyl-(E)-2,3-didehydro-2-aminobutanoyl-L-valyl-L-alanyl-L-glutamyl-L-phenylalanyl-L-valyl-L-isoleucyl-L-glutamylglycyl-L-seryl-(E)-2,3-didehydro-2-aminobutanoyl-L-isoleucyl-L-cysteinyl-L-leucyl-N-(2-mercaptoethenyl)-L-leucinamide cyclic (19-21)-sulfide	antibiotic	bacterial infection; cancer

dioxamycin; BE 16493	Preclinical	[2alfa,3alfa,4aalfa,9[2R*,3S*[1E(2S*,4S*,5S*),3E,5E],6R*],12ba lfa]-(+)-2,4-dimethyl-5-[7-oxo-7-[[[tetrahydro-2-methyl-6-(1,2,3,4,4a,7,12,12b-octahydro-2,3,4a,8,12b-pentahydroxy-3-methyl-1,7,12-trioxobenz[a]anthracen-9-yl)-2H-pyran-3-yl]oxy]-1,3,5-heptatrienyl]-1,3-dioxolane-2-carboxylic acid	antibiotic	cancer; bacterial infection
eponemycin; BMV 28647; BU 3862T	Discontinued	[2R-[2R*[S*(S*)]]]-N-[1-(hydroxymethyl)-2-[[1-[[2-(hydroxymethyl)oxiranyl]carbonyl]-3-methyl-3-butenyl]amino]-2-oxoethyl]-6-methylheptanamide	antibiotic	cancer
epoxomicin	Discontinued		antibiotic	cancer

Discontinued	antibiotic	cancer
esperatrucin; esperamicin A1; esperamycin; esperamcin; BMY 28175; BBM 1675A1; BBM 1675	<p>[(1R*,4Z,8S*,12S*,13E)]-4,5-dimethoxy-2-[[2-methoxy-1-oxo-2-propenyl)amino]benzoic acid 3'-(12)-ester with methyl [8-[[4,6-dideoxy-2-O-[2,4-dideoxy-3-O-methyl-4-[(1-methylethyl)amino]-alpha-L-threopentopyranosyl]-4-[[2,6-dideoxy-4-S-methyl-4-thio-beta-D-ribohexopyranosyl)oxy]amino]-beta-D-glucopyranosyl]oxy]-12-[(2,6-dideoxy-alpha-L-lyxohexopyranosyl)oxy]-1-hydroxy-13-[2-(methyltrithio)ethylidene]-11-oxobicyclo[7.3.1]trideca-4,9-diene-2,6-diyn-10-yl]carbamate</p>	

FCE 21424	Preclinical	8-acetyl-10-[[5-(hexahydro-2,4,6-trioxo-5-pyrimidinyl)octahydro-2-(2-hydroxypropyl)-4,10-dimethylpyrano[3,4-d]-1,3,6-dioxazin-8-yl]oxy]-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	antibiotic	cancer
FCE 24366	Preclinical	8-acetyl-10-[[5-(hexahydro-1,3-dimethyl-2,4,6-trioxo-5-pyrimidinyl)octahydro-2-(2-hydroxypropyl)-4,10-dimethylpyrano[3,4-d]-1,3,6-dioxazin-8-yl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	antibiotic	cancer

FCE 24367	Preclinical	8-acetyl-10-[[5-(hexahydro-4,6-dioxo-2-thioxo-5-pyrimidinyl)octahydro-2-(2-hydroxypropyl)-4,10-dimethylpyrano[3,4-d]-1,3,6-dioxazin-8-yl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	antibiotic	cancer
FK 317	Phase I		antibiotic	
fluorodaunorubicin hydrochloride	Preclinical	10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-8-(fluoroacetyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	antibiotic	cancer

batomamicin; YL 0358MA	Preclinical	[2R- [2alfa,3alfa,6alfa]1R* (S*),2Z,4E(1alfaS*,7 alfaR*)]]-6-[[4-(2,3- dihydrocyclopent[b]o xireno[c]pyridin- 7(1aH)-ylidene)-1-(1- hydroxypropyl)-3- methyl-2- butenyl]oxy]tetrahydr o-2-methyl-2H-pyran- 3-ol	antibiotic	cancer
	Discontinued		antibiotic	bacterial infection; cancer
himastatin; BMY 40800	Discontinued	[4S- (4alfa,4aalfa,5alfa,5aa lfa,6alfa,12aalfa)]-4- (dimethylamino)- 1,4,4a,5,5a,6,11,12a- octahydro- 3,5,10,12,12a- pentahydroxy-6- methyl-1,11-dioxo-2- naphthacenecarboxam ide	antibiotic	cancer; bacterial infection
K 818B	Discontinued		antibiotic	cancer
kedarcidin	Discontinued		antibiotic	bacterial infection; cancer
KT 5432	Discontinued		antibiotic	cancer

KW 2189	Phase II	(S)-8-(bromomethyl)-3,6,7,8-tetrahydro-2-methyl-4-[[[(4-methyl-1-piperazinyl)carbonyl]oxy]-6-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl]benzo[1,2-b:4,3-b']dipyrrole-1-carboxylic acid, methyl ester	antibiotic	cancer; bacterial infection
	Discontinued		antibiotic	cancer
lactimidomycin leinamycin; leinomycin; DC 107	Discontinued	[2'R*,6'R*(R*),9'E,11'R*,13'E,15'Z]]-4,11'-dihydroxy-2',4,9'-trimethylspiro[1,2-dithiolane-3,6-[19]thia[3,20]diazabicyclo[15.2.1]eicosa[1(20),9,13,15,17]pentamethyl-4',5,12'-trione 2-oxide	antibiotic	cancer
	Discontinued		antibiotic	cancer
leptolstatin	Preclinical		antibiotic	cancer
liblomycin; NK 313	Discontinued	N1-[3-[[3-bis[[3,4-bis(phenylmethoxy)phenyl]methyl]amino]propyl]methylamino]propyl]bleomycinamide	antibiotic	cancer; bacterial infection

nisamycin; antibiotic 106B	Preclinical	[1S-[1 α ,2 β ,2(2E,4E,6E),4(2E,4E),6 α]]-7-[4-[(5-cyclohexyl)-1-oxo-2,4-pentadienyl)amino]-2-hydroxy-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-2-yl]-2,4,6-heptatrienoic acid	antibiotic	bacterial infection; cancer
oligomycin E; MCI 2225	Discontinued	26-hydroxy-28-oxooligomycin A	antibiotic	cancer
oxaunomycin; D 788; R 20X2	Preclinical	[7R-(7 α ,8 β ,10 β)]-10-[(3-amino-2,3,6-trideoxy- α -L-lyxohexopyranosyl)oxy]-8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-5,12-naphthacenedione	antibiotic	cancer
phenazinomycin; (-)- phenazinomycin	Preclinical	[R-(E)]-5-[5-(2,2-dimethyl-6-methylenecyclohexyl)-3-methyl-2-pentenyl]-1(5H)-phenazinone	antibiotic	bacterial infection; cancer

pyrindamycin A	Discontinued	(2R-trans)-8-(chloromethyl)-1,2,3,6,7,8-hexahydro-4-hydroxy-2-methyl-1-oxo-6-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl]benzo[1,2-b:4,3-b']dipyrrole-2-carboxylic acid, methyl ester	antibiotic	cancer
pyrindamycin B	Discontinued	8-chloro-2,3,6,7,8,9-hexahydro-4-hydroxy-2-methyl-1-oxo-6-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl]-1H-pyrrolo[3,2-f]quinoline-2-carboxylic acid, methyl ester	antibiotic	cancer
saintopin	Discontinued	1,3,8,10,11-pentahydroxy-5,12-naphthacenedione	antibiotic	bacterial infection; cancer

saptomycin D	Discontinued	[2 α ,3 β (Z)]-10-[4-O-acetyl-2,3,6-trideoxy-3-(dimethylamino)-3-C-methyl- α -L-lyxohexopyranosyl]-11-hydroxy-5-methyl-2-[2-methyl-3-(1-propenyl)oxiranyl]-4H-anthra[1,2-b]pyran-4,7,12-trione	antibiotic	cancer; bacterial infection
SPM VIII	Discontinued	4-deoxy-4-[[[(1-oxododecyl)amino]acetyl]amino]-N-1H-purin-6-yl-L-glycero-beta-L-manno-heptopyranosylamine	antibiotic	cancer
tetrazomine; Y 09194L-B	Preclinical	3-hydroxy-N-[2 α ,3,4,5,6,6a,7,11b-octahydro-5-(hydroxymethyl)-11-methoxy-12-methyl-3,6-imino-1H-2-oxa-11c-azanaphth[1,2,3-cd]azulen-10-yl]-2-piperidinecarboxamide	antibiotic	bacterial infection; cancer
UCA 1064B	Discontinued		antibiotic	cancer
vicenistatin	Discontinued		antibiotic	cancer

Y 05460MA	Preclinical	4-amino-4,5,6-trideoxy-N-[1-(3,4-dihydro-8-hydroxy-1H-2-benzopyran-3-yl)-3-methylbutyl]-5-methylhexonamide	antibiotic	bacterial infection; cancer
drug delivery system, mitomycin; mitomycin Therapeutic Implant; MPI 5016	Discontinued		antibiotic; alkylating agent	cancer
MGI 114; HMAF	Phase II	(R)-6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro[cyclopropane-1,5'-[5H]inden]-7'(6'H)-one	antibiotic; alkylating agent; terpene	cancer
AGM 1470; TNP 470	Phase II	[3R-[3alpha, 4alpha (2R*,3R*),5beta, 6beta]]-5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl] carbamic acid chloroacetyl ester	antibiotic; angiogenesis inhibitor	cancer

AD 143	Preclinical	hexanedioic acid (2S-cis)-mono[2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[[2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-alpha-L-lyxohexopyranosyl]oxy]-2-naphthaceny]]-2-oxoethyl] ester	antibiotic; anthracycline; DNA intercalator	cancer
AD 198	Preclinical	Pentanoic acid (2S-cis)-2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[[2,3,6-trideoxy-3-[(phenylmethyl)amino]-alpha-L-lyxohexopyranosyl]oxy]-2-naphthaceny]]-2-oxoethyl ester	antibiotic; anthracycline; DNA intercalator	cancer
anthracycline analogue, BioChem Pharma	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
B 880308	Suspended	7-O-(3-N-methyl-3-N-(R)-glycidyl-alpha-L-daunosaminyl)-beta-rhodomyacinone	antibiotic; anthracycline; DNA intercalator	cancer

drug delivery system, ATRIGEL sustained release doxorubicin; doxorubicin ATRIGEL	Preclinical		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, doxorubicin; doxorubicin drug delivery system; AD 70; ADM OXD; GC 1004	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, doxorubicin; doxorubicin drug delivery system	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, doxorubicin; doxorubicin-tumor homing peptide; THP-doxorubicin	Preclinical		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, doxorubicin; doxorubicin Therapeutic Implant; MPI 5015	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, HPMA polymer-bound doxorubicin; doxorubicin HPMA polymer-bound; PK 1	Phase I		antibiotic; anthracycline; DNA intercalator	cancer

drug delivery system, Marketed liposome daunorubicin; daunorubicin liposome; VS 103; DaunoXome		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, Discontinued liposome doxorubicin; doxorubicin liposome; DOXOME		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, Pre- registration liposome doxorubicin; doxorubicin liposome; TLC D99; TLC DOX 99; DOX 99; EVACET; LIPODOX		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, Clinicals liposome doxorubicin; doxorubicin liposome		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, Phase III liposome doxorubicin; doxorubicin liposome		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, Preclinical micellar doxorubicin; doxorubicin micelles		antibiotic; anthracycline; DNA intercalator	cancer

drug delivery system, Phase I nanosphere doxorubicin; doxorubicin nanosphere			antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, Discontinued ONCHOLAB aclarubicin; aclarubicin ONCHOLAB			antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, Discontinued ONCHOLAB AD 32; AD 32 ONCHOLAB			antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, Marketed STEALTH liposome doxorubicin; doxorubicin STEALTH; DOXIL; DOX-SL; S-DOX; CAELYX			antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, Preclinical tetrapeptide doxorubicin; doxorubicin tetrapeptide; Super- Leu-Dox			antibiotic; anthracycline; DNA intercalator	cancer

epirubicin; pidorubicin; 4'-epi- doxorubicin; IMI 28; MSC 256942; FI 7701; PHARMORUBICIN; FARMORUBICIN; FARMORUBICINE	Marketed	(8S-cis)-10-[(3- amino-2,3,6-trideoxy- alpha-L-arabino- hexopyranosyl)oxy]- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-8- (hydroxyacetyl)-1- methoxy-5,12- naphthacenedione	antibiotic; anthracycline; DNA intercalator	cancer
FCE 27726	Discontinued	(7S-cis)-9-acetyl-7- [[[3-bis(2- chloroethyl)amino]- 2,3,6-trideoxy-4-O- (methylsulfonyl)- alpha-L-lyxo- hexopyranosyl]oxy]- 7,8,9,10-tetrahydro- 6,9,11-trihydroxy- 5,12- naphthacenedione	antibiotic; anthracycline; DNA intercalator	cancer
galarubicin; DA 125	Phase II	2-[(2S,4S)-4-[(2,6- dideoxy-2-fluoro- alpha-L-talopyran osyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthacenyl]-2- oxoethyl ester beta- alanine hydrochloride	antibiotic; anthracycline; DNA intercalator	cancer

GPX 100	Phase I			antibiotic; anthracycline; DNA intercalator	cancer
I-DOX	Phase I		4'-iodo-4'- deoxydoxorubicin	antibiotic; anthracycline; DNA intercalator	cancer
idarubicin; IMI 30; NSC 256439; IMI 22; ZAVEDOS; ZAVEDOSE; ZAVIDOS; IDAMYCIN; DAUNOBLASTINA; CERUBIDINE	Marketed		9-acetyl-7-[(3-amino- 2,3,6-trideoxy- α -L- xyo- hexopyranosyl)oxy]- 7,8,9,10-tetrahydro- 6,9,11-trihydroxy- 5,12- naphthacenedione	antibiotic; anthracycline; DNA intercalator	cancer
iododoxorubicin; FCE 21954; IODODOX	Phase II		[2R- [2 α fa(8S*,10S*),4bet a,5beta,6beta]]-10- [(4-aminotetrahydro- 5-iodo-6-methyl-2H- pyran-2-yl)oxy]- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-8- (hydroxyacetyl)-1- methoxy-5,12- naphthacenedione	antibiotic; anthracycline; DNA intercalator	cancer

KRN 8602; MX 2	Phase II	[7R-(7 α ,8 β ,10 β)-8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-[[[2,3,6-trideoxy-3-(4-morpholinyl)- α -L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione hydrochloride	antibiotic; anthracycline; DNA intercalator	cancer
ME 2303; FAD 104	Discontinued	heptanedioic acid, mono[2-[4-[(2,6-dideoxy-2-fluoro- α -L-talopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-oxoethyl] ester, (2S-cis)-	antibiotic; anthracycline; DNA intercalator	cancer

menogaril; 7-OMEN; NSC 269148; TUT 7; U 52047; TOMOSAR; TAMOSAR	Phase III	(2R,3S,4R,5R,6R,11R,13R)-4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-dimethyl-2,6-epoxy-2H-naphthaceno[1,2-b]oxocin-9,16-dione	antibiotic; anthracycline; DNA intercalator	cancer
pirarubicin; tirarubicin; theprubicin; THP- doxorubicin; THP- ADM; thepirubicin; THERARUBICIN; PINORUBIN; BERJURUBIN; THEPRUBICINE	Marketed	[8S-[8alpha,10alpha(S*)]-10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione	antibiotic; anthracycline; DNA intercalator	cancer

ruboxyl	Phase II	(2S-cis)-4-[[1-[4[(3-amino-2,3,6-trideoxy- α -L-lyxohexopyranosyl)oxy]1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazono-2,2,6,6-tetramethyl-1-piperidinyl]oxyl	antibiotic; anthracycline; DNA intercalator	cancer
valrubicin; antibiotic AD 32; AD 32; NSC 246131; VALSTAR	Marketed	Pentanoic acid, (2S-cis)-2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[[[(trifluoroacetyl)amino]- α -L-lyxohexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethyl ester	antibiotic; anthracycline; DNA intercalator	cancer
ZYN 198	Suspended		antibiotic; anthracycline; DNA intercalator	cancer
ZYN-LINKER conjugated doxorubicin	Suspended		antibiotic; anthracycline; DNA intercalator	cancer
doxorubicin + estrone; estrone + doxorubicin; DDS- DEA	Marketed		antibiotic; anthracycline; DNA intercalator; estrogen	cancer

SD-144110.1

amrubicin; SM 5887	Phase II	(7S-cis)-9-acetyl-9-amino-7-[(2-deoxy-beta-D-erythropentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione hydrochloride	antibiotic; anthracycline; DNA topoisomerase inhibitor	cancer
MEN 10755; BMS 195615	Phase I	(7S-cis)-7-[[4-O-(3-amino-2,3,6-trideoxy-alpha-L-lyxohexopyranosyl)-2,6-dideoxy-alpha-L-lyxohexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-5,12-naphthacenedione hydrochloride	antibiotic; anthracycline; DNA topoisomerase inhibitor	cancer
BU 4704	Discontinued	1-(4-methoxyphenyl)-4-(4-hydroxysulfonyloxyphenyl)-2,3-diisocyano-1,3-butadiene	antibiotic; antifungal	mycosis; cancer
NK 860279I	Discontinued	44-homooligomycin B	antibiotic; antifungal	mycosis; cancer
NK 860279II	Discontinued	44-homooligomycin A	antibiotic; antifungal	mycosis; cancer

reveromycin A	Preclinical	10-[9-butyl-8-[4-carboxy-3-methyl-1(E),3(E)-butadienyl]-9-(hydroxysuccinyl)-3-methyl-1,7-dioxaspiro-[5.5]undec-2-yl]-5-hydroxy-4,8-dimethyl-2(E),6(E),8(E)-decatricarboxylic acid	antibiotic; antifungal	bacterial infection; cancer; mycosis
sultricin	Discontinued	5,6-dihydro-5-hydroxy-6-(6-hydroxy-5-methyl-4-hydroxysulfonyloxyheptadec-1,7,9,11-tetraenyl)-2H-pyran-2-one	antibiotic; antifungal	cancer; mycosis
JSM ASB001	Preclinical		antibiotic; antioxidant; cicatrizant	cancer; bacterial infection; gastrointestinal disorder; skin ulcer
JSM BCYL001	Preclinical		antibiotic; antioxidant; cicatrizant	cancer; bacterial infection; gastrointestinal disorder; skin ulcer
JSM BIAS001	Preclinical		antibiotic; antioxidant; cicatrizant	cancer; bacterial infection; gastrointestinal disorder; skin ulcer
beta lactam derivatives, Pliva	Preclinical		antibiotic; beta lactam	cancer

clavulanine; SYN 1931; Ro 22-5417	Preclinical	[3S-[3alpha(R*),5alpha]]-alpha-amino-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-3-propanoic acid	antibiotic; beta lactam	cancer
SYN 1127	Preclinical	3-(hydroxymethyl)-4-oxa-1-azabicyclo[3.2.0]heptan-7-one	antibiotic; beta lactam	cancer
SYN 1932	Preclinical	[3R-[3alpha(alphaS*,beta R*),5alpha]]-alpha-amino-7-oxo-beta-(phenylmethoxy)-4-oxa-1-azabicyclo[3.2.0]heptane-3-propanoic acid	antibiotic; beta lactam	cancer
MAB, doxorubicin conjugate	Preclinical		antibiotic; biotechnology; monoclonal antibody; anthracycline; DNA intercalator	cancer
MAB, drug delivery system, liposome doxorubicin conjugate; MAB, STEALTH doxorubicin conjugate; SPI 49	Preclinical		antibiotic; biotechnology; monoclonal antibody; anthracycline; DNA intercalator	cancer
drug delivery system, micellar doxorubicin; doxorubicin micelle	Preclinical		antibiotic; DNA intercalator; anthracycline	cancer

IST 622; A 132; NSC 639830	Phase II	3-ethoxypropanoic acid (S)-10-[[6-deoxy-2-O-(6-deoxy-3-O-methyl- α -D-galactopyranosyl)-3,4-O-(phenylmethylene)-beta-D-galactopyranosyl]oxy]-5,12-dihydro-1-methyl-5,12-dioxobenzo[h][1]benzopyranol[5,4,3-cde][1]benzopyran-6-yl ester	antibiotic; DNA topoisomerase inhibitor	cancer
NSC 655649; BMY 27557	Phase I	1,11-dichloro-6-[2-(diethylamino)ethyl]-12,13-dihydro-12-(4-O-methyl-beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione	antibiotic; DNA topoisomerase inhibitor; DNA intercalator	cancer
WIN 58161	Preclinical	(S)-10-(2,6-dimethyl-4-pyridinyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid	antibiotic; DNA topoisomerase inhibitor; quinolone	cancer
MI 4337F11; MI 43	Preclinical		antibiotic; immunostimulant	cancer

gludapcin; FK 565; FK 41565	Discontinued	heptanoyl-gamma-D-glutamyl-(L)-meso-diaminopimelyl-(D)-alanine	antibiotic; immunostimulant; peptide	cancer; HIV infection
feldamycin; BMY 28565	Discontinued	(S)-N-methyl-L-histidyl-N3-[1-carboxy-2-(1H-imidazol-4-yl)ethyl]-L-threo-2,3-diaminobutanoic acid	antibiotic; melanin synthesis inhibitor	cancer
cordycepin; NSC 63984	Phase I		antibiotic; nucleoside; antimetabolite	cancer
C 1027	Preclinical	Antibiotic C	antibiotic; peptide	cancer; bacterial infection
cecropin B	Discontinued		antibiotic; peptide	bacterial infection; cancer
lytic peptides, Proteus International	Discontinued		antibiotic; peptide	bacterial infection; cancer
verucopeptin; BU 3983T; BMY 28782	Discontinued		antibiotic; peptide	cancer
placatin A	Preclinical		antibiotic; peptide	cancer
placatin B	Preclinical		antibiotic; platelet antiaggregant	thrombosis; bacterial infection; cancer
MS 073	Preclinical	5-(3-(40(10,11-dihydro-5H-dibenzo(a,d)cycloheptene-5-yl)piperazin-1-yl)2-hydroxypropoxy)quinoline	antibiotic; platelet antiaggregant	thrombosis; bacterial infection; cancer
			antibiotic; quinoline	cancer

A 74932	Discontinued	6-[2-[(2-amino-1-oxopentyl)amino]-1-pyrrolidinyl]-5-fluoro-3-oxo-3H-pyrido[3,2,1-k]phenoxazine-2-carboxylic acid monohydrochloride	antibiotic; quinolone	cancer
E 7010	Discontinued	N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide	antibiotic; sulfonamide	cancer
E 7070	Phase I		antibiotic; sulfonamide	cancer
ER 34410	Preclinical	N-(10,11-dihydro-2-fluoro-5H-dibenzo[b,e][1,4]diazepin-6-yl)-4-methoxybenzenesulfonamide	antibiotic; sulfonamide	cancer
ER 35744	Preclinical	N-(3-chloro-1H-indol-7-yl)-1,4-benzene-disulfonamide	antibiotic; sulfonamide	cancer
HMN 214	Preclinical	(E)-N-[(4-methoxyphenyl)sulfonyl]-N-[2-[2-(1-oxido-4-pyridinyl)ethenyl]phenyl]acetamide	antibiotic; sulfonamide	cancer
andrographolide	Preclinical		antibiotic; terpene	cancer
PN 271; PN 27,1;	Phase II		antibiotic; terpene	cancer; restenosis
AndroCar				

SD-144110.1

PN 272	Preclinical			antibiotic; terpene	cancer
PN 273	Preclinical			antibiotic; terpene	cancer
PN 274	Preclinical			antibiotic; terpene	cancer
PN 275	Preclinical			antibiotic; terpene	cancer
gircodazole; girodazole; giroline; (+)-giroline; RP 49532; RP 49532A; NSC 627434	Discontinued	[S-(R*,R*)]-2-amino- alfa-(2-amino-1- chloroethyl)-1H- imidazole-4-methanol		antibiotic; tRNA synthetase inhibitor	cancer
glycopine; glucosaminylmuramy l dipeptide; GMDP; LIKOPID; LIKOPID	Marketed	N2-[N-[N-acetyl-4-O- [2-(acetyl-amino)-2- deoxy-beta-D- glucopyranosyl]mura moyl]-L-alanyl]-D- alpha-glutamine		antibiotic; vaccine adjuvant; immunostimulant; glycopeptide	psoriasis; cancer; leukopenia; septic shock; infectious disease; eye disease
antiestrogens, AVAX Technologies	Preclinical			antiestrogen	cancer
antiestrogens, BioNumerik	Preclinical			antiestrogen	cancer
antiestrogens, Ligand	Preclinical			antiestrogen	cancer; endometriosis
clomifene analogues	Suspended			antiestrogen	cancer
droloxifene; droloxifene citrate; 3- hydroxytamoxifen; K 21060E citrate	Pre- registration	(E)-alpha-[p-[2- (dimethylamino)ethox y]phenyl]-alpha- ethyl-3-stilbenol		antiestrogen	cancer; osteoporosis
drug delivery system, GEOMATRIX controlled release tamoxifen; tamoxifen GEOMATRIX	Discontinued			antiestrogen	cancer

EM 139	Preclinical	(7alpha,16alpha,17beta)-N-butyl-16-chloro-3,17-dihydroxy-N-methylestra-1,3,5(10)-triene-7-undecanamide	antiestrogen	cancer
EM 170	Preclinical	(7alpha,16alpha,17beta)-N-butyl-16-chloro-3,17-dihydroxy-N-methylestra-1,3,5(10)-triene-7-undecanamide	antiestrogen	cancer
EM 800	Phase III	2,2-dimethylpropanoic acid (S)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl ester	antiestrogen	cancer
estrogen antagonists, Telik	Discontinued		antiestrogen	cancer
fulvestrant; ZD 182780; ZM 182780; Zeneca 182780; ICI 182780; FASLODEX	Phase III	(7alpha,17beta)-7-[9-[(4,4,5,5-pentafluoropentyl)sulphonyl]nonyl]-estra-1,3,5(10)-triene-3,17-beta-diol	antiestrogen	cancer; gynecological

iproxifene; TAT 59	Phase III	(E)-4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-[4-(1-methylethyl)phenyl]-1-butenyl]phenol dihydrogen phosphate (ester)	antiestrogen	cancer
MDL 103323	Suspended	(E)-4-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylbutanamine	antiestrogen	cancer
panomifene; EGIS 5650; GYKI 13504	Discontinued	(E)-2-[[2-[p-(3,3-trifluoro-1,2-diphenylpropenyl)phenoxy]ethyl]amino]ethanol	antiestrogen	cancer
R 1128B	Discontinued	1,3,6-trihydroxy-8-n-butylanthraquinone	antiestrogen	cancer
RU 53637	Discontinued	(11beta,17alpha)-3,17-dihydroxy-N-methyl-N-(methylethyl)-19-norpregna-1,3,5(10)-trien-20-yne-11-undecanamide	antiestrogen	cancer
RU 58668; RU 59428	Discontinued		antiestrogen	cancer
SH 646	Phase I		antiestrogen	cancer
tolemifene; tolemifene; FC 1157a; NK 622; FARESTON; TREMIFEN	Marketed	2-(p-((Z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine	antiestrogen	cancer

zindoxifene; D 16726	Discontinued	2-[4-(acetyloxyphenyl)-1-ethyl-3-methyl-1H-indol-5-yl acetate (ester)]	antiestrogen	cancer
arzoxifene; LY 35381	Phase II	2-(4-methoxyphenyl)-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]benzo[b]thiophene-6-ol	antiestrogen; estrogen agonist	cancer
ERA 923	Preclinical		antiestrogen; estrogen agonist	cancer
estrogen receptor modulator, Genaisance; estrogen receptor modulator, Telik	Preclinical		antiestrogen; estrogen agonist	cancer; osteoporosis
estrogen receptor modulators, Nanodesign	Preclinical		antiestrogen; estrogen agonist	cancer; osteoporosis
idoxifene; SB 223030; CB 7432	Phase II	(E)-1-[2-[4-[1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl]pyrrolidine	antiestrogen; estrogen agonist	cancer
LY 326315	Preclinical	6-(4-hydroxyphenyl)-5-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]-2-naphthalenol hydrochloride	antiestrogen; estrogen agonist	cancer

raloxifene; keoxifene; LY 139481; LY 156758; EVISTA	Marketed	[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone	antiestrogen; estrogen agonist	osteoporosis; hyperlipidemia; myocardial infarction; cancer
aminopterin; aminopterine; pteramina; NSC 739; APGA	Phase II	N-[4-[[[(2,4-diamino-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid	antifolate	cancer
anticancer agent, Eisai	Discontinued	N-[4-[3-(2,4-diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidin-5-yl)propyl]benzoyl]-L-glutamic acid	antifolate	cancer
edatrexate; aminopterin, O-ethyl-10-deaza; 10 EDAM; EDAM 10; CGP 30694	Discontinued	N-[p-1-[(2,4-diamino-6-pteridinyl)methyl]propyl]benzoyl]-L-glutamic acid	antifolate	cancer
lometrexol; LY 249543; LY 264618	Phase I	(R)-N-[4-[2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl]-L-glutamic acid	antifolate	cancer

LY 254155	Phase I	N-[[5-[2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl)ethyl]-2-thienyl]carbonyl]-L-glutamic acid	antifolate	cancer
LY 335580	Preclinical	N-((2,4-diamino-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidine-6-yl)ethyl)-2-thienylcarbonyl-L-glutamic acid	antifolate	cancer
PT 523	Preclinical	(S)-2-[[[4-carboxy-4-[[4-[[[(2,4-diamino-6-pteridyl)methyl]amino]butano]benzoyl]amino]butyl]amino]carbonyl]benzoic acid	antifolate	cancer
TNP 351	Discontinued	N-[4-[3-(2,4-diamino-1H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]-L-glutamic acid	antifolate; antimetabolite	cancer
piritrexim; BW 301U; NSC 351521	Phase II	6-[(2,5-dimethoxyphenyl)-methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine	antifolate; dihydrofolate reductase inhibitor	cancer; pneumocystis; toxoplasmosis

translation inhibitor, Trega Biosciences/RiboGen	Preclinical		antifungal	viral infection; mycosis; cancer
liarazole; liarazole hydrochloride; liarazole fumarate; R 75251; R 85246; LIAZAL	Pre- registration	5-[(3-chlorophenyl)- 1H-imidazol-1-yl- methyl]-1H- benzimidazole	antifungal; androgen synthesis inhibitor; imidazole	cancer; psoriasis
BBR 3438	Preclinical		antifungal; anthrapyrazole	cancer
BBR 3439	Discontinued		antifungal; anthrapyrazole	cancer
DUP 942	Discontinued		antifungal; anthrapyrazole	cancer
losoxantrone; losoxantrone hydrochloride; biantrazole; CI 941; DuP 941; NSC 357885; PD 113785; BIANDA	Phase III	7-hydroxy-2-[2-[(2- hydroxyethyl)amino]e thyl]-5-[[2-[(2- hydroxyethyl)amino]e thyl]amino anthra[1,9- cd]pyrazol-6(2H)- one,	antifungal; anthrapyrazole	cancer
teloxantrone; teloxantrone hydrochloride; moxantrazole; DUP 937; CI 937; PD 113309; NSC 355644	Discontinued	7-10-dihydroxy-2-[2- [(2- hydroxyethyl)amino]e thyl]-5-[[2- (methylamino)ethyl]a mino]anthra[1,9- cd]pyrazol-6(2H)- one, dihydrochloride, monohydrate	antifungal; anthrapyrazole	cancer

cancer therapy, Lorus Therapeutics/lon	Preclinical		antifungal; imidazole	cancer
clotrimazole; BAY 5097; CUTAMYCON; ENSCHENT; FUNGIZID; HAKUSERIN; LOTRIMIN AF; MYCO-HERMAL; MYKO CORDES; TRIGENTAX; CANESTEN; LOTRIMIN	Marketed		antifungal; imidazole	mycosis; sickle cell anemia; cancer; diarrhea
jaspalakinolide; jaspamide	Preclinical	[2S-(2R*,4E,6S*,8R*)]-N-[2-bromo-N-(8-hydroxy-2,4,6-trimethyl-1-oxo-4-nonenyl)-L-alanyl]-N-methyl-D-tryptophyl]-L-3-(4-hydroxyphenyl)-beta-alanine rho-lactone	antifungal; peptide	mycosis; cancer
aminoimidazole carboxamide ribonucleotide formyltransferase inhibitors, Agouron; AICART inhibitors, Agouron	Discontinued		antifungal; ribonucleotide formyltransferase inhibitor; NSAID; imidazole	cancer; inflammation

26-epibryostatin 1	Preclinical	(2E,4E)-2,4-octadienoic acid, (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-[(1S)-1-hydroxyethyl]-5-13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13.7.111,15]nona cos-8-en-12-yl ester	antimetabolite	cancer
capecitabine; Ro 091978; XELODA	Marketed	pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate	antimetabolite	cancer
doxifluridine; DFUR; Ro 219738; FURTOLON; FURTULON	Marketed	5-deoxy-5-fluorouridine	antimetabolite	cancer
drug delivery system, ATRIGEL sustained release fluorouracil; fluorouracil ATRIGEL	Preclinical		antimetabolite	cancer

drug delivery system, fluorouracil; fluorouracil Therapeutic Implant; MPI 5003; AccuSite	Marketed		antimetabolite	cancer; psoriasis; viral infection
drug delivery system, fluorouracil; fluorouracil Therapeutic Implant; MPI 5011; INTRADOSE-FU	Discontinued		antimetabolite	cancer
drug delivery system, fluorouracil; fluorouracil Therapeutic Adhesive	Preclinical		antimetabolite	cancer
drug delivery system, methotrexate; methotrexate delivery system; HYAL CV1281	Discontinued		antimetabolite	cancer
drug delivery system, sustained release methotrexate; methotrexate DepoFoam	Discontinued		antimetabolite	cancer
fazarabine; arabinosyl-5- azacytosine; ara-AC; NSC 281272	Phase II	4-amino-1-beta-D- arabino furanosyl- 1,3,5-triazin-2(1H)- one	antimetabolite	cancer
fludarabine + chlorambucil; chlorambucil + fludarabine	Discontinued		antimetabolite	cancer

SD-144110.1

folic acid analogue, Glaxo Wellcome	Discontinued	N-alpha-(5-deaza-5,6,7,8-tetrahydropteroyl)-L-ornithine	antimetabolite	cancer
levamisole + fluorouracil; fluorouracil + levamisole	Registered		antimetabolite	cancer
T 506	Discontinued	mono[2-(trimethylammonio)ethyl ester of 2'-deoxy-5-fluoro-5'-uridylic acid 3'-(9-octadecenoate) hydroxide inner salt	antimetabolite	cancer
TAS 102	Phase I		antimetabolite	cancer
tegafur; BMS 20060401; MJF 12264; NSC 148958; DAIYALOSE; FENTAL; FTORAFUR; FTORALON; FURAFLOL; FUTRAFUL; LAMAR; NEBERK; TORAFURIN; UFT	Marketed	5-fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)pyrimidin edione	antimetabolite	cancer
ZYN-LINKER conjugated fluorouracil	Suspended		antimetabolite	cancer

brequinar; brequinar sodium; DUP 785; NSC 368390	Suspended	6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-4-quinolinecarboxylic acid	antimetabolite; immunosuppressant	cancer; autoimmune disease; transplant rejection
ZYN-LINKER conjugated methotrexate	Suspended		antimetabolite; NSAID	cancer; rheumatoid arthritis; psoriasis
cytarabine ocfosfate; phosphate sodium; YNK 01; C18PCA; STARASID	Marketed	4-amino-1-[5-O-[hydroxy(octadecyloxy)phosphinyl]-beta-D-arabinofuranosyl] 2(1H)-pyrimidinone	antimetabolite; nucleoside analogue	cancer
drug delivery system, DepoFoam cytarabine; cytarabine DepoFoam; DTC 101; DepoCyt; SAVEDAR	Marketed		antimetabolite; nucleoside analogue	cancer
nucleotide thio analogues, Oklahoma University	Preclinical		antimetabolite; nucleoside analogue	cancer
LY 207702	Preclinical	2',2'-difluoro-2'-deoxyribofuranosyl-2,6-diaminopurine (dFdAP)	antimetabolite; ribonucleotide reductase inhibitor	cancer
antineoplaston A10	Phase II		antineoplaston; peptide	cancer
antineoplaston AS2-1	Phase II		antineoplaston; peptide	HIV infection; cancer

nitroxide antioxidant, NIH	Preclinical		antioxidant; free radical scavenger; NSAID	respiratory distress syndrome; inflammation; cancer; reperfusion injury
antioxidants, University of California	Preclinical		antioxidant; NSAID	skin disease; inflammation; cancer
naphterpin; CL 190Y2	Preclinical	(4aS-cis)-3,4a,5,12b- tetrahydro-8,10- dihydroxy-2,5,5,9- tetramethyl-4H- benzo[d]naphtho[2,3- b]pyran-7,12-dione	antioxidant; NSAID	diabetes; cardiovascular disease; cancer; inflammation
OS 535	Preclinical		antiplasmin	cancer
LG 1127	Preclinical		antiprogesterone	cancer; endometriosis
LG 1147	Preclinical		antiprogesterone	cancer; endometriosis
LG 1447	Preclinical	1,2-dihydro-2,2,4- trimethyl-6-phenyl- quinoline	antiprogesterone	cancer; endometriosis
mifepristone; RU 486; RU 4866; RU 38486; R 38486; MIFEGYNE	Marketed	(11beta,17beta)-11- [4- (dimethylamino)phen yl]-17-hydroxy-17-(1- propynyl)estra-4,9- dien-3-one	antiprogesterone	abortion; cancer; contraception

onapristone; ZK 98299; SH 549; ZK 299	Discontinued	(11beta,13alpha,17alpha)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)estra-4,9-dien-3-one	antiprogesterone	cancer; contraception
ORG 31710	Discontinued	(6beta,11beta,17beta)-11-[4-(dimethylamino)phenyl]-4',5'-dihydro-6-methyl-spiro[estra-4,9-diene-17,2'(3'H)-furan]-3-one	antiprogesterone	cancer
ORG 31806	Discontinued	(7beta,11beta,17beta)-11-[4-(dimethylamino)phenyl]-4',5'-dihydro-7-methyl-spiro[estra-4,9-diene-17,2'(3'H)-furan]-3-one	antiprogesterone	cancer
ORG 33245	Discontinued		antiprogesterone	cancer; abortion
ORG 33628	Discontinued	(11beta,17alpha)-11-(4-acetylphenyl)-17,23-epoxy-19,24-dinorchola-4,9,20-trien-3-one	antiprogesterone	cancer
ORG 33832	Discontinued		antiprogesterone	cancer; abortion
RU 46556	Discontinued	(11beta,17beta)-11-[4-(methylthio)phenyl]spiro[estra-4,9-diene-17,2'(5H)-furan]-3-one	antiprogesterone	cancer; endometriosis; labor induction

RU 49295	Discontinued	(11beta,17beta)-11-(4-acetylphenyl)spiro[estra-4,9-diene-17,2'(5'H)-furan]-3-one	antiprogesterone	cancer; endometriosis
SH 207	Phase I		antiprogesterone	cancer
ZK 112993	Discontinued	(11beta,17beta)-11-(4-acetylphenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one	antiprogesterone	cancer
ZK 136798	Discontinued	4-[[[11alpha,17beta,17(Z)-9,11-dihydro-17-hydroxy-17-(3-propenyl)-3-oxo-4'Hnaphth[3',2':1',10',9,11]estra-4,9(11)-dien-6'-yl]benzonitrile	antiprogesterone	cancer
21-substituted progesterone derivatives, NIH	Preclinical		antiprogesterone; hormone replacement therapy	endometriosis; labor induction; hormone deficiency; cancer
topsentin; topsentine; topsentin B1; topsentine B1	Preclinical	(6-hydroxy-1H-indol-3-yl)[4-(1H-indol-3-yl)-1H-imidazol-2-yl]methanone	antiproliferative agent	cancer

carboxamidotriazole ; CAI; NSC 609974; L 651582	Phase I	5-amino-1-[[3,5- dichloro-4-(4- chlorobenzyl)phenyl] methyl]-1H-1,2,3- triazole-4- carboxamide	antiproliferative agent; cancer imidazole	
antisense oligonucleotide, BCL-X	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotide, c-fos	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotide, c-jun	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotide, calcium binding protein in placenta; antisense oligonucleotide, CAPL	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotide, DNA methyltransferase; MG 98	Phase I		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotide, Epstein Barr virus; antisense oligonucleotide, EBV	Preclinical		antisense; oligonucleotide; biotechnology	cancer

antisense oligonucleotide, jun kinase-1	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotide, transforming growth factor beta; antisense oligonucleotide, TGF- beta; antisense oligonucleotide, cancer	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotides, basic fibroblast growth factor	Preclinical		antisense; oligonucleotide; biotechnology	cancer
oligonucleotides, cancer, Children's Hospital of Orange County	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotide, multiple drug resistance	Preclinical		antisense; oligonucleotide; biotechnology; mRNA translation inhibitor	cancer
anticancer agents, OSI/Pfizer	Preclinical		apoptosis inducer	cancer
apoptosis inhibitors, Oxford Asymmetry/LXR Biotechnology	Preclinical		apoptosis inducer	cancer; cardiac therapy; transplant rejection; gastrointestinal disorder

breast cancer therapy, Temple University; breast cancer therapy, Alliance	Preclinical		apoptosis inducer	cancer
C 857	Preclinical	2-[(1-nitro-9- acridinyl)amino]ethan- ol monohydrochloride	apoptosis inducer	cancer
cancer therapy, Axiom Biotechnologies/Zaiy a	Preclinical		apoptosis inducer	cancer
cancer therapy, BioChem Pharma/ImmunoGen	Preclinical		apoptosis inducer	cancer
cancer therapy, Hitachi; cancer therapy, Nippon Chemiphar	Phase I		apoptosis inducer	cancer
cancer therapy, Idun/Abbott	Preclinical		apoptosis inducer	cancer
cancer therapy, Rigel	Preclinical		apoptosis inducer	cancer
DDE 313	Preclinical		apoptosis inducer	cancer
Fas modulators, Menarini	Preclinical		apoptosis inducer	cancer
K 22175; K22.175	Preclinical		apoptosis inducer	cancer
ONCODON	Preclinical		apoptosis inducer	cancer
small cell lung carcinoma therapy, Cadus	Preclinical		apoptosis inducer	cancer
E2F inhibitors, Prolifix	Preclinical		apoptosis inducer; antiproliferative agent	cancer; psoriasis; viral infection; restenosis

apoptosis inducer, IDUN	Preclinical		apoptosis inducer; caspase inhibitor	cancer
CP 461	Phase I		apoptosis inducer; phosphodiesterase inhibitor	cancer
exisulind; FGN 1; PREVATAC	Phase III	(1Z)-5-fluoro-2- methyl-1-[[4- (methylsulfonyl)phen- yl]methylene]-1H - indene-3-acetic acid	apoptosis inducer; phosphodiesterase inhibitor	cancer
apoptosis inhibitor, Biota	Discontinued		apoptosis inhibitor	cancer
apoptosis modulators, University of Colorado	Preclinical		apoptosis inhibitor; apoptosis inducer	cancer; autoimmune disease; neurodegeneration
anastrozole; ZD 1033; ICI D1033; ARIMIDEX	Marketed	alpha, alpha, alpha', alp ha'-tetramethyl-5- (1H-1,2,4-triazol-1- ylmethyl)-1,3- benzenediacetonitrile	aromatase inhibitor	cancer
aromatase inhibitor, Menarini	Preclinical		aromatase inhibitor	cancer
aromatase inhibitor, Merrell Dow	Discontinued	19-acetylenic- androstenedione	aromatase inhibitor	cancer
aromatase inhibitors, Washington Research Foundation	Preclinical		aromatase inhibitor	cancer
atamestane; SH 489; ZK 95639	Discontinued	1-methylandrosta-1,4- diene-3,17-dione	aromatase inhibitor	cancer; benign prostate hypertrophy
CGP 47645	Discontinued		aromatase inhibitor	cancer

CGS 18320B; CGS 18320	Discontinued	4,4'-(1H-imidazol-1-ylmethylene)bis(benzonitrile) compound with butanedioic acid (2:1)	aromatase inhibitor	cancer
dexamethasone; D 3967	Phase III	3-(4-aminophenyl)-3-ethyl-2,6-piperidinedione	aromatase inhibitor	cancer
exemestane; FCE 24304; PNU 971; ONC 0028; AROMASIN	Pre-registration	6-methyleneandrost-1,4-diene-3,17-dione	aromatase inhibitor	cancer
fadrozole; CGS 16949A; AFEMA	Marketed	4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile	aromatase inhibitor	cancer
formestane; CGP 32349; AT 0931; LENTARON; LENTARE	Marketed	4-hydroxyandrostene-3,17-dione	aromatase inhibitor	cancer
letrozole; CGS 20267; FEMARA	Marketed	4,4'-(1H-1,2,4-triazol-1-ylmethylene)bisbenzonitrile	aromatase inhibitor	cancer
minamestane; FCE 24928	Discontinued	4-aminoandrost-1,4,6-triene-3,17-dione	aromatase inhibitor	cancer
MPV 2213; MPV 2213ad	Phase I	4-[3-(4-fluorophenyl)-2-hydroxy-1-(1H-1,2,4-triazol-1-yl)propyl]benzonitrile	aromatase inhibitor	cancer; benign prostate hypertrophy

NKS 01	Discontinued	14alpha-hydroxy-4-androstene-3,6,17-trione	aromatase inhibitor	cancer
ORG 30958	Discontinued	19-(ethylidithio)androst-4-ene-3,17-dione	aromatase inhibitor	cancer
ORG 33201	Discontinued	(3alphaR)-trans-1-[(3alpha-ethyl-9-(ethylthio)-2,3,3alpha,4,5,6-hexahydro-1H-phenalen-2-yl)-methyl]-1H-imidazole HCl	aromatase inhibitor	cancer; endometriosis
pentrozole; SH 582; ZK 154065	Preclinical	17-[(1-oxohexyl)oxy]-19-norpregn-4-ene-3,20-dione	aromatase inhibitor	cancer
rogletimide; pyridoglutethimide	Discontinued	(+,-)-3-ethyl-3-(4-pyridinyl)-2,6-piperidinedione	aromatase inhibitor	cancer
RU 54115	Discontinued	10-[2-(methylthio)ethyl]estra-4,9(11)-diene-3,17-dione	aromatase inhibitor	cancer; endometriosis
SAE 9	Discontinued		aromatase inhibitor	cancer
TAN 931	Preclinical	4-(2,6-dihydroxybenzoyl)-3-formyl-5-hydroxybenzoic acid	aromatase inhibitor	cancer

vorozole; R 76713; R 83842; JK 201; RIVIZOR	Phase III	6-[(4-chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl]-1-methyl-1H-benzotriazole	aromatase inhibitor	cancer
YM 511	Phase II	4-[[[(4-bromophenyl)methyl]-4H-1,2,4-triazol-4-ylamino]benzonitrile	aromatase inhibitor	cancer; endometriosis
YM 553	Preclinical	4-[[[(3,5-difluorophenyl)methyl]-5-pyrimidinylamino]benzonitrile	aromatase inhibitor	cancer
sparfosic acid; sparfosate sodium; PALA; platinum complex; CI 882; NSC 224131; Pt 268; NSC 328005	Phase III	N-(phosphonoacetyl)-L-aspartic acid, disodium salt	aspartate transcarbamylase inhibitor	cancer; viral infection
AV 04	Discontinued		azaanthraquinone	cancer
AV 17	Discontinued		azaanthraquinone	cancer
AV 38	Discontinued		azaanthraquinone	cancer
AV 43	Discontinued		azaanthraquinone	cancer
AV 57	Discontinued	6,9-dihydro-4-methyl-6-(2-nitrophenyl)-pyrido[3,2-g]quinoline-2,5,10(1H)-trione	azaanthraquinone	cancer
AV 61	Discontinued		azaanthraquinone	cancer
AV 66	Discontinued		azaanthraquinone	cancer
AV 80	Discontinued		azaanthraquinone	cancer

ImuVert	Discontinued			biological response modifier	cancer
ONO 4005	Discontinued			biological response modifier	cancer
ONO 4007	Phase II	(S)-2-deoxy-2-[[1-oxo-3-[1-oxo-9-phenylonyloxy]tetradecyl]amino-D-glucose, 3-benzenenonanoate 4-(hydrogensulfate), monosodium salt.		biological response modifier	cancer
VIRULIZIN	Registered			biological response modifier	cancer
RS 83277	Discontinued			biological response modifier; peptide	cancer
adiposin; lipotropin	Preclinical			biotechnology	obesity; cancer
alpha mutein; mutein, Preclinical alpha; HT 003	Preclinical			biotechnology	cancer
anticancer oligonucleotides, MicroProbe	Preclinical			biotechnology	cancer
ATF HI 8	Preclinical			biotechnology	cancer
B 2036PEG; PEG-B 2036; TROVERT	Phase II			biotechnology	cancer
cancer immunotherapy, MedImmune	Discontinued			biotechnology	retinopathy; acromegaly; cancer; diabetes; kidney disease
				biotechnology	cancer

cancer therapy, University Technologies International	Preclinical		biotechnology	cancer
cell lysis factor, Texas University	Preclinical		biotechnology	cancer
colon cancer therapy, Axis Genetics	Preclinical		biotechnology	cancer
cytolytic factor; CF	Preclinical		biotechnology	cancer
DCC tumor suppressor gene	Preclinical		biotechnology	cancer
drug delivery system, HIT breast cancer	Preclinical		biotechnology	cancer
drug delivery system, ONYX 015; ONYX 015, viraMASC coating; ONYX 015	Preclinical		biotechnology	cancer
drug delivery system, ONYX 838; ONYX 838, viraMASC coating	Preclinical		biotechnology	cancer
G 207	Phase I		biotechnology	cancer
gene discovery, hereditary glioma, Myriad	Preclinical		biotechnology	cancer
gene discovery, leukemia, Myriad	Preclinical		biotechnology	cancer
gene discovery, lung cancer, Myriad	Preclinical		biotechnology	cancer
gene therapy, anti-erbB-2 single chain	Preclinical		biotechnology	cancer

gene therapy, antisense insulin-like growth factor-1; gene therapy, antisense IGF-1	Phase I		biotechnology	cancer
gene therapy, breast cancer; gene therapy, brcal, MB 200	Preclinical		biotechnology	cancer
gene therapy, interleukin-2	Preclinical		biotechnology	cancer
HER-2/neu oncogene protein	Discontinued		biotechnology	cancer
HGF/NK1	Preclinical		biotechnology	cancer
hPRL G129R	Preclinical		biotechnology	cancer
HSV 1716	Phase I		biotechnology	cancer
human chorionic gonadotropin; hCG; OVIDREL	Phase III		biotechnology	infertility; cancer
IL-2 analogue; INGN 301; F42K	Preclinical		biotechnology	cancer
iroplact; platelet factor 4; PF4; endostatin B; REPLISTATIN	Phase II		biotechnology	heparin neutralization; psoriasis; HIV infection; cancer; diabetes
mismatched double stranded RNA; poly(I)poly(C(sub12)U); AMPLIGEN	Pre-registration		biotechnology	allergy; viral infection; blood clotting disorder; cancer; chronic fatigue syndrome
neu differentiation factor; NDF	Discontinued		biotechnology	cancer
NV 1020	Preclinical		biotechnology	cancer

SD-144110.1

ONYX 015	Phase II				
osteoprotegerin; OPG	Phase I				cancer
p53 gene	Preclinical			biotechnology	osteoporosis; cancer
prostate cancer therapy, Axis Genetics	Preclinical			biotechnology	cancer
protein replacement therapy, retinoblastoma protein; protein replacement therapy, Rb protein	Preclinical			biotechnology	cancer
Salmonella typhimurium, mutagenized; mutagenized S typhimurium	Preclinical			biotechnology	cancer
single chain antigen binding protein; SCA	Preclinical			biotechnology	diagnosis; cancer
transcription factor, GM-CSF	Preclinical			biotechnology	cancer
urogenital sinus-derived growth inhibitory factor; UGIF; ps20	Preclinical			biotechnology	cancer; benign prostate hypertrophy
vaccine, beta-human chorionic gonadotrophin, Vaxcel; vaccine, cancer	Preclinical			biotechnology	cancer
vaccine, cancer, Ludwig Institute/SIGA	Preclinical			biotechnology	cancer

SD-144110.1

vaccine, non-Hodgkin's B cell lymphoma	Preclinical		biotechnology	cancer
verotoxin	Preclinical		biotechnology	cancer
angiogenesis inhibitor, Genzyme	Preclinical		biotechnology; angiogenesis inhibitor	cancer
angiopoietin 2	Preclinical		biotechnology; angiogenesis inhibitor	cancer
ANGIOSTATIN	Preclinical		biotechnology; angiogenesis inhibitor	retinopathy; cancer
BST 2001; ANGIOCOL	Preclinical		biotechnology; angiogenesis inhibitor	cancer
gene therapy, endostatin	Preclinical		biotechnology; angiogenesis inhibitor	cancer
Del-1 angiogenic protein based therapies	Preclinical		biotechnology; angiogenesis inhibitor; angiogenesis inducer	cancer; ischemia; restenosis
drug delivery system, TCS, antisense oligonucleotide, VEGFR; antisense oligonucleotide, VEGFR, TCS	Preclinical		biotechnology; angiogenesis inhibitor; antisense; oligonucleotide	cancer
BST 2002	Preclinical		biotechnology; angiogenesis inhibitor; peptide	cancer
antisense oligonucleotide, -myb; LR 3001; INX 3001	Phase I		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, c-kit	Preclinical		biotechnology; antisense; oligonucleotide	cancer

SD-144110.1

antisense oligonucleotide, c- myb	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, cancer, Enzo	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, cancer, INSERM	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, chimeric 2-5A, chronic myelogenous leukemia	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, chronic myelogenous leukemia; RGA 1512	Discontinued		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, epidermal growth factor receptor; antisense oligonucleotide, EGFR	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, insulin-like growth factor-1 receptor; antisense oligonucleotide, IGF- 1R; INX 4437	Phase I		biotechnology; antisense; oligonucleotide	cancer

antisense oligonucleotide, mdm2	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, multi-drug resistance protein-1; antisense oligonucleotide, MDR-1	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, myelogenous leukemia; GT 1102	Discontinued		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, myelogenous leukemia; GT 1106	Discontinued		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, p120; ISIS 3466	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, phospholipase A2; antisense oligonucleotide, PLA2	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, protein kinase A; GEM 231	Phase II		biotechnology; antisense; oligonucleotide	cancer

antisense oligonucleotide, protein kinase C- alpha; antisense oligonucleotide, cancer; ISIS 3521; CGP 64128A; ISI 641A	Phase II		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, protein kinase type I; antisense oligonucleotide; PKA-I	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, tumor necrosis factor; AR 797	Discontinued		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, vascular endothelial growth factor; AR 639	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, vascular endothelial growth factor; antisense oligonucleotide, VEGF; GEM 220	Preclinical		biotechnology; antisense; oligonucleotide	retinopathy; cancer; skin disease
antisense oligonucleotides, cancer, Matritech	Discontinued		biotechnology; antisense; oligonucleotide	cancer

antisense oligonucleotides, human papillomavirus 16/18; antisense oligonucleotides, HPV 16/18	Preclinical		biotechnology; antisense; oligonucleotide	cancer; viral infection
antisense oligonucleotides, multi-drug resistance protein; antisense oligonucleotides, MRP	Preclinical		biotechnology; antisense; oligonucleotide	cancer
drug delivery system, antisense oligonucleotide, erbB-2	Preclinical		biotechnology; antisense; oligonucleotide	cancer
drug delivery system, antisense oligonucleotide, p27	Preclinical		biotechnology; antisense; oligonucleotide	cancer
drug delivery system, TCS antisense oligonucleotide, c- myb; antisense oligonucleotide, TCS c-myb; INX 3000, TCS	Preclinical		biotechnology; antisense; oligonucleotide	cancer
drug delivery system, TCS INX 3280; INX 3280 TCS; INXC 6295	Preclinical		biotechnology; antisense; oligonucleotide	cancer

drug delivery system, TCS, antisense oligonucleotide, IGF-1R; antisense oligonucleotide, IGF-1R, TCS; INX 4437, TCS	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, bcl-2; G 3139	Phase II		biotechnology; antisense; oligonucleotide; chemosensitizer	cancer
antisense oligonucleotide, raf-1, Neopharm; drug delivery system, antisense oligonucleotide, raf-1, Neopharm	Preclinical		biotechnology; antisense; oligonucleotide; radiosensitizer	cancer
antisense oligonucleotide, p65 NF-kappaB	Preclinical		biotechnology; antisense; oligonucleotide; transcription factor regulator	cancer
tumor necrosis factor apoptosis inducing ligand; TRAIL	Preclinical		biotechnology; apoptosis inducer	cancer
secreted apoptosis related proteins; SARPS	Preclinical		biotechnology; apoptosis inducer; apoptosis inhibitor	cancer; myocardial infarction; stroke
keratinocyte growth factor antagonist, NeXstar; KGF antagonist	Preclinical		biotechnology; aptamer; oligonucleotide	cancer

PDGF antagonist, NeXstar	Preclinical		biotechnology; aptamer; oligonucleotide	cancer
TGF-beta antagonist, NeXstar	Preclinical		biotechnology; aptamer; oligonucleotide	cancer
NX 1838	Phase I		biotechnology; aptamer; oligonucleotide; angiogenesis inhibitor	cancer; diabetes; retinopathy
MIG	Preclinical		biotechnology; chemokine; angiogenesis inhibitor	cancer
somatomedin binding protein; insulin-like growth factor binding protein; IGF BP-1	Suspended		biotechnology; cicatrizant	skin ulcer; cancer
interleukin-1 beta; IL- 1 beta	Discontinued		biotechnology; cicatrizant; cytokine; vaccine adjuvant	cancer; infectious disease
avotermine; transforming growth factor beta-3; TGF beta-3; CGP 46614	Phase II	transforming growth factor beta3 (human), dimer	biotechnology; cicatrizant; growth factor	cancer; skin ulcer; mucositis
tumor growth factor- alpha; TGF-alpha	Discontinued		biotechnology; cicatrizant; growth factor	eye disease; cancer; skin ulcer
fibroblast anticollagenase; FIBAC; anticollagenase fibroblast	Suspended		biotechnology; cicatrizant; NSAID	arthritis; cancer; skin ulcer; arthritis

tissue inhibitor of metalloproteinase 2; TIMP-2	Discontinued		biotechnology; collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; gene	cancer
BC 1; AS 122; AngioMab	Phase I		biotechnology; contrast medium; monoclonal antibody; radiotherapeutic; radiodiagnostic; angiogenesis inhibitor	cancer; diagnosis
senescence derived inhibitor 1; Sdi 1	Discontinued		biotechnology; cyclin dependent kinase inhibitor	cancer; psoriasis; eye disease; cancer
multiple tumor suppressor 1-based therapy	Preclinical		biotechnology; cyclin dependent kinase inhibitor; gene	cancer
AR 324	Discontinued		biotechnology; cytokine	cancer
canarypox IL-2; ALVAC-hIL-2	Phase II		biotechnology; cytokine	cancer
drug delivery system, interleukin secreting implant; interleukin secreting implant	Preclinical		biotechnology; cytokine	cancer
IL-2 conjugate, Ajinomoto; Gal3 modified IL-2	Preclinical		biotechnology; cytokine	cancer

interleukin-3/interleukin-6 mutein chimeric molecule; IL-3/IL-6 m chimeric molecule	Suspended		biotechnology; cytokine	cancer; thrombocytopenia
interleukin-6; IL-6	Suspended		biotechnology; cytokine	cancer
interleukin-6; IL-6; SDZ ILS 969; ILS 969	Discontinued		biotechnology; cytokine	cancer; thrombocytopenia; leukopenia
interleukin-6; IL-6; SIGOSIX	Phase II		biotechnology; cytokine	cancer; thrombocytopenia
interleukin-6 mutein; IL-6 mutein; FCE 27809	Phase I		biotechnology; cytokine	cancer; thrombocytopenia
magrestipen; magrestip; BB 10010; MIP-1alpha	Discontinued	(human clone pAT464 macrophage inflammatory reduced), 26-L-alanine-lymphokine MIP 1alpha	biotechnology; cytokine	cancer; HIV infection
SC 68420; MPO 1	Discontinued		biotechnology; cytokine	cancer
sonermin; tumor necrosis factor; TNF; PT 050; TIENEF; TINEF	Discontinued	3-157-tumor necrosis factor (human)	biotechnology; cytokine	cancer
sonermin; tumor necrosis factor; TNF; PAC 4D	Pre-registration	3-157-tumor necrosis factor (human)	biotechnology; cytokine	cancer; psoriasis

tasonermin; tumor necrosis factor alpha; TNF-alpha; FK 516; BEROMUN	Registered		biotechnology; cytokine	cancer
tumor necrosis factor; TNF	Discontinued		biotechnology; cytokine	cancer
tumor necrosis factor; TNF	Discontinued		biotechnology; cytokine	cancer
tumor necrosis factor alpha; TNF-alpha	Preclinical		biotechnology; cytokine	cancer
tumor necrosis factor alpha tip mutants; TNF-alpha tip mutants	Discontinued		biotechnology; cytokine	cancer
gene therapy, IL-12; gene therapy, cancer	Preclinical		biotechnology; cytokine; gene therapy; biotechnology; immunostimulant	cancer
gene therapy, interferon-alpha; gene therapy, cancer	Phase II		biotechnology; cytokine; gene therapy; immunostimulant; interferon	cancer

daniplestim; interleukin-3 synthokine; IL-3 synthokine; SC 55494	Discontinued	14-ala-18-ile-25-his- 29-arg-32-asn-37-pro- 42-ser-45-met-51-arg- 55-thr-59-leu-62-val- 67-his-69-glu-73-gly- 76-ala-79-arg-82-gln- 87-ser-93-ser-98-ile- 101-ala-105-gln-109- glu-116-val-120-gln- 123-glu-14-125- interleukin 3 (human clone D11)	biotechnology; cytokine; growth factor	cancer
IL-6/IL-2 fusion protein	Preclinical		biotechnology; cytokine; growth factor; hematopoietic factor	cancer
interleukin-6; IL-6; BETATROPIN	Suspended		biotechnology; cytokine; growth factor; hematopoietic factor	cancer; thrombocytopenia
aldestleukin; interleukin-2; IL-2; PROLEUKIN	Marketed	125-L-serine-2-133- interleukin 2 (human reduced)	biotechnology; cytokine; immunostimulant	cancer; HIV infection
cancer therapy, monkey vero cell line secreting IL-2; vero- IL2	Phase II		biotechnology; cytokine; immunostimulant	cancer

celmoleukin; interleukin-2; IL-2; TAKELEUKIN; CELEUK	Marketed	A-P-T-S-S-S-T-K-K- T-Q-L-Q-L-E-H-L-L- L-D-L-Q-M-I-L-N-G- I-N-N-Y-K-N-P-K-L- T-R-M-L-T-F-K-F-Y- M-P-K-K-A-T-E-L- K-H-L-Q-C-L-E-E-E- L-K-P-L-E-E-V-L-N- L-A-Q-S-K-N-F-H-L- R-P-R-D-L-I-S-N-I- N-V-I-V-L-E-L-K-G- S-E-T-T-F-M-C-E-Y- A-D-E-T-A-T-I-V-E- F-L-N-R-W-I-T-F-C- Q-S-I-S-T-L-T	biotechnology; cytokine; immunostimulant	viral infection; cancer
drug delivery system, aldesteukin; drug delivery system, interleukin-2; aldesteukin DepoFoam	Discontinued		biotechnology; cytokine; immunostimulant	cancer; HIV infection
drug delivery system, interleukin-2; interleukin-2 delivery system; drug delivery system, IL-2	Discontinued		biotechnology; cytokine; immunostimulant	viral infection; cancer
drug delivery system, liposome interleukin- 2; interleukin-2 liposome; OTx 287; OncoLipin-2; OncoLipin	Phase II		biotechnology; cytokine; immunostimulant	cancer

interferon alfa-N1; IFN alfa-N1; WELLFERON; SUMIFERON; HUMOFERON	Marketed		biotechnology; cytokine; immunostimulant	cancer; viral infection
interleukin-1; IL-1	Discontinued		biotechnology; cytokine; immunostimulant	cancer
interleukin-1 alpha; IL-1a	Discontinued		biotechnology; cytokine; immunostimulant	cancer
interleukin-1 alpha derivative; OCT 7000	Suspended		biotechnology; cytokine; immunostimulant	cancer
interleukin-1 beta; IL-1 beta; OCT 43; OCTIN	Pre- registration		biotechnology; cytokine; immunostimulant	cancer
interleukin-2; IL-2	Suspended		biotechnology; cytokine; immunostimulant	cancer
interleukin-2; IL-2; NSC 600664; LEUFERON 2	Phase III		biotechnology; cytokine; immunostimulant	cancer
interleukin-2; IL-2	Discontinued		biotechnology; cytokine; immunostimulant	cancer
interleukin-5; IL-5	Discontinued		biotechnology; cytokine; immunostimulant	cancer
interleukin-6; IL-6	Suspended		biotechnology; cytokine; immunostimulant	cancer

interleukin-7; IL-7	Preclinical		biotechnology; cytokine; immunostimulant	cancer
mitoflaxone + interleukin-1; interleukin-1 + mitoflaxone	Discontinued		biotechnology; cytokine; immunostimulant	cancer
oprelvekin; interleukin-11; IL-11; YM 294; NEUMEGA	Marketed		biotechnology; cytokine; immunostimulant	cancer; HIV infection; mucositis; Crohn disease
polyethylene glycol interleukin 2; PEG IL-2; interleukin 2 macrogol	Phase II		biotechnology; cytokine; immunostimulant	HIV infection; cancer
SC 71858; PMP	Phase I		biotechnology; cytokine; immunostimulant	cancer
interleukin-1 beta; IL-1 beta	Preclinical		biotechnology; cytokine; immunostimulant; cicatrizant	cancer; skin ulcer
interleukin-3; IL-3; ALLEVORIN	Suspended		biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer
interleukin-3; IL-3	Discontinued		biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer

interleukin-3; IL-3	Phase I		biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer; leukopenia
leridistim; SC 70935; MPO	Phase III		biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer
muplestim; interleukin-3; IL-3; SDZ ILE964; ILE 964; HEMOKINE	Phase III	human interleukin 3	biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer; thrombocytopenia; leukopenia
drug delivery system, ProLease interferon alfa; interferon alfa ProLease	Discontinued		biotechnology; cytokine; immunostimulant; interferon	viral infection; cancer
MAB, ch14.18-IL-2 fusion protein	Preclinical		biotechnology; cytokine; immunostimulant; monoclonal antibody	cancer
interleukin-4; IL-4; SCH 39400; QUADRAKINE	Phase II		biotechnology; cytokine; immunostimulant; NSAID	cancer; viral infection; rheumatoid arthritis
interleukin-12; IL-12; natural killer cell stimulatory factor; NKSF; YM 01C	Phase II		biotechnology; cytokine; immunostimulant; vaccine adjuvant	viral infection; cancer

interleukin-1 deletion mutants	Preclinical		biotechnology; cytokine; vaccine adjuvant; radioprotectant; immunostimulant	cancer; infectious disease
antisense oligonucleotide, cancer; DNA binding antisense oligonucleotide	Preclinical		biotechnology; DNA transcription inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, epidermal growth factor receptor; triple helix oligonucleotide, EGFR; T 03101	Discontinued		biotechnology; DNA transcription inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, her-2; triple helix oligonucleotide, her-2	Discontinued		biotechnology; DNA transcription inhibitor; antisense; oligonucleotide	cancer
sense oligonucleotide, NF-kappaB decoy	Discontinued		biotechnology; DNA transcription inhibitor; oligonucleotide; transcription factor regulator	cancer; viral infection
methioninase; AC 9301; ONCase	Preclinical		biotechnology; enzyme	cancer

acidic fibroblast growth factor-Pseudomonas exotoxin fusion protein; aFGF-Pseudomonas exotoxin fusion protein	Discontinued		biotechnology; fusion toxin	cancer
DWP 408	Preclinical		biotechnology; fusion toxin	cancer
epidermal growth factor diphtheria toxin chimeric protein; EGF diphtheria toxin chimeric protein; EGF fusion protein; DAB 389-EGF; DAB 389-EGF	Phase II		biotechnology; fusion toxin	cancer; restenosis; psoriasis
fusion toxin, interleukin-13 fusion protein; hLL13.E13K-PE4E	Preclinical		biotechnology; fusion toxin	cancer
GM-CSF diphtheria toxin chimeric protein; DT388 GM-CSF	Discontinued		biotechnology; fusion toxin	cancer
heregulin-Pseudomonas exotoxin fusion protein	Preclinical		biotechnology; fusion toxin	cancer

IL-4 fusion toxin; IL-4(38-37)-PE38KDEL; interleukin-4 fusion toxin; NBI 3001	Phase II		biotechnology; fusion toxin	cancer
IL13-PE38QQR; interleukin-13/pseudomonas exotoxin derivative	Preclinical		biotechnology; fusion toxin	cancer
interleukin-4-pseudomonas exotoxin A; IL-4-PE	Preclinical		biotechnology; fusion toxin	cancer
interleukin-6 diphtheria toxin chimeric protein; IL-6 diphtheria toxin chimeric protein; IL-6 fusion protein	Preclinical		biotechnology; fusion toxin	HIV infection; cancer
interleukin-6-Pseudomonas exotoxin 40 chimeric protein; IL-6-PE40	Preclinical		biotechnology; fusion toxin	cancer
interleukin-6-Pseudomonas exotoxin 66(4Glu) chimeric protein; IL-6-PE66(4Glu)	Preclinical		biotechnology; fusion toxin	cancer
melanocyte stimulating hormone diphtheria toxin chimeric protein; MSH diphtheria toxin chimeric protein; MSH fusion protein	Preclinical		biotechnology; fusion toxin	cancer

mitotoxin fibroblast growth factor-saporin; mitotoxin, FGF-saporin; PANTARIN	Discontinued		biotechnology; fusion toxin	cancer; restenosis; eye disease
TGFalpha-PE38; TGFalpha PE38 fusion toxin	Preclinical		biotechnology; fusion toxin	cancer
transferrin-CRM107; transferrin-toxin; HN 66000	Phase II		biotechnology; fusion toxin	cancer
transforming growth factor alpha-Pseudomonas exotoxin 40 chimeric protein; TGF alpha-PE40; TGFa-PE40	Preclinical		biotechnology; fusion toxin	cancer
interleukin-4 diphtheria toxin chimeric protein; IL-4 diphtheria toxin chimeric protein; IL-4 fusion protein	Preclinical		biotechnology; fusion toxin; immunosuppressant	autoimmune disease; transplant rejection; cancer; HIV infection
denileukin difitox; interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion protein; DAB 389-IL-2; LY 335348; DAB389IL2; ONTAK	Marketed	1-388-toxin (Corynebacterium diphtheriae strain C7), N-L-methionyl-387-L-histidine-388-L-alanine, (388.fwdarw.2')-protein with 2-133-interleukin 2 (human clone pTIL2-21a)	biotechnology; fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; psoriasis; cancer

interleukin-2 diphtheria toxin; chimeric protein; interleukin-2 fusion toxin; IL-2 fusion toxin; DAB 486-IL-2; D-IL-2	Discontinued		biotechnology; fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; cancer
cancer therapy, int6	Preclinical		biotechnology; gene	cancer
cancer therapy, tumor suppressor, University Technologies International	Preclinical		biotechnology; gene	cancer; diagnosis
melastatin	Preclinical		biotechnology; gene	cancer
BRUSH-1 gene based therapy; cancer therapy	Preclinical		biotechnology; gene therapy	cancer
cancer therapy, modified adenovirus, Onyx; ONYX 838	Preclinical		biotechnology; gene therapy	cancer
gene therapy, adenoviral herpes simplex virus thymidine kinase; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, anti- metastasis technology	Clinicals		biotechnology; gene therapy	cancer
gene therapy, anti- cancer stem cell; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer

gene therapy, anticancer T cell; gene therapy, CC49; CC 49	Phase II		biotechnology; gene therapy	cancer
gene therapy, antisense c-myc; gene therapy, prostate cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, Bcl-xS, cancer, IDUN	Preclinical		biotechnology; gene therapy	cancer
gene therapy, BCR-ABL transcription inhibitor protein	Preclinical		biotechnology; gene therapy	cancer
gene therapy, bcral, Vanderbilt University	Phase II		biotechnology; gene therapy	cancer
gene therapy, breast cancer; gene therapy, bcral, MB 300	Preclinical		biotechnology; gene therapy	cancer
gene therapy, breast cancer, Bavarian Nordic Research Institute; Procon CYP2B1	Preclinical		biotechnology; gene therapy	cancer
gene therapy, c-fos; gene therapy, cancer	Phase I		biotechnology; gene therapy	cancer
gene therapy, cancer; GENECEUTICALS	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cancer; gene therapy, T-body	Discontinued		biotechnology; gene therapy	cancer
gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer

gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cancer; gene therapy, cationic lipid vectors	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cancer; gene therapy, immunostimulatory genes	Phase II		biotechnology; gene therapy	cancer
gene therapy, cancer, Copernicus Gene Systems	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cancer, Vion	Preclinical		biotechnology; gene therapy	cancer
gene therapy, chronic myelogenous leukemia	Phase I		biotechnology; gene therapy	cancer
gene therapy, CIITA; gene therapy, MHC class II deficiency	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cytosine deaminase	Phase I		biotechnology; gene therapy	cancer
gene therapy, cytotoxic T cells; gene therapy, cancer	Suspended		biotechnology; gene therapy	cancer
gene therapy, del-1; gene therapy, vascular disease; del-1	Preclinical		biotechnology; gene therapy	coronary artery disease; peripheral vascular disease; cancer
gene therapy, delta-like protein	Preclinical		biotechnology; gene therapy	cancer
gene therapy, drug activation	Preclinical		biotechnology; gene therapy	cancer

SD-144110.1

gene therapy, E1A repressor; gene therapy, cancer; RGG 0853; RGA 0853; tgDCC-E1A	Phase II		biotechnology; gene therapy	cancer
gene therapy, Egr-1 + TNF-alpha; gene therapy, Ad5.Egr-TNF; gene therapy, radiation-controlled technology	Preclinical		biotechnology; gene therapy	cancer
gene therapy, ErbB2-R; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, fas ligand; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, fas deltaTM; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, G156A MGMT; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, glioblastoma; G207	Preclinical		biotechnology; gene therapy	cancer
gene therapy, glioma	Discontinued		biotechnology; gene therapy	cancer
gene therapy, GM-CSF	Preclinical		biotechnology; gene therapy	cancer
gene therapy, H-Nuc	Preclinical		biotechnology; gene therapy	cancer
gene therapy, H19; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer

SD-144110.1

gene therapy, herpes simplex thymidine kinase	Phase I		biotechnology; gene therapy	cancer
gene therapy, herpes simplex tyrosine kinase; gene therapy HS-tk	Preclinical		biotechnology; gene therapy	cancer
gene therapy, HLA-B7; gene therapy, melanoma	Preclinical		biotechnology; gene therapy	cancer
gene therapy, human papillomavirus; gene therapy, HPV	Preclinical		biotechnology; gene therapy	cancer
gene therapy, IL-12 fusion protein	Preclinical		biotechnology; gene therapy	cancer; viral infection
gene therapy, interleukin-2; AdCAIL-2	Phase I		biotechnology; gene therapy	cancer
gene therapy, interleukin-7	Discontinued		biotechnology; gene therapy	cancer
gene therapy, LelF	Discontinued		biotechnology; gene therapy	cancer
gene therapy, leukemia, Novartis; GVH 313	Phase I		biotechnology; gene therapy	cancer
gene therapy, macrophage colony-stimulating factor	Preclinical		biotechnology; gene therapy	cancer
gene therapy, mda-7; gene therapy, melanoma	Preclinical		biotechnology; gene therapy	cancer

gene therapy, MDR-1; gene therapy, cancer	Phase I		biotechnology; gene therapy	cancer
gene therapy, men1; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, multi-drug resistance	Preclinical		biotechnology; gene therapy	cancer
gene therapy, multiple drug resistance-1; gene therapy, MDR-1	Discontinued		biotechnology; gene therapy	cancer
gene therapy, p16, Introgen; gene therapy, cancer, Introgen; INGN 221	Preclinical		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, cancer; SCH 58500	Phase II		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, retroviral p53; INGN 101	Phase II		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, adenovirus p53; INGN 201	Phase II		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, cancer; p53 TCS	Preclinical		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, p53/MDM2	Preclinical		biotechnology; gene therapy	cancer

SD-144110.1

gene therapy, p53/WAF1	Discontinued		biotechnology; gene therapy	cancer
gene therapy, pancreatic cancer, Bavarian Nordic Research Institute; Procon CYP2B1	Phase I		biotechnology; gene therapy	cancer
gene therapy, pRb2/p130; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, pro-drug activation	Preclinical		biotechnology; gene therapy	cancer
gene therapy, prostate cancer, Calydon; CN 706	Phase I		biotechnology; gene therapy	cancer
gene therapy, PTEN; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, RB 94; SG 94; RB 94	Preclinical		biotechnology; gene therapy	cancer
gene therapy, recombinant oncolytic HSV expressing CYP2B1; rRp450	Preclinical		biotechnology; gene therapy	cancer
gene therapy, retinoblastoma gene; gene therapy, Rb gene; ACNRB	Preclinical		biotechnology; gene therapy	cancer

gene therapy, ribozyme, cancer, City of Hope Medical Center; ribozyme, cancer, City of Hope Medical Center	Preclinical		biotechnology; gene therapy	cancer
gene therapy, scFv-RAS; INGN 212	Preclinical		biotechnology; gene therapy	cancer
gene therapy, solid tumors, Oxford BioMedica; MetXia	Preclinical		biotechnology; gene therapy	cancer
gene therapy, T cell chimeric receptor; gene therapy, cancer	Discontinued		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, cancer; gene therapy, HS-tk; SDZ GLI328; GLI 328	Phase III		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, leptomenigeal carcinomatosis; gene therapy, HS-tk gene	Discontinued		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk; gene therapy, mesothelioma	Phase I		biotechnology; gene therapy	cancer

SD-144110.1

gene therapy, thymidine kinase; gene therapy, HS-tk; gene therapy brain cancer	Phase I		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk	Discontinued		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk	Suspended		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk	Phase I		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk	Preclinical		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, cancer; INXC-gTK	Preclinical		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase, National Institute of Neurological Disorders and Stroke; gene therapy, HS-tk, NINDS	Phase I		biotechnology; gene therapy	cancer

SD-144110.1

gene therapy, TNF alpha	Preclinical		biotechnology; gene therapy	cancer
gene therapy, tumor necrosis factor alpha; gene therapy, solid tumor	Phase II		biotechnology; gene therapy	cancer
toxigenes	Preclinical		biotechnology; gene therapy	cancer
gene therapy, epithelial cell cancer, Cobra Therapeutics; CTL 302	Preclinical		biotechnology; gene therapy; alkylating agent	cancer
gene therapy, liver cancer, Cobra Therapeutics; CTL 203	Preclinical		biotechnology; gene therapy; alkylating agent	cancer
gene therapy, prostate cancer, Cobra Therapeutics; CTL 401	Preclinical		biotechnology; gene therapy; alkylating agent	cancer
gene therapy, angiogenesis	Preclinical		biotechnology; gene therapy; angiogenesis inhibitor	cancer
gene therapy, antiangiogenesis genes, cancer	Preclinical		biotechnology; gene therapy; angiogenesis inhibitor	cancer
gene therapy, cancer; gene therapy, angiogenesis inhibition	Preclinical		biotechnology; gene therapy; angiogenesis inhibitor	cancer

gene therapy, antisense K-ras; antisense oligonucleotide, K-ras; INGN 111	Preclinical		biotechnology; gene therapy; antisense; oligonucleotide	cancer
gene therapy, chemotherapy-resistance genes; gene therapy, MDR	Preclinical		biotechnology; gene therapy; chemoprotectant; hematoprotectant	cancer
gene therapy, MDR; gene therapy, cancer; gene therapy, MDR-1; MDRx1	Phase I		biotechnology; gene therapy; chemoprotectant; hematoprotectant	cancer
gene therapy, MDR-1; gene therapy, cancer	Phase I		biotechnology; gene therapy; chemoprotectant; hematoprotectant	cancer
gene therapy, gp91phox; gene therapy chronic granulomatous disease	Preclinical		biotechnology; gene therapy; coagulation factor	cancer
gene therapy, Sdi 1; gene therapy, cancer	Discontinued		biotechnology; gene therapy; cyclin dependent kinase inhibitor	cancer
gene therapy, cancer; gene therapy, VV-GM	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer

gene therapy, cancer; gene therapy, cytokine; gene therapy, immunostimulatory cell surface molecules	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, consensus interferon; gene therapy, IFN- con1; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, IL-2; gene therapy, cancer; BIWB 2	Phase II		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, IL-3, IntroGene; gene therapy, cancer, IntroGene	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interferon beta; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-12; gene therapy, cancer	Phase II		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-12/B7-1; gene therapy, AdIL12.B7-1; gene therapy, cancer; AdIL12.B7-1	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer

SD-144110.1

gene therapy, interleukin-2; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, melanoma	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer	Phase II		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer; AC 9401; MetaGene	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer; VCL 1102; LEUVECTIN	Phase II		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, breast cancer; AVECTIN	Discontinued		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer; BIWB 1	Discontinued		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer

SD-144110.1

gene therapy, interleukin-2; gene therapy, neuroblastoma	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, colon cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, IL-2; gene therapy, melanoma	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2 + interferon gamma; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2 + thymidine kinase; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2, interferon gamma, thymidine kinase; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-4; gene therapy, melanoma	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-7; gene therapy, IL-7; gene therapy, malignant melanoma	Suspended		biotechnology; gene therapy; cytokine; immunostimulant	cancer

gene therapy, interleukin-7; gene therapy, IL-7	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, tumor necrosis factor; gene therapy, TNF; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, tumor necrosis factor; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
NV 1030	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant; angiogenesis inhibitor	cancer
gene therapy, granulocyte macrophage-colony stimulating factor, Geniva; gene therapy, cancer, Geniva	Phase I		biotechnology; gene therapy; cytokine; immunostimulant; vaccine	cancer
gene therapy, MDR, GenPak; gene therapy, cancer	Phase II		biotechnology; gene therapy; hematoprotectant; chemoprotectant	cancer
gene therapy, MRP; gene therapy, cancer	Preclinical		biotechnology; gene therapy; hematoprotectant; chemoprotectant	cancer

gene therapy, HLA-B7; gene therapy, cancer; gene therapy, HLA-B7/cytoflectin complex; ALLOVECTIN-7	Phase III		biotechnology; gene therapy; immunostimulant	cancer
gene therapy, IL-2; gene therapy, small cell lung cancer; gene therapy, BPV vector	Phase I		biotechnology; gene therapy; immunostimulant	cancer
gene therapy, suicide gene + immunotherapeutic; gene therapy, cancer	Preclinical		biotechnology; gene therapy; immunostimulant	cancer
gene therapy, gamma interferon; gene therapy, cancer	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, GM-CSF; gene therapy, cancer; vaccine, cancer; GVAX	Phase II		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-10; gene therapy, cancer	Preclinical		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-2; gene therapy, melanoma; gene therapy, tyrosinase promoter	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer

gene therapy, interleukin-2; gene therapy, melanoma	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-2; gene therapy, melanoma	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-2; gene therapy, melanoma	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-2; gene therapy, AdCAIL-2; gene therapy, cancer; AdCAIL-2	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-4; gene therapy, cancer	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-4; gene therapy, melanoma	Preclinical		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, leukemia; gene therapy, immunostimulatory molecules	Preclinical		biotechnology; gene therapy; immunostimulant; cytokine	cancer

gene therapy, interferon alfa	Preclinical		biotechnology; gene therapy; immunostimulant; cytokine; interferon	cancer
gene therapy, interferon gamma; gene therapy, cancer	Preclinical		biotechnology; gene therapy; immunostimulant; cytokine; interferon	cancer
gene therapy, MRP; gene therapy, cancer	Preclinical		biotechnology; gene therapy; MDR inhibitor	cancer
gene therapy, multidrug resistance; gene therapy, MDR	Discontinued		biotechnology; gene therapy; MDR inhibitor	cancer
gene therapy, herpes simplex thymidine kinase gene; gene therapy, cancer	Phase I		biotechnology; gene therapy; NSAID	rheumatoid arthritis; restenosis; cancer
gene therapy, transforming growth factor beta; oligonucleotide, TGF beta	Phase I		biotechnology; gene therapy; oligonucleotide	cancer
gene therapy, hammerhead ribozyme, cancer, Berlex Biosciences; ribozyme, c-erb-B2, Berlex Biosciences	Preclinical		biotechnology; gene therapy; oligonucleotide; ribozyme	cancer

gene therapy, Ad(GV)CD.10; gene therapy, cytosine deaminase; gene therapy, colon cancer	Phase II		biotechnology; gene therapy; radiosensitizer	cancer
gene therapy, p53; vaccine, p53; gene therapy, cancer	Preclinical		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, B cell lymphoma	Phase I		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, carcinoembryonic antigen; vaccine, gene-based, pGT37; vaccine, gene-based, cancer	Preclinical		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, E7; vaccine, gene-based cancer	Preclinical		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, gp100; vaccine, gene-based, melanoma	Phase I		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, gp100 + MART-1; vaccine, gene-based, melanoma	Phase II		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, MART-1; vaccine, gene-based, cancer	Phase I		biotechnology; gene therapy; vaccine	cancer

vaccine, gene-based, melanoma, Bavarian Nordic Research Institute; gene therapy, melanoma, Bavarian Nordic Research Institute; MVA TYR	Preclinical		biotechnology; gene therapy, vaccine	cancer
vaccine, gene-based, NY-ESO-1; vaccine, gene-based, cancer	Preclinical		biotechnology; gene therapy, vaccine	cancer
vaccine, gene-based, T cell cancer	Preclinical		biotechnology; gene therapy, vaccine	cancer
vaccine, human papillomavirus antigens; vaccine HPV antigens; vaccine, cervical cancer	Discontinued		biotechnology; gene therapy, vaccine	cancer
anti-dorsalizing morphogenetic protein-1	Preclinical		biotechnology; growth factor	cancer
heregulin; Neu differentiation factor; NDF	Discontinued		biotechnology; growth factor	cancer
megakaryocyte stimulating factor	Discontinued		biotechnology; growth factor	cancer
Red blood cell growth factor	Preclinical		biotechnology; growth factor	cancer
transforming growth factor beta; TGF beta; BMS 196725	Preclinical		biotechnology; growth factor	cancer; mucositis

transforming growth factor beta; TGF-beta	Preclinical		biotechnology; growth factor	mucositis; cancer; musculoskeletal disorder
keratinocyte growth factor 2; KGF 2; HG 03400	Phase II		biotechnology; growth factor; cicatrizant; chemoprotectant; cytoprotectant	cancer; mucositis; skin ulcer; alopecia; kidney disease
granulocyte macrophage colony stimulating factor muteins; GM-CSF muteins	Preclinical		biotechnology; growth factor; hematopoietic factor	cancer
polyethylene glycol hemoglobin; PEG-hemoglobin	Phase I		biotechnology; growth factor; hematopoietic factor	cancer; anemia
polyethylene glycol megakaryocyte growth and development factor; PEG-MGDF	Discontinued		biotechnology; growth factor; hematopoietic factor	cancer; thrombocytopenia
polyethylene granulocyte macrophage colony stimulating factor glycol; PEG-GM-CSF; PolyMASC-GM-CSF	Preclinical		biotechnology; growth factor; hematopoietic factor	cancer
thrombopoietin; TPO; megakaryocyte growth and development factor; MGDF	Phase III		biotechnology; growth factor; hematopoietic factor	cancer; thrombocytopenia

thrombopoietin; TPO	Discontinued		biotechnology; growth factor; hematopoietic factor	cancer; thrombocytopenia
thrombopoietin; TPO	Preclinical		biotechnology; growth factor	cancer; thrombocytopenia
milodistim; granulocyte macrophage colony stimulating factor/interleukin-3 chimeric; GM- CSF/IL-3 chimeric protein; PIXY 321; BMS 185032; PIXYKINE	Discontinued	APARSPSPST QPWEHVNAIQ EALRLLDLSR DTAAEMNEEV EWISEMFDLQ EPTCLQTRLE LYKQGLRGSL TKLKGPLTMM ASHYKQHCPP TPETSCATQI ITFESFKENL KDFLLVIPFD CWEPVQEGGG GSGGGGGSAD MTQTPLKTS WVDCSNMIDE IITHLKQPPL PLLDENNNG EDQDILMENN LRRPNLEAFN RAVKSQDAS AIESILKNLL PCLPLATAAP TRPHIKDG DWNERRKLT FYLKTLNAQ AQQTTLALF	biotechnology; growth factor; hematopoietic factor; cytokine; immunostimulant	cancer

cilmostim; macrophage colony stimulating factor; M- CSF; MACSTIM	Discontinued		biotechnology; growth factor; hematopoietic factor; immunostimulant	hyperlipidemia; bacterial infection; cancer
filgrastim; granulocyte colony stimulating factor; G- CSF; neutropoietin; KRN 8601; NEUPOGEN; GRANULOKINE; GRAN; GRIMATIN	Marketed	N-L-methionyl- colony-stimulating factor (human clone 1034)	biotechnology; growth factor; hematopoietic factor; immunostimulant; cicatrizant	cancer; HIV infection; pneumonia; leukopenia; skin ulcer
filgrastim SD01; PEG-granulocyte- colony stimulating factor; PEG-GCSF; SD-NEUPOGEN	Phase II		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer; HIV infection; pneumonia; leukopenia
granulocyte macrophage colony stimulating factor; GM-CSF; LEUCOTROPIN	Phase III		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer; leukopenia
macrophage inflammatory protein- 1 alpha; MIP-1 alpha	Preclinical		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer

molgramostim; granulocyte macrophage colony stimulating factor; GM-CSF; GMC 89107; SCH 39300; CSF 39300; LEUCOMAX	Marketed	colony stimulating factor 2 (human clone pHG25 protein moiety reduced)	biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer; leukemia
marograsim; granulocyte colony stimulating factor munein; G-CSF munein; KW 2228; NEU-UP	Marketed	1-(N-L-methionyl-L- alanine)-3-L- threonine-4-L- tyrosine-5-L-arginine- 17-L-serine-colony- stimulating factor (human clone 1034)	biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer; leukemia
pegnartograsim; pegylated G-CSF munein; PEG-G; Ro 258315; Ro 25-8315; Ro 25-8315/000	Suspended	Pegnartograsim	biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer
polyethylene glycol granulocyte colony stimulating factor; PEG-G-CSF; granulocyte colony stimulating factor macrogol	Discontinued		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer
progenipoietin; progenipoietin G; SD 1091	Preclinical		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer

totipotent stem cell factor; T-SCF	Preclinical		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer
FLT3 ligand, DNAX Research Institute; FLT 3	Preclinical		biotechnology; growth factor; immunostimulant; hematopoietic factor	cancer
Flt3 ligand, Immunex; FLT 3; FLT 003; MOBIST	Phase II		biotechnology; growth factor; immunostimulant; hematopoietic factor; vaccine adjuvant	cancer
stem cell proliferation factor; SCPF	Preclinical		biotechnology; growth factor; immunostimulant; hematopoietic factor	cancer
DWP 404	Preclinical		biotechnology; hematopoietic factor; growth factor	cancer; thrombocytopenia
TPO-Rp	Preclinical		biotechnology; hematopoietic factor; growth factor; peptide	thrombocytopenia; cancer
thyroid stimulating hormone; TSH; THYROGEN	Marketed	thyrotropin (human .beta.-subunit) complex with chorionic gonadotropin (human .alpha.-subunit)	biotechnology; hormone	cancer; diagnosis; hypothyroidism
polyethylene glycol arginase; PEG-arginase; arginase macrogol	Discontinued		biotechnology; hydrolase; arginase; enzyme	cancer

pegaspargase; polyethylene glycol L-asparaginase; PEG- L-asparaginase; asparaginase macrogol; ONCASPARG	Marketed	pegaspargase	biotechnology; hydrolase; asparaginase; enzyme	cancer
cervical cancer therapy, Transgene	Preclinical		biotechnology; immunostimulant	cancer
immunotherapeutic, cancer, Transgene	Phase II		biotechnology; immunostimulant	cancer
mistletoe lectin; mistellektin	Preclinical		biotechnology; immunostimulant	cancer
totipotent stem cell receptor; FLK 2	Discontinued		biotechnology; immunostimulant	cancer
gene therapy, macrophage activated killer cells plus bispecific antibody; MAK therapy; MAK	Phase II		biotechnology; immunostimulant; gene therapy	cancer
ancestim; stem cell factor; SCF; STEMGEN	Pre- registration	N-L-methionyl-1- 165-hematopoietic cell growth factor KL (human clone V19.8:hSCF162) dimer	biotechnology; immunostimulant; growth factor; hematopoietic factor	cancer
granulocyte colony- stimulating factor; BM 800001	Suspended		biotechnology; immunostimulant; growth factor; hematopoietic factor	cancer

interleukin-9; IL-9	Discontinued		biotechnology; immunostimulant; growth factor; hematopoietic factor	cancer
lenograstim; granulocyte colony stimulating factor; G- CSF; pluripoietin; NEUTROGIN; GRANOCYTE; EUPROTIN; MYELOSTIM	Marketed	133-[O-[O-(N-acetyl- alpha-neuraminosyl)- (2-3)-O-beta-D- galactopyranosyl-(1- 3)-2-(acetyl-amino)-2- deoxy-beta-D- galactopyranosyl]-L- threonine]-colony stimulating factor (human clone 1034)	biotechnology; immunostimulant; growth factor; hematopoietic factor	anemia; HIV infection; cancer; leukopenia
sargramostim; granulocyte macrophage colony stimulating factor; GM-CSF; BI 61012; thu GM-CSF; LEUKINE; PROKINE; INTERBERIN	Marketed	23-L-leucine colony- stimulating factor 2 (human clone pHG25 protein moiety)	biotechnology; immunostimulant; growth factor; hematopoietic factor; vaccine adjuvant	cancer; infectious disease; HIV infection; leukopenia
stem cell factor; SCF	Discontinued		biotechnology; immunostimulant; growth factor; hematopoietic factor	cancer
ImmTher	Phase II		biotechnology; immunostimulant; peptide	cancer

vaccine, prostate cancer; JT 1001; Onco Vax-P; Onco Vax-Pr	Phase II		biotechnology; immunostimulant; vaccine	cancer
cytokine cocktail; BC-IL; leukocyte interleukin injection; MULTIKINE	Phase II		biotechnology; immunostimulant; vaccine adjuvant; cytokine	cancer; infectious disease; HIV infection
ZYN-LINKER conjugated superantigens	Suspended		biotechnology; immunosuppressant; immunostimulant; NSAID	rheumatoid arthritis; cancer
MAb, human interleukin-6 receptor; MAb, human IL-6 receptor; hPM-1; MRA	Phase I		biotechnology; immunosuppressant; monoclonal antibody	autoimmune disease; cancer
E 21R	Preclinical		biotechnology; immunosuppressant; NSAID	cancer; inflammation; allergy
G28-5 sFV-PE40	Preclinical		biotechnology; immunotoxin	cancer
immunotoxin, lymphoma	Discontinued		biotechnology; immunotoxin	cancer
MAb, glioma/neuroblastoma -gelonin; GLIOMAB-H	Phase I		biotechnology; immunotoxin	cancer
immunotoxin, cancer, Immunomedics/NCI	Preclinical		biotechnology; immunotoxin; monoclonal antibody	cancer

MAb, epidermal growth factor receptor-DM1; MAb, EGFR-DM1	Preclinical		biotechnology; immunotoxin; monoclonal antibody	cancer
MAb, interleukin-13-PE38QQR; immunotoxin, IL-13-PE38QQR	Preclinical		biotechnology; immunotoxin; monoclonal antibody	cancer
MAB, ricin A immunotoxin; MAb, colorectal cancer; ZD 0490; ICI D0490	Discontinued		biotechnology; immunotoxin; monoclonal antibody	cancer
MAB, SS(dsFv)-PE38	Preclinical		biotechnology; immunotoxin; monoclonal antibody	cancer
MAB, venus flytrap cluster conjugate	Preclinical		biotechnology; immunotoxin; monoclonal antibody	cancer; diagnosis

macolomab tafenatox; MAB, C242- staphylococcal enterotoxin A; Fab, C242-staphylococcal enterotoxin A; PNU 214565; LS 4565; TTMA LS 4585	Phase I	20-244- immunoglobulin G1, anti-(human colorectal tumor antigen C242) Fab fragment (mouse monoclonal r- C242Fab-SEA clone pKP941 gamma1- chain) fusion protein with enterotoxin A (Staphylococcus aureus), disulfide with mouse monoclonal r- C242Fab-SEA clone pKP941 kappa-chain	biotechnology; immunotoxin; monoclonal antibody	cancer
MAB, doxorubicin conjugate; MAB, BR 96-doxorubicin; MAB, BR 96-DOX; BMS 182248; BMS 18224801	Phase II		biotechnology; immunotoxin; monoclonal antibody; anthracycline; antibiotic; DNA intercalator	cancer
MAB, B43-genistein; B43-Gen immunoconjugate	Phase I		biotechnology; immunotoxin; monoclonal antibody; tyrosine kinase inhibitor	cancer

drug delivery system, interferon alfa; interferon alfa drug delivery system; SUMIFERON	Pre-registration		biotechnology; interferon	viral infection; cancer
MINIPELLET				
drug delivery system, interferon beta; interferon beta delivery system; drug delivery system, IFN beta	Discontinued		biotechnology; interferon	cancer; viral infection; cancer; viral infection
drug delivery system, oral interferon alfa-2a; IFN alfa-2a, oral	Suspended		biotechnology; interferon	cancer; viral infection
interferon alfa, natural; IFN-alfa, natural; EGIFERON	Marketed		biotechnology; interferon	cancer; viral infection
interferon alpha, hybrid; hybrid interferon alpha	Preclinical		biotechnology; interferon	viral infection; cancer
interferon alpha, natural; FPI 31	Pre-registration		biotechnology; interferon	viral infection; cancer
interferon beta; IFN-beta; DL 8234; FERON	Marketed		biotechnology; interferon	viral infection; cancer; retinopathy
interferon beta; IFN-beta	Discontinued		biotechnology; interferon	cancer; viral infection
interferon beta-1a; IFN beta; AVONEX	Marketed	interferon beta-1a	biotechnology; interferon	viral infection; multiple sclerosis; cancer

interferon beta-1a; interferon beta; IFN- beta; REBIF	Marketed		biotechnology; interferon	cancer; viral infection; multiple sclerosis; inflammatory bowel disease
interferon beta-1b; interferon beta-serine; SH 579; ZK 157046; BETASERON; BENESERON; BETAFERON	Marketed	2-166-interferon beta 1 (human fibroblast reduced)	biotechnology; interferon	multiple sclerosis; cancer; viral infection
interferon omega; IFN omega	Phase II		biotechnology; interferon	viral infection; cancer
polyethylene glycol interferon alfa-2b; PEG-interferon alfa- 2b; interferon alfa-2b macrogol; PEG- INTRON A	Phase III		biotechnology; interferon; cytokine	viral infection; cancer
interferon alfa-2b; IFN alfa-2b; SCH 30500; YM 1490; INTRON A; CIBIAN; VIRAFERON	Marketed		biotechnology; interferon; cytokine; immunostimulant	cancer; viral infection
tumor necrosis factor + interferon alfa-2a; interferon alfa-2a + tumor necrosis factor; TNF + IFN alfa-2a	Discontinued		biotechnology; interferon; growth factor	cancer

SD-144110.1

interferon alfa-2a; IFN alfa-2a; Ro 228181; ROFERON A; CANFERON A; ROFERON	Marketed	(human leukocyte protein moiety) interferon alpha A	biotechnology; interferon; immunostimulant	viral infection; cancer
interferon gamma-1a; SUN 4800; BIOGAMMA	Marketed		biotechnology; interferon; immunostimulant	cancer
interferon gamma-1b; interferon gamma; IFN gamma; ACTIMMUNE; IMUKIN; IMUFOR GAMMA	Marketed		biotechnology; interferon; immunostimulant	cancer; bacterial infection; chronic granulomatous disease; tuberculosis
interferon, consensus; consensus interferon; interferon alfacon-1; YM 643; INFERGEN	Marketed	interferon alpha 1 (human lymphoblast reduced), N-L-methionyl-22-L-arg-76-L-ala-78-L-asp-79-L-glu-86-L-tyr-90-L-tyr-156-L-thr-157-L-asn-158-L-leu-	biotechnology; interferon; immunostimulant	viral infection; cancer
3622W94; BW 3622W94	Phase II		biotechnology; monoclonal antibody	cancer
antibodies, Sdi 1	Discontinued		biotechnology; monoclonal antibody	cancer
detumomab; MAb, idiotype B cell lymphoma; MAb, B cell lymphoma; B cell lymphoma MAb; SPECIFID	Discontinued		biotechnology; monoclonal antibody	cancer

drug delivery system, liposome MAb, 273-34A; MAb, 273-34A liposome; liposome, MAb 273-34A	Preclinical		biotechnology; monoclonal antibody	cancer
edrecolomab; MAb, 17-1A; MAb, colorectal cancer; MAb, CO17-1A; 17-1A; C-1; PANOREX	Marketed	immunoglobulin G 2a (mouse monoclonal 17-1A gamma-chain anti-human colon cancer tumour-associated antigen), disulfide with mouse monoclonal 17-1A light chain dimer	biotechnology; monoclonal antibody	cancer
lintuzumab; MAb, humanized M195; MAb, humanized CD33; SMART M195; HuM195	Phase III	immunoglobulin G1 (human-mouse monoclonal HuM195.gamma.1-chain anti-human antigen CD 33), disulfide with human monoclonal HuM195.kappa.-chain, dimer	biotechnology; monoclonal antibody	cancer
lintuzumab-bismuth-213; MAb, humanized M195-213Bi	Phase I		biotechnology; monoclonal antibody	cancer
LYM 2	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, 12G5	Preclinical		biotechnology; monoclonal antibody	cancer

SD-144110.1

MAB, 2A11; MAB, gastrin releasing peptide	Phase II		biotechnology; monoclonal antibody	cancer
MAB, 323A3; 323A3	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, 3F8; IgG3 anti-ganglioside GD 2; MAB, neuroblastoma	Phase I		biotechnology; monoclonal antibody	cancer
MAB, 42/6; MAB, transferrin receptor	Phase I		biotechnology; monoclonal antibody	cancer
MAB, 88BV59-phenium 186	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, 977; MAB, bladder cancer	Preclinical		biotechnology; monoclonal antibody	cancer; diagnosis
MAB, 9D9	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, adrenomedullin	Preclinical		biotechnology; monoclonal antibody	cancer; diabetes; Alzheimer disease; diagnosis
MAB, anti-ganglioside GM2; KM 966	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, antinuclear auto-antibodies; MAB, cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, B cell lymphoma; 1D10	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, B-E4; MAB, interleukin-6; MAB, IL-6; B-E4	Phase I		biotechnology; monoclonal antibody	cancer
MAB, B4-DC1	Discontinued		biotechnology; monoclonal antibody	cancer

MAB, B6.2/212 single chain antibody; MAB, B6.2/212 SCA	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, BCD F9- radionuclide; MAB, breast cancer; BCD F9	Phase I		biotechnology; monoclonal antibody	cancer; diagnosis
MAB, bispecific F(ab') ₂ OC/TR; OCTR	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, bispecific hu- bsF(ab') ₂	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, bladder carcinoma; RG 355	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, BR 96; BR 96	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, breast cancer antigen; Pro 1.5.3	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, BW 494	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, c-Nd2; c-Nd2	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, C215- staphylococcal enterotoxin; FAb, C215-SEA	Phase II		biotechnology; monoclonal antibody	cancer
MAB, C242; MAB, colonic adenocarcinoma	Discontinued		biotechnology; monoclonal antibody	cancer; diagnosis
MAB, C242-DM 1 conjugate; huC242- DM1	Preclinical		biotechnology; monoclonal antibody	cancer

SD-144110.1

MAB, C242-maytansine conjugate	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, cancer	Phase III		biotechnology; monoclonal antibody	cancer
MAB, cancer; MAB, EpCAM	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, cancer; BW 1209W95	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, cancer; hybrid antibody, anti-Her-2, anti-CD3	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, cancer and Fc; bispecific antibody, melanoma, glioma, neuroblastoma; MDX 260	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, cancer, BioInvent	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, cancer, PPL	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, cancer, XTL Biopharmaceuticals; MAB, cancer, Neoprobe	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, carcinoembryonic antigen; MAB, CEA	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, carcinoembryonic antigen; MAB, CEA	Preclinical		biotechnology; monoclonal antibody	cancer

MAB, carcinoma; MAb, SK-1; MAb, cancer; MONOPHARM C	Phase I		biotechnology; monoclonal antibody	cancer
MAB, CC49; MAB, TAG B723; MAB, B723 second generation	Phase II		biotechnology; monoclonal antibody	cancer
MAB, CC49-interleukin-2; fusion protein, CC49-IL-2	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, CC49-lutetium 177; MAB, anti-TAG-72-lutetium 177	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, CC83; MAB, TAG B723; MAB, B723 second generation	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, CD19/CD3; bispecific antibody, cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, CD28/CD30; Bi-MoAb	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, CD3/CD30; Bi-MoAb; bispecific antibody, CD3, CD30	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, CD34; anti-CD34	Phase I		biotechnology; monoclonal antibody	cancer
MAB, CD87; MAB, cancer, Willex Biotechnology	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, ch14.18	Phase II		biotechnology; monoclonal antibody	cancer

MAB, chemotherapeutic conjugates, IDEC	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, chimeric CC49; MAB, chimeric TAG B723	Phase I		biotechnology; monoclonal antibody	cancer
MAB, chimeric CC83; MAB, TAG B723	Phase I		biotechnology; monoclonal antibody	cancer
MAB, chimeric IgG1 anti CD20	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, colon-DMI	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, colorectal cancer	Phase I		biotechnology; monoclonal antibody	cancer; diagnosis
MAB, CYT 372 humanized; MAB, C46 humanized; MAB, humanized panadenocarcinoma	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, directed enzyme prodrug therapy; ADEPT, cancer therapy	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, directed enzyme prodrug therapy + CMDA; ADEPT + CMDA; ZD 2767	Phase II		biotechnology; monoclonal antibody	cancer
MAB, EGF-R and Fc; bispecific antibody, cancer; MDX 447; H 447; EMD 82633	Phase II		biotechnology; monoclonal antibody	cancer

MAB, epidermal growth factor receptor; MAB, EGF receptor; EMD 55900	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, epidermal growth factor receptor; MAB, EGF receptor; MAB, 528; MoAb528	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, epidermal growth factor receptor; MAB, EGFR; C 225	Phase III		biotechnology; monoclonal antibody	cancer
MAB, epidermal growth factor receptor; MAB, EGFR; ICR 62	Phase I		biotechnology; monoclonal antibody	cancer
MAB, epidermal growth factor, humanized; MAB, EGF, humanized; EMD 72000	Phase I		biotechnology; monoclonal antibody	cancer
MAB, erbB-2; MAB, cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, erbB2	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, F(ab)2 NRC002-rhenium 186; MAB, antiCEA	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, F4	Preclinical		biotechnology; monoclonal antibody	cancer

SD-144110.1

MAB, Fab NRLU10- radionuclide; MAB, lung cancer; MAB, prostate cancer	Phase I		biotechnology; monoclonal antibody	cancer; diagnosis
MAB, fas; MAB, bladder cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, FC-2.15	Phase II		biotechnology; monoclonal antibody	cancer
MAB, fibroblast growth factor receptor; MAB, FGFR	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, germ cell cancer; ImmuRAID- HCG	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, gp75; MELVAX II	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, heparanase	Preclinical		biotechnology; monoclonal antibody	cancer; diagnosis
MAB, HER-2 immunoliposome	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, HER2/neu20 immunoliposomes, breast cancer; C 6.5	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, Hodgkin's lymphoma	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, human antiganglioside	Phase II		biotechnology; monoclonal antibody	cancer
MAB, human chorionic gonadotropin; MAB, hCG; CTP 103	Preclinical		biotechnology; monoclonal antibody	cancer

MAB, human chorionic gonadotropin, human; MAB, hCG, human	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, human EpCAM; UBS 54	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, humanized LL2; MAB, B cell lymphoma; LymphoCide	Phase II		biotechnology; monoclonal antibody	cancer
MAB, humanized N901-DC1	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, humanized, cancer; MAB, cancer humanized	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, IgG1 fragment	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, IGX	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, ING-1; MAB, carcinoma	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, interleukin-6; MAB, IL-6	Phase I		biotechnology; monoclonal antibody	cancer
MAB, KAI1; MAB, cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, KM641; KM 641	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, L 6; L 6	Discontinued		biotechnology; monoclonal antibody	cancer

MAB, L6 alkaline phosphatase conjugate; L6 alkaline phosphatase MAB conjugate; MAB, carcinoma	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, Lewis Y; ABL 364; SDZ ABL 364	Phase I		biotechnology; monoclonal antibody	cancer
MAB, Lewis Y, humanized; HuABL 364; SMART ABL 364; BR 55-2	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, LL2-rhenium 188; Re-188-LL2	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, MAB fragment, REC A33-nuclide	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, mB43-technetium 99m; Tru-Scint OV	Phase II		biotechnology; monoclonal antibody	cancer; diagnosis
MAB, MDX 11; MAB, myeloid leukemia; MAB, CD15; MDX 11; PM 81	Phase II		biotechnology; monoclonal antibody	cancer
MAB, melanoma; MAB, cancer; MONOPHARM M	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, melanoma, Novartis; CGP 62360	Phase I		biotechnology; monoclonal antibody	cancer
MAB, MN-14 carcinoembryonic antigen; MAB, MN-14 CEA; CEA-Cide	Phase II		biotechnology; monoclonal antibody	diagnosis; cancer

SD-144110.1

MAb, MRK 20; MRK 20	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, multiple myeloma, U-BiSys	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, oncology, Glaxo Wellcome	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, ONS M21; ONS M21	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, P-67; MAB, acute myelogenous leukemia	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, PAM4	Phase I		biotechnology; monoclonal antibody	cancer
MAB, polymorphic epithelial mucin; MAB, PEM; AS 125	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, prostate cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, prostate cancer	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, prostate cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, SM3 phosphorus 32	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, TAG-72	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, TAG-72 and Fc; bispecific antibody, cancer; MDX 220	Phase II		biotechnology; monoclonal antibody	cancer

MAB, TB94, human; MAB, TB94, IgA1k; MAB, small cell lung cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, TH69	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, transcobalamin II; MAB, vitamin B12 carrier protein, Receptagen	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, transferrin receptor targeted immunotoxin; MAB, tfnR targeted immunotoxin; tfnR- CRM107	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, tumor necrosis factor; MAB, TNF; SMA TNF	Preclinical		biotechnology; monoclonal antibody	Crohn disease; cancer; septic shock
MAB, tumor necrosis factor alpha; MAB, TNF-alpha; MAB32	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, U36/E48	Discontinued		biotechnology; monoclonal antibody	cancer
MAbs, cancer, human, Medarex	Preclinical		biotechnology; monoclonal antibody	cancer
MAbs, chimeric, cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAbs, pancreaticoma, B-cell tumor; bispecific antibody, cancer	Preclinical		biotechnology; monoclonal antibody	cancer

prostate carcinoma tumor antigens	Discontinued		biotechnology; monoclonal antibody	cancer; diagnosis
rituximab; MAb, CD20; MAb, pan-B; IDEC 2B8; Ro 425294; IDEC 102; RITUXAN; MabThera	Marketed	immunoglobulin G1 (human-mouse monoclonal IDEC- C2B8 gamma 1-chain anti-human antigen CD 20), disulfide with human-mouse monoclonal IDEC- C2B8 kappa-chain, dimer	biotechnology; monoclonal antibody	cancer
SDZ MMA 383; MMA 383	Phase I		biotechnology; monoclonal antibody	cancer
trastuzumab; HERCEPTIN	Marketed	immunoglobulin G1, anti-(human p185neu receptor) (human- mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human- mouse monoclonal rhuMab HER2 light chain dimer	biotechnology; monoclonal antibody	cancer
MAb, KDR; MAb, vascular endothelial growth factor receptor; DC 101	Preclinical		biotechnology; monoclonal antibody; angiogenesis inhibitor	cancer
MAb, KDR; MAb, vascular endothelial growth factor receptor; CP1C11	Preclinical		biotechnology; monoclonal antibody; angiogenesis inhibitor	cancer

MAb, VNR integrin; LM 609; VITAXIN	Phase II		biotechnology; monoclonal antibody; angiogenesis inhibitor	cancer
MAb, CEA and doxorubicin; MAb, 26-61-10; bispecific antibody, CEA and doxorubicin	Preclinical		biotechnology; monoclonal antibody; anthracycline; DNA intercalator; antibiotic	cancer
MAb, antilaminin gamma2 chain; BST 1004	Preclinical		biotechnology; monoclonal antibody; contrast medium	cancer; diagnosis
MAb, cancer; MAb, tumor necrosis technology; MAb, TNT	Preclinical		biotechnology; monoclonal antibody; contrast medium; radiodiagnostic; radiotherapeutic	cancer
MAb, cancer, radiolabeled; NOVOMAb-G2	Phase I		biotechnology; monoclonal antibody; contrast medium; radiodiagnostic; radiotherapeutic	cancer; diagnosis
MAb, epidermal growth factor receptor; MAb, EGFr; DiaCIM; TheraCIM; RadioTheraCIM	Phase I		biotechnology; monoclonal antibody; contrast medium; radiotherapeutic; radiodiagnostic	cancer; diagnosis
MAb, TC5-Au198	Preclinical		biotechnology; monoclonal antibody; contrast medium; radiotherapeutic; radiodiagnostic	cancer; diagnosis

MAb, B cell-cytokine fusion protein	Preclinical		biotechnology; monoclonal antibody; cytokine	cancer
interleukin-2, antiganglioside chimeric protein; G2-IL2 fusion protein; MAb-G2 IL-2 fusion protein; ch14.18-IL2	Preclinical		biotechnology; monoclonal antibody; cytokine; growth factor	cancer
MAb, L49-sFv-beta-lactamase	Preclinical		biotechnology; monoclonal antibody; enzyme	cancer
MAb, 2C11.F(ab') ₂ + microbeads; MAb, anti-CD3 + microbeads; PLATAR construct	Discontinued		biotechnology; monoclonal antibody; immunostimulant	bacterial infection; cancer
MAb, c-erbB-2 and CD16; bispecific antibody, c-erbB-2 and CD16; 2B1	Phase I		biotechnology; monoclonal antibody; immunostimulant	cancer
MAb, c-Mpl; MAb, thrombocytopenia; BAH 1	Preclinical		biotechnology; monoclonal antibody; immunostimulant	thrombocytopenia; cancer
MAb, CD3 F(ab') ₂ + microbeads; MAb, CD3 + microbeads; PLATAR construct	Discontinued		biotechnology; monoclonal antibody; immunostimulant	bacterial infection; cancer

MAb, HER-2 and Fc; bispecific antibody, ovarian and breast cancer; bispecific antibody 520C9x22; MDX 210	Phase II			biotechnology; monoclonal antibody; immunostimulant	cancer
daclizumab; dacliximab; MAb, Tac; MAb, humanized Tac; MAb, SMART Tac; Ro 247375; ZENAPAX	Marketed	immunoglobulin G1 (human-mouse monoclonal clone 1H4 gamma chain anti-human antigen Tac), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer		biotechnology; monoclonal antibody; immunosuppressant	transplant rejection; cancer; autoimmune disease; eye disease
MAb, alpha-tubulin	Preclinical			biotechnology; monoclonal antibody; immunosuppressant	cancer; autoimmune disease; diagnosis
MAb, T cell antigen receptor; TM 29	Preclinical			biotechnology; monoclonal antibody; immunosuppressant	cancer; Crohn disease
MAbs, B cells; migis	Discontinued			biotechnology; monoclonal antibody; immunosuppressant	autoimmune disease; cancer
MAb, MHC class II	Preclinical			biotechnology; monoclonal antibody; immunosuppressant; NSAID	autoimmune disease; transplant rejection; graft versus host disease; cancer

MAB, 791T/36-ricin A immunotoxin; immunotoxin- colorectal cancer; XOMAZYME 791	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, A7 mitomycin C-dextran conjugate; MAB, A7-MMCD; MAB, colon cancer mitomycin C-dextran conjugate	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, alpha CD80- gelonin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, alphaCD86- gelonin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, Anti-Tac Pseudomonas exotoxin; immunotoxin, T cell cancers	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, B3- Pseudomonas exotoxin; immunotoxin B3-PE 38; LMB 1	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, B4-blocked ricin; MAB, B4-bR; ONCOLYSIN B	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, B7- immunotoxin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer

MAb, BACH 250-gelonin conjugate; immunotoxin, BACH 250-gelonin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, basic fibroblast growth factor receptor-saporin; MAb, bFGF receptor-SAP; 11A8	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, CD33-calicheamicin; CMA 676; CDP 771	Phase III		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, CMB 401-calicheamicin; MAb, ovarian cancer; CMB 401; CDP 671	Phase II		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, CYT 103-aminopterin; MAb, B72.3-aminopterin; ONCOTHER 130	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, epidermal growth factor receptor immunotoxin; OLX 103; TP 40; L 691912	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer

MAB, erbB-2-Pseudomonas exotoxin; immunotoxin, single chain erbB-2-Pseudomonas exotoxin; OLX 209; AR 209	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, F(ab') ₂ HRS-3 deglycosylated ricin A; MAB, HRS-3 deglycosylated ricin A; MAB, F(ab') ₂ HRS-3 dgA; Mab, HRS-3 deglycosylated ricin A; MAB, F(ab') ₂ HRS-3 dgA; MAB, IRac dgA	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, F(ab') ₂ IRac deglycosylated ricin A; MAB, IRac deglycosylated ricin A; MAB, F(ab') ₂ IRac dgA	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, Fv B3-Pseudomonas exotoxin; immunotoxin Fv B3-PE 38; LMB 7; NSC 658931	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer

MAb, FvB1-Pseudomonas exotoxin; immunotoxin FvB1-PE33	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, LJ2-Pseudomonas exotoxin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, ME20-Pseudomonas exotoxin; immunotoxin ME20-LysPE40	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, N901-blocked ricin; immunotoxin, N901-bR; ONCOLYSIN S	Phase II		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, N901-DM1; immunotoxin, N901-DM1	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, OVB3-Pseudomonas exotoxin conjugate; immunotoxin OVB3-PE	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, RFB4(dsFv)-PE38; immunotoxin, RFB4(dsFv)-PE38; BL 22; NSC 691237	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, RFT5-ricin A (CD25) immunotoxin; RFT5.dgA	Phase II		biotechnology; monoclonal antibody; immunotoxin	cancer

MAb, ricin A immunotoxin conjugate; melanoma; XOMAZYME-MEL	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, SN7-ricin A; immunotoxin SN7-ricin A; SN7-RA	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, Tac(Fv)-PE38; immunotoxin Tac(Fv)-PE38; LMB 2	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, Tac(Fv)-PE40 immunotoxin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, transferrin receptor targeted immunotoxin; MAb, tfnR targeted immunotoxin; 454A12-rRA	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, tumor immunotoxins, Menarini	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, UV72 immunotoxin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, VEGF receptor/ligand complex-dgA; immunotoxin VEGF receptor/ligand complex-dgA	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer

MABs, CD22-saporin; Phase II immunotoxin, bispecific, cancer; ITF 1265 + ITF 1269			biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, doxorubicin conjugates; MAB, CC49-doxorubicin	Discontinued		biotechnology; monoclonal antibody; immunotoxin; anthracycline; antibiotic; DNA intercalator	cancer
MAB, anthracycline amine derivative	Preclinical		biotechnology; monoclonal antibody; immunotoxin; antibiotic	cancer
MAB, CD5-momordin; immunotoxin CD5-momordin; ITF 1532	Phase II		biotechnology; monoclonal antibody; immunotoxin; immunosuppressant	cancer; transplant rejection
MAB, humanized, MRK 16; MRK 16	Preclinical		biotechnology; monoclonal antibody; MDR inhibitor	cancer
MAB, MRK 17; MRK 17	Discontinued		biotechnology; monoclonal antibody; MDR inhibitor	cancer
MAB, humanized, leukemia; MAB, IgG2B; LDP 03; BW 7U; CAMPATH; CAMPATH-1H	Phase II		biotechnology; monoclonal antibody; NSAID	rheumatoid arthritis; cancer; multiple sclerosis; transplant rejection
iodine 131 tositumomab; MAB, CD20-iodine 131; BEXXAR	Phase III		biotechnology; monoclonal antibody; radiotherapeutic	cancer

MAB, 16.88-yttrium 90	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, 35-67Cu; MAB, murine colon carcinoma; MAB, cancer	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, 88BV59-yttrium 90	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, B3-yttrium 90	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, CC49-yttrium	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, CD20-iodine 131	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, CD20-streptavidin + biotin-yttrium 90	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, CEA rhenium-188; MAB, colorectal cancer; IMMURAIT-Rhenium	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, CG250-iodine 131	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, chimeric L6-iodine 131; BMS 180548	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer

MAB, CYT 103- yttrium 90; MAB, B72.3-yttrium 90; ONCORAD OV103; ONCORAD CR103	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, ERIC1 yttrium 90	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, F(ab)2 NRLU10-rhenium 186; MAB, F(ab)2 pancarcinoma; RHENEX	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, G250-iodine 131	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, humanized MN-14; MAB, humanized carcinoembryonic antigen; MN 14; CEA-Cide	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, iodine-131, DNA-associated antigens; 131I- chTNT-1/B; COTARA; Tumor Necrosis Therapy; TNT	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, LL2-iodine 131; LymphoCide; ImmuRAIT-LL2	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer

SD-144110.1

MAb, LYM-1-iodine 131; LYM 1; ONCOLYM	Phase III		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, MAb fragment, REC A33-TFM-nuclide; CDP 833	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, NRLU13-streptavidin + biotin-yttrium 90; AVICIDIN	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, OKB7-iodine 131; OKB7	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, pan-B-yttrium; MAb, B-cell radiation therapy; IDEC Y2B8	Phase III		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, PEM-antisense oligonucleotide-radionuclide; AS 102	Preclinical		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, PF1-A; MAb, squamous cell carcinoma; AS 114	Preclinical		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, UJ13A yttrium 90	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer
yttrium Y 90 capromab; MAb, CYT 356-yttrium 90; MAb, 7E11C5-yttrium 90; MAb, prostate cancer; OncoRad PR	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer

SD-144110.1

MAb, 4B5; MAb, anti-GD2 anti-idiotypic; NOVOVAC-M1	Preclinical		biotechnology; monoclonal antibody; vaccine	cancer
MAb, BEC-2; vaccine, BEC-2; EMD 60205; BEC2	Phase III		biotechnology; monoclonal antibody; vaccine	cancer
MAb, CA 125; vaccine, cancer; B43.13; OvaRex	Phase III		biotechnology; monoclonal antibody; vaccine	cancer
MAb, CA19.9; AR 44.6; GivaRex	Preclinical		biotechnology; monoclonal antibody; vaccine	cancer
MAb, idiotypic CEA; vaccine, cancer; cancer vaccine; CeaVac	Phase II		biotechnology; monoclonal antibody; vaccine	cancer
MAb, idiotypic GD2; vaccine, cancer; cancer vaccine; TriGem	Phase II		biotechnology; monoclonal antibody; vaccine	cancer; psoriasis
MAb, idiotypic, MUC1; vaccine, cancer; cancer vaccine; TriAb	Phase II		biotechnology; monoclonal antibody; vaccine	cancer
MAb, MUC1; vaccine, cancer; AR 20.5; BrevaRex	Phase I		biotechnology; monoclonal antibody; vaccine	cancer
MAb, PSA; ProstaRex	Preclinical		biotechnology; monoclonal antibody; vaccine	cancer

monoclonal antibody, anti-idiotypic, cancer	Clinicals		biotechnology; monoclonal antibody; vaccine	cancer
antisense oligonucleotide, B cell lymphoma	Preclinical		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, c-myc	Preclinical		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, cancer	Discontinued		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, cancer; mRNA translation inhibitor, cancer	Preclinical		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, Ha-ras; ISIS 2503	Phase II		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, Kaposi's sarcoma	Discontinued		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer

antisense oligonucleotide, Philadelphia chromosome; antisense oligonucleotide, chronic myelogenous leukemia; G 1128	Phase II		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotides, Ki- ras	Preclinical		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
GPs 0193; NAVIN	Discontinued		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	HIV infection; cancer
LR 3523	Discontinued		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
BCG A4	Preclinical		biotechnology; oligonucleotide	cancer
LR 5165	Discontinued		biotechnology; oligonucleotide	cancer
oligonucleotide directed DNA therapy	Discontinued		biotechnology; oligonucleotide	cancer; genetic disorder; viral infection; bacterial infection
oligonucleotide, cancer, Kimeragen	Preclinical		biotechnology; oligonucleotide	cancer
oligonucleotide; chronic myelogenous leukemia, Kimeragen	Preclinical		biotechnology; oligonucleotide	cancer

antisense oligonucleotide, bcl- 2; ODN 2009	Preclinical		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, cancer, GeneSense Technologies; GTI 2040	Preclinical		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, cancer, GeneSense Technologies; GTI 2501	Preclinical		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, cancer, Isis/AstraZeneca	Preclinical		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, raf kinase; antisense oligonucleotide, cancer; ISIS 5132; CGP 69846A; CGP 69846A; ODN 698	Phase II	d(P-thio) (T-C-C-C- G-C-C-T-G-T-G-A- C-A-T-G-C-A-T-T-)	biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, TAG 6; TAG 6	Preclinical		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotides, non- Hodgkins lymphoma, Fox Chase Cancer Center	Preclinical		biotechnology; oligonucleotide; antisense	cancer

oligonucleotides, VimRx	Preclinical		biotechnology; oligonucleotide; ribozyme	cancer; psoriasis
ribozyme, bcl-2, Ribozyme	Preclinical		biotechnology; oligonucleotide; ribozyme	cancer
ribozyme, europium-tetraphyrin, cancer; ribozyme, europium tetraphyrin, viral infection	Preclinical		biotechnology; oligonucleotide; ribozyme	cancer; viral infection
ribozyme, K-ras	Preclinical		biotechnology; oligonucleotide; ribozyme	cancer
sense oligonucleotides, GenSet; transcription factor decoys, GenSet	Discontinued		biotechnology; oligonucleotide; transcription factor regulator	cancer; viral infection
polyethylene glycol uricase; PEG-uricase; uricase macrogol	Discontinued		biotechnology; oxidoreductase; uricase	gout; cancer
class II restricted melanoma antigens, National Institutes of Health	Preclinical		biotechnology; peptide cancer	
urokinase receptor antagonists, Chiron	Preclinical		biotechnology; peptide cancer; inflammation	
interferon-inducible protein-10; IP-10	Preclinical		biotechnology; peptide; chemokine	cancer
interferon-inducible protein-10; IP-10	Preclinical		biotechnology; peptide; chemokine	cancer; eye disease

antibody-derived anticancer peptides, Antisoma	Discontinued		biotechnology; peptide; contrast medium	cancer; diagnosis
RecepTox-GnRH	Preclinical		biotechnology; peptide; fusion toxin	cancer
chimeric peptides, National Institutes of Health	Preclinical		biotechnology; peptide; vaccine	cancer; viral infection
plasminogen activator inhibitor; PAI-2	Phase II		biotechnology; plasminogen activator inhibitor; cicatrizant	cancer; inflammation; skin ulcer
matrix metalloproteinase inhibitor	Discontinued		biotechnology; proteinase inhibitor; matrix metalloproteinase inhibitor; NSAID	arthritis; cancer; arthritis
maspin; mammary serine proteinase inhibitor; LXR 023; METAREX	Preclinical		biotechnology; proteinase inhibitor; serine proteinase inhibitor	cancer
neutral endopeptidase; NEP	Discontinued		biotechnology; proteinase; metalloproteinase	cancer; migraine; inflammatory bowel disease; inflammation; asthma; respiratory disease
oligonucleotides, acute promyelocytic leukemia	Preclinical		biotechnology; ribozyme; oligonucleotide	cancer
oligonucleotides, multiple drug resistance	Preclinical		biotechnology; ribozyme; oligonucleotide	cancer

ribozyme, BCR-ABL	Preclinical		biotechnology; ribozyme; oligonucleotide	cancer
ribozyme, ras, Ribozyme	Preclinical		biotechnology; ribozyme; oligonucleotide	cancer
ribozyme, vascular endothelial growth factor receptor; ribozyme, VEGF receptor; RPI 4610; ANGIOZYME	Phase I		biotechnology; ribozyme; oligonucleotide	retinopathy; cancer
screening technology, growth regulatory compounds	Preclinical		biotechnology; target based screening	drug design technology; cancer
drug delivery system, verotoxin fusion protein cancer vaccine; vaccine, cancer	Preclinical		biotechnology; vaccine	cancer
epidermal growth factor; EGF	Phase I		biotechnology; vaccine	cancer
MEDI 501	Phase I		biotechnology; vaccine	cancer; viral infection
MEDI 503	Preclinical		biotechnology; vaccine	cancer
MEDI 504	Preclinical		biotechnology; vaccine	cancer
tumor associated antigen; PP4X	Preclinical		biotechnology; vaccine	cancer
tumor associated antigen; CTAA 79 AV1017	Preclinical		biotechnology; vaccine	cancer

vaccine, B cell lymphoma specific idiotype-granulocyte macrophage colony stimulating factor; vaccine, Id/MoGM-CSF	Preclinical		biotechnology; vaccinecancer	
vaccine, breast cancer; immunotherapy, breast cancer; MUVAC	Preclinical		biotechnology; vaccinecancer	
vaccine, breast cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, breast cancer, CelSci	Preclinical		biotechnology; vaccinecancer	
vaccine, canarypox CEA; vaccine, cancer; ALVAC-CEA	Phase I		biotechnology; vaccinecancer	
vaccine, cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, cancer, MedImmune	Discontinued		biotechnology; vaccinecancer	
vaccine, cervical cancer; vaccine, Hsp65-HPV E7 fusion protein; Hsp65E7; HspE7; ONCOCINE	Phase I		biotechnology; vaccinecancer	
vaccine, colorectal and lung cancers; colorectal and lung cancers vaccine; OncoVax-CL	Phase II		biotechnology; vaccinecancer	

vaccine, colorectal cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, Epstein Barr viral coat protein; vaccine, EBV	Preclinical		biotechnology; vaccineglandular fever; cancer	
vaccine, Epstein-Barr virus gp 220-340; vaccine, EBV	Clinicals		biotechnology; vaccinecancer	
vaccine, gp75 antigen; vaccine, cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, hepatitis B core antigen fusion proteins, National Institutes of Health; vaccine, cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, HER/neu-2 oncogene; vaccine, breast cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, human papilloma virus; vaccine, cervical cancer; vaccine, HPV	Phase I		biotechnology; vaccinecancer	
vaccine, human papillomavirus; therapeutic antigen, cervical cancer; vaccine, HPV; TA-HPV	Phase II		biotechnology; vaccinecancer; viral infection	

vaccine, human papillomavirus; therapeutic antigen, genital warts; vaccine, HPV; TA-GW	Phase II		biotechnology; vaccine	viral infection; cancer
vaccine, mage-1; vaccine, melanoma; TBC-Mage-1; MAGEVAC	Discontinued		biotechnology; vaccine	cancer
vaccine, MART-1; vaccine, melanoma	Phase I		biotechnology; vaccine	cancer
vaccine, mutant p53 and ras peptide activated monocytes	Phase I		biotechnology; vaccine	cancer
vaccine, neu; vaccine, breast and ovarian cancer; TBC-NEU	Preclinical		biotechnology; vaccine	cancer
vaccine, papilloma virus HPV 16; vaccine, cervical cancer	Discontinued		biotechnology; vaccine	cancer
vaccine, prostate cancer; immunotherapy, prostate cancer; PROSTVAC	Phase I		biotechnology; vaccine	cancer
vaccine, prostate cancer	Preclinical		biotechnology; vaccine	cancer
vaccine, prostate cancer; prostate cancer vaccine; NORELIN	Phase II		biotechnology; vaccine	cancer

SD-144110.1

vaccine, prostate cancer, CelSci	Preclinical		biotechnology; vaccine	cancer
vaccine, ras; vaccine, colorectal cancer; TBC-RAS; RASVAC	Discontinued		biotechnology; vaccine	cancer
vaccine, recombinant dendritic cells, Duke University	Phase I		biotechnology; vaccine	cancer
vaccine, TBC-CEA; vaccine, cancer; TBC-CEA	Phase II		biotechnology; vaccine	cancer
vaccine, tumor; tumor vaccine	Discontinued		biotechnology; vaccine	cancer
virus derived particles, human papillomavirus; VDPs, HPV	Discontinued		biotechnology; vaccine	cancer
thymalfasin; thymosin alpha-1; T-1; ZADAXIN	Marketed	(N-acetyl)-ser-asp-ala-ala-val-asp-thr-ser-ser-glu-ile-thr-thr-lys-asp-leu-lys-glu-lys-lys-glu-val-val-glu-glu-ala-glu-asn-OH	biotechnology; vaccine; adjuvant; immunostimulant; peptide	cancer; viral infection
vaccine, human papilloma E7 antigen; vaccine, HPV; vaccine, cervical cancer	Preclinical		biotechnology; vaccine; biotechnology	cancer
vaccine, gene-based, cancer	Preclinical		biotechnology; vaccine; gene therapy	cancer

vaccine, gene-based, non-Hodgkin's B cell lymphoma; VAXID	Phase II		biotechnology; vaccine; gene therapy	cancer
vaccine, gene-based, T cell lymphoma; APL 400020; GENEVAX	Preclinical		biotechnology; vaccine; gene therapy	cancer
vaccine, ALVAC-hB7.1; vaccine, ovarian carcinoma; AUT-OV-ALVAC-hB7.1	Phase I		biotechnology; vaccine; immunostimulant	cancer
vaccine, cervical intraepithelial neoplasia; TA-CIN; TA-CIN	Preclinical		biotechnology; vaccine; immunostimulant	cancer
MAb, I-Mel-1; I-Mel-1; MELIMMUNE-1	Discontinued		biotechnology; vaccine; monoclonal antibody	cancer
MAb, I-Mel-1 + MAb, I-Mel-2; MAb, I-Mel-2 + MAb, I-Mel-1; MELIMMUNE	Discontinued		biotechnology; vaccine; monoclonal antibody	cancer
MAb, idiotypic 105AD7; MAb, anti-idiotypic gp72; 105AD7	Phase III		biotechnology; vaccine; monoclonal antibody	cancer
MAb, neuroblastoma/glioma; MAb, NG 1; MAb, cancer; NG 1; MONOPHARM G	Preclinical		biotechnology; vaccine; monoclonal antibody	cancer

SD-144110.1

vaccine, MAb, anti-idiotype, cancer; vaccine, cancer; MAb, cancer	Preclinical			biotechnology; vaccine; monoclonal antibody	cancer
vaccine, melanoma; MAb, MK2-23	Phase II			biotechnology; vaccine; monoclonal antibody	cancer
minodronic acid; YM 529; YH 529	Phase II	(1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethylidene)bisphosphonic acid		bisphosphonate	osteoporosis; hypercalcemia; cancer
meridronic acid; aminohexane diphosphonate; AHDP Na	Discontinued	(6-amino-1-hydroxyhexylidene)diphosphonic acid		bisphosphonate	Paget disease; osteoporosis; cancer
pamidronic acid; pamidronate disodium; APD; CGP 2339AE; ARELIA; OSTEOKIT	Marketed	(3-amino-1-hydroxypropylidene)bisphosphonic acid		bisphosphonate	osteoporosis; cancer
ibandronic acid; ibandronate sodium; BM 210955; BONDRONAT	Marketed	[1-hydroxy-3-(methylpentylamino)propylidene]bisphosphonic acid		bisphosphonate; postmenopausal osteoporosis	osteoporosis; cancer; hypercalcemia

RC 3095	Phase I	(3R)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carbonyl-L-glutamyl-L-tryptophyl-L-alanyl-L-valylglycyl-N-[[1(S)-1-[(1S)-1-(aminocarbonyl)-3-methylbutyl]amino]methyl]-3-methylbutyl]-L-histidinamide	bombesin antagonist	cancer
D 22213	Phase I	[1(R),6[S-(R*,R*)]]-N2-[(2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl)carbonyl]-L-glutamyl-L-tryptophyl-L-alanyl-L-valylglycyl-N-[[1-(aminocarbonyl)-3-methylbutyl]amino]methyl]-3-methylbutyl]-L-histidinamide monoacetate	bombesin antagonist; peptide	cancer

PAK 200	Discontinued	5-(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-1-[2-(4-morpholinyl)ethyl]-4-(3-nitrophenyl)-3-pyridinecarboxylic acid 2-[phenyl(phenylmethyl)amino]ethyl ester, P-oxide	calcium antagonist	cancer
dilazep; ANGOSIR IS	Marketed	tetrahydro-1H-1,4-diazepine-1,4(SH)-dipropanol 3,4,5-trimethoxybenzoate (diester)	calcium channel blocker; hematoprotectant; chemoprotectant	cancer; cardiac therapy
D 1465	Discontinued		calcium channel blocker; MDR inhibitor	cancer
CP 55940	Preclinical	(1alpha,2beta,5alpha)-(-)-5-(1,1-dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol	cannabinoid	cancer
casein kinase inhibitors, ICOS	Preclinical		casein kinase inhibitor; immunosuppressant; NSAID	inflammation; cancer
aragusterol A; YTA 0040	Preclinical		Cdk/cyclin inhibitor	cancer
ONCONEX	Preclinical		chelating agent	cancer

glucarolactam; ND 2001	Discontinued	5-amino-5-deoxy-D-glucosaccharic acid-delta-lactam	chemoprotectant	cancer
myeloid progenitor inhibitory factor; MPIF-1; HG 00300	Phase II		chemoprotectant; biotechnology; hematoprotectant; hematopoiesis inhibitor; stem cell division inhibitor; chemokine	cancer
dexrazoxane; razoxane (+), (S); ICRF 187; NSC 169780; ADR529; ICI 59118; CARDIOXANE; EUCARDION; RAZOXIN; ZINECORE; ZINECARD; ANTRAGARD	Marketed	(+)-(S)-4,4'-propylenedi-2,6-piperazinedione	chemoprotectant; cytoprotectant	cancer; heart failure
gamma-linolenic acid + eicosapentaenoic acid; EF 27; AMELORAD; TARAGAM	Discontinued		chemoprotectant; cytoprotectant	cancer
ICRF 197	Preclinical		chemoprotectant; cytoprotectant	cancer; heart failure
MGI 136	Discontinued	diethyldithiocarbamate	chemoprotectant; cytoprotectant	cancer

WR 151327; NSC 335662	Preclinical	3-[[3-(methylamino)propyl]amino]-1-propanethiol dihydrogen phosphate ester	chemoprotectant; cytoprotectant	cancer; HIV infection
amifostine; ethiofos; gammaphos; WR 2721; NSC 296961; YM 08310; WR 2721C; ETHYOL	Marketed	2-[(3-aminopropyl)amino]ethanethiol dihydrogen phosphate	chemoprotectant; cytoprotectant; radioprotectant	cancer
hematopoietic growth factor inhibitors, Ligand	Preclinical		chemoprotectant; hematopoiesis inhibitor	cancer
hematopoietic progenitor cell inhibitor, University of Indiana	Preclinical		chemoprotectant; hematoprotectant; hematopoiesis inhibitor; stem cell division inhibitor	cancer
stem-cell division inhibitors, Terry Fox Laboratory	Discontinued		chemoprotectant; stem cell division inhibitor; hematopoiesis inhibitor	cancer
stem cell inhibitory factor, natural; SCIF	Discontinued		chemoprotectant; stem cell division inhibitor; hematoprotectant; hematopoiesis inhibitor	cancer
CRL 1095	Discontinued		chemosensitizer	cancer
CRL 1605	Preclinical		chemosensitizer	cancer
glutathione-S-transferase inhibitors, Telik	Preclinical		chemosensitizer	cancer

SD-144110.1

mapavin	Preclinical	3-[[[2-[(4-azido-2-nitrophenyl)amino]ethyl]amino]carbonyl]-4-O4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine	chemosensitizer	cancer
TER 199	Preclinical	(2R)-L-gamma-glutamyl-S-(phenylmethyl)-L-cysteiny]-2-phenylglycine	chemosensitizer	cancer
declopramide; OXI 104	Phase II		chemosensitizer; apoptosis inducer; radiosensitizer	cancer
CMDA; CJS 8	Preclinical	N-[4-[(2-chloroethyl)[2-(methylsulfonyl)oxy]ethyl]amino]benzoic acid	chlormethine derivative; alkylating agent	cancer
galamustine; galactose-6-mustard; C6 GLM; G 6 M	Discontinued	6-[bis(2-chloroethyl)amino]-6-deoxy-D-galactopyranose	chlormethine derivative; alkylating agent	cancer
SN 23862	Preclinical	5-[bis(2-chloroethyl)amino]-2,4-dinitrobenzamide	chlormethine derivative; alkylating agent	cancer
spiromustine; spirohydantoin mustard; SHM; speratine; NSC 172112	Phase II	3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione	chlormethine derivative; alkylating agent	cancer

tallimustine; FCE 24517	Discontinued	N-[5-[(3-amino-3-aminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[[4-bis(2-chloroethyl)amino]benzoyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrole-2-carboxamide	chlormethine derivative; alkylating agent	cancer
veramine; RL 0017	Preclinical	(3beta,16beta,17beta,22S,25S)-17-methyl-18-norspirosola-5,12-dien-3-ol	chlormethine derivative; alkylating agent	cancer
flunitript; SR 27897; SR 27897B	Phase II	2-[[[4-(2-chlorophenyl)-2-thiazolyl]amino]carbonyl]-1H-indole-1-acetic acid	cholecystokinin A antagonist; cholecystokinin antagonist	eating disorder; cancer
docosanol, n-; docosanol, l-; behenyl alcohol; LIDAKOL	Pre-registration	1-docosanol	cicatrizant	viral infection; skin ulcer; cancer
Myc/Max inhibitors, Apoptosis Technology; Myc/Max inhibitors, ICRF	Discontinued		cicatrizant	cancer; skin ulcer
OLX 501	Discontinued		collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	septic shock; cancer; vascular leakage

OLX 514	Discontinued			collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	septic shock; cancer
MAB, carcinoembryonic antigen; PR1A3	Phase I			contrast medium; monoclonal antibody; biotechnology; radiotherapeutic; radiodiagnostic	cancer; diagnosis
NLCQ 1	Preclinical	4-[3-(2-nitroimidazolyl)propylamino]-7-trifluoromethylquinoline hydrochloride		contrast medium; MRI contrast agent; imidazole	diagnosis; cancer
vasoactive intestinal peptide-iodine 123; VIP-I 123	Phase II			contrast medium; peptide	diagnosis; cancer
cancer therapy, Angstrom/Diatide	Preclinical			contrast medium; radiotherapeutic; radiodiagnostic	cancer
fludarabine + prednisone; prednisone + fludarabine	Discontinued			corticosteroid	cancer
ORG 6632	Discontinued	21-chloro-9alpha-fluoro-11beta-hydroxy-16alpha,17alpha-dimethylpregna-1,4-diene-3,20-dione		corticosteroid; immunosuppressant	cancer; rheumatoid arthritis

HX.0836	Preclinical	(E)-3-(3,4-dihydroxyphenyl)-1-(2,5-dimethoxyphenyl)-2-propen-1-one	COX inhibitor; 5-lipoxygenase inhibitor	cancer
celecoxib; SC 58635; YM 177; CELEBREX; CELEBRA	Marketed	4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis; pain; cancer
cyclocreatine; AM 285	Discontinued	2-amino-4,5-dihydro-1H-imidazole-1-acetic acid	creatine kinase modulator	cancer; viral infection
cdk2 inhibitors, Molecumetics	Preclinical		cyclin dependent kinase inhibitor	cancer
cyclin-dependent kinase inhibitor, Agouron; cancer therapy, Agouron	Preclinical		cyclin dependent kinase inhibitor	cancer
cyclin-dependent kinase/cyclin inhibitors, Mitotix; Cdk/cyclin inhibitors, Mitotix	Preclinical		cyclin dependent kinase inhibitor	cancer
cyclin-dependent kinase4 modulators, Pharmacopeia; cdk4 modulator, Pharmacopeia	Preclinical		cyclin dependent kinase inhibitor	cancer

flavopiridol; NSC 649890; HMR 1275	Phase II	cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-4H-1-benzopyran-4-one hydrochloride	cyclin dependent kinase inhibitor	cancer
CYC 202	Preclinical		cyclin dependent kinase inhibitor; apoptosis inducer	cancer
tumor necrosis factor alpha, natural; TNF alpha, natural; tinermin; MHR 24	Pre-registration		cytokine	cancer
granulocyte-colony stimulating factor agonists, Pharmacopeia; granulocyte-colony stimulating factor agonists, Regeneron	Preclinical		cytokine agonist	cancer
interferon agonists, Ligand	Preclinical		cytokine agonist; NSAID	cancer; viral infection; infectious disease; multiple sclerosis
cytokine trap, Regeneron	Preclinical		cytokine antagonist	cancer; asthma; rheumatoid arthritis; allergy
IL-6 receptor antagonist, Peptor	Preclinical		cytokine antagonist; peptide; NSAID	cancer

CNI 1493	Phase I	N,N'-bis[3,5-bis[(1-[(aminiminomethyl)hydrazono]ethyl]phenyl]-decanediamide tetrahydrochloride	cytokine synthesis inhibitor	cancer
drug delivery system, IL-2, Biovector Therapeutics	Preclinical		cytokine; biotechnology	cancer
delivery system, gene therapy, IL-2, Biovector Therapeutics; gene therapy, IL-2, Biovector Therapeutics	Preclinical		cytokine; biotechnology; gene therapy; immunostimulant	cancer
cytotoxic lymphocyte maturation factor; CLMF	Discontinued		cytokine; immunostimulant	cancer
LY 295501; ILX 295501	Phase I	N-[[[(3,4-dichlorophenyl)amino]carbonyl]-2,3-dihydro-5-benzofuransulfonamide	diarylsulfonylurea	cancer
sulofenur; LY 186641	Discontinued	N-[[[(4-chlorophenyl)amino]carbonyl]-2,3-dihydro-5-1H-indene-5-sulfonamide	diarylsulfonylurea	cancer
AN 9; PIVANEX	Phase II	butanoic acid (2,2-dimethyl-1-oxopropoxy)methyl ester	differentiation inducer	cancer

SD-144110.1

CBHA	Preclinical	N-hydroxy-3-[3-(hydroxyamino)-3-oxo-1-propenyl]-benzamide	differentiation inducer	cancer
EMBA	Preclinical	diethyl bis-(pentamethylene-N,N-dimethylcarboxamide)malonate	differentiation inducer	cancer
hexamethylene bisacetamide; HMB; NSC 95580; HEXABID	Phase II	N,N'-1,6-hexanediybisacetamide	differentiation inducer	cancer
NF 036	Preclinical	8-[(7-chloro-4-quinoliny)amino]-1,3,5-naphthalenetrisulfonic acid trisodium salt	differentiation inducer	cancer
SAHA; SW 064652	Preclinical	suberoylanilide hydroxamic acid	differentiation inducer	cancer
TI 66	Preclinical	6-fluoro-7,7,8,8-tetramethyl-2,4-bis(phenylmethyl)-2,4-diazabicyclo[4.2.0]octane-3,5-dione	differentiation inducer	cancer
CDDO	Preclinical	2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid	differentiation inducer; antiproliferative agent	cancer

alitretinoin; LGD 1057; LG 1057; LGN 1057; ALRT 1057; NSC 659772; PANRETIN	Marketed	9-cis-retinoic acid	differentiation inducer; retinoid agonist; RAR agonist; RXR agonist	cancer; psoriasis
AG 187	Discontinued	2,4-diamino-6-(N-(4-(phenylsulfonyl)benzyl)methylamino)quinazoline	dihydrofolate reductase inhibitor	cancer
LY 298207	Preclinical	N-[4-[4-(2,4-diamino-5-pyrimidinyl)butyl]benzoyl]-L-glutamic acid	dihydrofolate reductase inhibitor	cancer
LY 316373	Preclinical	N-[4-[3-(2,4-diamino-5-pyrimidinyl)propyl]benzoyl]-L-glutamic acid	dihydrofolate reductase inhibitor	cancer
trimetrexate; trimetrexate glucuronate; TMQ; NSC 249008; CI 898; NeuTrexin	Marketed	5-methyl-6-[[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediazine	dihydrofolate reductase inhibitor; antifolate; NSAID	cancer; psoriasis; rheumatoid arthritis; pneumocystis
drug delivery system, methotrexate; methotrexate Therapeutic Implant; MPI 5004; IntraDose-MTX; INTRADOSE-MTX	Discontinued		dihydrofolate reductase inhibitor; antimetabolite	cancer

MDAM	Phase I	N-[4-[2-(2,4-diamino-6-pteridinyl)ethyl]benzoyl]-4-methylene-DL-glutamic acid	dihydrofolate reductase inhibitor; NSAID; immunosuppressant	cancer; transplant rejection; rheumatoid arthritis; asthma
eniluracil; 5-ethynyluracil; 5-EU; 776C85; BW 776C85	Phase III	5-ethynyl-2,4-(1H,3H)-pyrimidinedione	dihydropyrimidine dehydrogenase inhibitor; antimetabolite	cancer
spirogermanium; NSC 192965; SPIRO-32	Discontinued	8,8-diethyl-N,N-dimethyl-2-aza-8-germaspiro[4.5]decan-2-propanamine	DMARD; NSAID	malaria; multiple sclerosis; rheumatoid arthritis; cancer
acridine-derived bisintercalators, NIH	Preclinical		DNA intercalator	cancer
anticancer agents, Kyowa Hakko	Discontinued		DNA intercalator	cancer
BBR 2778	Phase I	6,9-bis[(2-aminoethyl)amino]benz[g]isoquinoline-5,10-dione (Z)-2-butenedioate (1:2)	DNA intercalator	cancer
bisnafide; DMP 840	Phase II	[R-(R*,R*)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)dione] dimethanesulfonate	DNA intercalator	cancer
BW 7U85	Discontinued		DNA intercalator	cancer
BW A502U; BW 502U83	Discontinued		DNA intercalator	cancer

crisnatol; mesilate; BW 770U82; BWA 770U	Discontinued	2-[(6-chrysenylmethyl)amino]-2-methyl-1,3-propanediol	DNA intercalator	cancer
D 1411	Discontinued		DNA intercalator	cancer
DMP 315	Preclinical	[R-(R*,R*)]-5-[1-methyl-2-[[2-(5-nitro-1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)propyl]amino]ethyl]amino]ethyl-4H-benzo[de]pyrido[3,4-g]isoquinoline-4,6(5H)dione dimethanesulfonate	DNA intercalator	cancer
ledoxantrone; CI 958 isomer; PD 121373	Phase II	5-[(2-aminoethyl)amino]-2-[[2-(diethylamino)ethyl]-2H-[1]benzothiopyrano[4,3,2-cd]indazol-8-ol	DNA intercalator	cancer
mitonafide; NSC 3002888	Phase II	2-[2-(dimethylamino)ethyl]-5-nitro-1H-benz[de]isoquinoline-1,3(2H)-dione	DNA intercalator	cancer

S 160202; S 16020-2; Phase II S 16020; NSC 659687; NSC D659687		N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide dihydrochloride	DNA intercalator	cancer
cyclopentantraquinones, Sloan Kettering Institute	Preclinical		DNA intercalator; anthraquinone	cancer
OC 4845	Preclinical	1,1a,2,2a,5,10-hexahydro-3[[[methylethyl]oxy]methyl]-azirino[2',3':3,4]cyclopenta[1,2-a]anthracene-5,10-dione	DNA intercalator; anthraquinone	cancer
C 1311	Phase I	5-[[2-(diethylamino)ethyl]amino]-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one	DNA intercalator; DNA topoisomerase inhibitor	cancer
NLP.1	Preclinical	5-[3-(2-nitro-1H-imidazol-1-yl)propyl]phenanthridinium bromide	DNA intercalator; radiosensitizer	cancer

aphidicolin glycinate; NSC 303812	Preclinical	glycine, (3 α ,4 α ,5 α ,17 α)- 3,17-dihydroxy-4- methyl-9,15-cyclo- C,18-dinor-14,15- secoandrostane-4,17- dimethanol ester hydrochloride	DNA polymerase inhibitor	cancer
DNA polymerase beta inhibitors, Agouron	Discontinued		DNA polymerase inhibitor; radiosensitizer; chemosensitizer	cancer
NU/ICRF 505	Discontinued		DNA topoisomerase inducer	cancer
UCT 4B; UCTB 4	Discontinued	2-[1-hydroxy-2- [1,2,3,4,4a,7,8,8a- octahydro-3-hydroxy- 5-(hydroxymethyl)- 1,2,4a-trimethyl-4- oxo-1- naphthalenyl]ethyl]- alpha-oxo- oxiraneacetaldehyde	DNA topoisomerase inducer; antibiotic	bacterial infection; cancer
9- aminocamptothecin; 9-AC; NSC 603071 (S); NSC 629971 (+, -); FCE 28044	Phase II	(S)-10-amino-4-ethyl- 4-hydroxy-1H- pyrano[3',4':6,7]indoli- zino[1,2-b]quinoline- 3,14(4H,12H)-dione	DNA topoisomerase inhibitor	cancer
AMP 53; azonafide 53	Discontinued		DNA topoisomerase inhibitor	cancer

asulacrine; amsalog; CI 921; NSC 343499; SN 21407	Phase I	9-[[[2-methoxy-4- [(methylsulfonyl)ami- no]phenyl]amino]- N,5-dimethyl-4- acridinecarboxamide (5R-cis)-5,6,11,11a- tetrahydro-5-(4- hydroxy-3,5- dimethoxyphenyl)- 1H,3H- oxazolo[3,4-b]indol-3-one do[3,4-b]indol-3-one	DNA topoisomerase inhibitor	cancer
azatoxin; NSC 640737	Preclinical	(5R-cis)-5,6,11,11a- tetrahydro-5-(4- hydroxy-3,5- dimethoxyphenyl)- 1H,3H- oxazolo[3,4-b]indol-3-one	DNA topoisomerase inhibitor	cancer
BE 10988	Discontinued	2-(5-amino-4,7- dihydro-1-methyl- 4,7-dioxo-1H-indol- 3-yl)-4- thiazolecarboxamide	DNA topoisomerase inhibitor	cancer
BE 13793C	Discontinued	12,13-dihydro-1,11- dihydroxy-5H- indolo[2,3- a]pyrrolo[3,4- c]carbazole-5,7(6H)- dione	DNA topoisomerase inhibitor	cancer
BE 22179	Discontinued		DNA topoisomerase inhibitor	cancer
BN 80915	Phase I		DNA topoisomerase inhibitor	cancer
BNP 1350	Phase I		DNA topoisomerase inhibitor	cancer
BNPI 1100	Preclinical		DNA topoisomerase inhibitor	cancer

BO 2367	Discontinued	(-)-7-[1R*,2R*,6R*)-2-amino-8-azabicyclo[4.3.0.]non-3-en-8-yl]-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid	DNA topoisomerase inhibitor	cancer
camptothecin analogues, Research Triangle Institute	Preclinical		DNA topoisomerase inhibitor	cancer
camptothecin derivatives, Daiichi	Discontinued		DNA topoisomerase inhibitor	cancer
CKD 602	Phase I	4-ethyl-4-hydroxy-11-[2-[(1-methylethyl)amino]ethyl]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione	DNA topoisomerase inhibitor	cancer
DM II 33	Preclinical		DNA topoisomerase inhibitor	cancer
DNA topoisomerase inhibitor, second generation, Xenova; XR 5942 series; XR 5942	Preclinical		DNA topoisomerase inhibitor	cancer
DRF 1042	Preclinical		DNA topoisomerase inhibitor	cancer

drug delivery system, camptothecin; camptothecin delivery system; MPI 5019	Preclinical			DNA topoisomerase inhibitor	cancer
drug delivery system, liposome lurtotecan; lurtotecan liposome; NX 211	Phase I			DNA topoisomerase inhibitor	cancer
drug delivery system, microspheres 10-hydroxycamptothecin; 10-hydroxycamptothecin microspheres	Preclinical			DNA topoisomerase inhibitor	cancer
DX 8951; DX 8951f	Phase II		(1S-trans)-1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10H,13H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione monomethanesulfonate	DNA topoisomerase inhibitor	cancer

ED 110	Discontinued	12-beta-D-glucopyranosyl-12,13-dihydro-1,11-dihydroxy-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione	DNA topoisomerase inhibitor	cancer
ER 37328	Preclinical	12,13-dihydro-5-[2-(dimethylamino)ethyl]-4H-benzo[c]pyrimido[5,6,1-jk]carbazole-4,6,10(5H,11H)-trione	DNA topoisomerase inhibitor	cancer
F 11782; F 1267; L 0084	Preclinical	[5R-[5alpha,5abeta,8aalpha,9beta(R*)]]-5-[3,5-dimethoxy-4-(phosphonoxy)phenyl]-9-[[4,6-O-ethylidene-2,3-bis-O-[(pentafluorophenoxy)acetyl]-beta-D-glucopyranosyl]oxy]-5,8,8a9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one	DNA topoisomerase inhibitor	cancer

fostriecin; NSC 339638; CI 920; CL 1565A	Phase I	5,6-dihydro-6- [3,6,13-trihydroxy-3- methyl-4- (phosphonoxy)- 1,7,9,11- tridecatetraenyl]-2H- pyran-2-one monosodium salt	DNA topoisomerase inhibitor	cancer
HAR 7	Preclinical		DNA topoisomerase inhibitor	cancer
intoplicine; RP 60475; NSC D645008	Phase I	11-[[3- (dimethylamino)prop yl]amino]-8-methyl- 7H- benzo[e]pyrido[4,3- b]indol-3-ol	DNA topoisomerase inhibitor	cancer
irinotecan; irinotecan hydrochloride; camptothecin 11; CPT 11; DQ 2805; SN 3811; U 101440E; CPT 11; CAMPTO; TOPOTECIN; CAMPTOSAR; IRKAN	Marketed	(1,4'-bipiperidine)-1'- carboxylic acid (S)- 4,11-diethyl- 3,4,12,14-tetrahydro- 4-hydroxy-3,14- dioxo-1H- pyrano(3',4':6,7)indoli zino(1,2-b)quinolin- 9-yl ester, monohydrochloride	DNA topoisomerase inhibitor	cancer

lurtotecan; lurtotecan dihydrochloride; GG 211; GI 147211; GI 147211A; GI 147211C	Suspended	(S)-8-ethyl-2,3-dihydro-8-hydroxy-15-[(4-methyl-1-piperazinyl)methyl]-11H-1,4-dioxino[2,3-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-9,12(8H,14H)-dione	DNA topoisomerase inhibitor	cancer
MPI 6003	Discontinued		DNA topoisomerase inhibitor	cancer
NB 506	Phase I	N-(12-beta-D-glucopyranosyl)-5,7,12,13-tetrahydro-1,11-dihydroxy-5,7-dioxo-6H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-6-yl)-formamide	DNA topoisomerase inhibitor	cancer
NC 190; NCU 190	Discontinued	6-[[[2-(dimethylamino)ethyl]amino]carbonyl]-5-hydroxy-10-methoxybenzo[a]phenazine-9-carboxylic acid monosodium salt	DNA topoisomerase inhibitor	cancer
NCA 0465	Preclinical		DNA topoisomerase inhibitor	cancer
NK 109; NK 106	Phase I	1-Hydroxy-2-methoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridinium, sulfate (1:1) (salt)	DNA topoisomerase inhibitor	cancer

NU/ICRF 500	Discontinued		DNA topoisomerase inhibitor	cancer
NU/ICRF 506	Discontinued		DNA topoisomerase inhibitor	cancer
polyethylene glycol-camptothecin; PEG-camptothecin; camptothecin macrogol; PROTHECAN	Preclinical		DNA topoisomerase inhibitor	cancer
tubitecan; 9-nitrocamptothecin; RFS 2000	Phase III		DNA topoisomerase inhibitor	cancer
sobuzoxane; MST 16; Marketed PERAZOLIN	Marketed	1,2-ethanediy]bis[(2,6-dioxo-4,1-piperazinediy])methyl]ene]bis(2-methylpropyl) carbonic acid ester	DNA topoisomerase inhibitor	cancer
TAN 1496	Discontinued		DNA topoisomerase inhibitor	cancer

TAN 1518A	Discontinued	2-hydroxybenzoic acid 3-(aminocarbonyl)-8-[2,6-dideoxy-4-O-(2-methyl-1-oxo-2-butenyl)hexopyranosyl]-1,4,4a,6,11,11a,12,12a-octahydro-2,4a,5,7-tetrahydroxy-11-methoxy-11-methyl-4,6-dioxo-1-naphthacenyl ester	DNA topoisomerase inhibitor	cancer
TAS 103	Phase I	6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one	DNA topoisomerase inhibitor	cancer
teniposide; VM 26; NSC 122819; VUMON; BEKNOS; VEHEM SANDOZ	Marketed	[5R-[5-alpha,5beta,8alpha,9beta(R*)]]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-beta-D-glucopyranosyl]oxy]furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one	DNA topoisomerase inhibitor	cancer

TOP 53	Phase I	[5R-(5alpha,5beta,8alpha,9beta)]-9-[2-[[2-(dimethylamino)ethyl]-[methylethylamino]ethyl]-5,8,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one]	DNA topoisomerase inhibitor	cancer
topoisomerase inhibitor, Biota	Preclinical		DNA topoisomerase inhibitor	cancer
topotecan; hycamtamine; SKF 104864; SKF 104864A; HYCAMTIN	Marketed	(S)-10-[[[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione]	DNA topoisomerase inhibitor	cancer
WIN 63320	Discontinued		DNA topoisomerase inhibitor	cancer
WIN 64593	Discontinued		DNA topoisomerase inhibitor	cancer
XR 5000; NSC 601316; DACA	Phase I	N-[2-(dimethylamino)ethyl]-4-acridinecarboxamide	DNA topoisomerase inhibitor	cancer

AD 312	Preclinical	(8S-cis)-8-acetyl-10-[[[3-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	DNA topoisomerase inhibitor; anthracycline; alkylating agent; antibiotic	cancer
elsamitrucin; elsamicin A; BMY 28090; NSC 369327; BMS 181171	Discontinued	10-[[2-O-(2-amino-2,6-dideoxy-3-O-methyl- α -D-galactopyranosyl)-6-deoxy-3-C-methyl-beta-D-galactopyranosyl]oxy]-6-hydroxy-1-methylbenzo[h][1]benzopyrano[5,4,3-cde][1]benzopyran-5,12-dione	DNA topoisomerase inhibitor; antibiotic	cancer
DNA topoisomerase inhibitors, AVAX Technologies	Preclinical		DNA topoisomerase inhibitor; antifungal	cancer; mycosis; parasitic infection
elinafide; LU 79553	Phase I	2,2'-[1,3-propanediylbis(imino-2,1-ethanediyl)]bis-1H-benz[de]isoquinolone-1,3(2H)-dione	DNA topoisomerase inhibitor; DNA intercalator	cancer

LU 55446	Discontinued			DNA topoisomerase inhibitor; DNA intercalator	cancer
dosergoside; AF 1	Discontinued		[8beta(1S,2R,3E)]-N-[2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl]-6-methylergoline-8-carboxamide	dopamine agonist	cancer; infertility
drug delivery system, bromocriptine; bromocriptine delivery system; ERGOSET	Pre-registration			dopamine agonist	diabetes; obesity; cancer
ST 557	Discontinued			dopamine agonist; immunostimulant	cancer
ST 570	Discontinued			dopamine agonist; immunostimulant	cancer
Pan-Her inhibitors, SUGEN; Her2 inhibitors, SUGEN	Preclinical			EGF receptor inhibitor	cancer
LFM A12	Preclinical		(Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethoxy)phenyl]-2-butenamide	EGF receptor inhibitor; tyrosine kinase inhibitor	cancer

ABT 627; A 127722; A 147627	Phase II	[2S-(2alpha,3beta,4alpha)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid	endothelin antagonist; endothelin A antagonist	cancer; restenosis; myocardial infarction
BE 14348B	Discontinued	2(S),3(S)-3-methyl-4',5,7-trihydroxy-flavanone	estrogen agonist	cancer
GW 5638	Preclinical	(E,Z)-3-[4-(1,2-diphenyl-1-butenyl)phenyl]-2-propenoic acid	estrogen agonist; antiestrogen	osteoporosis; cancer; coronary artery disease
CP 336156	Phase II	(5R,6S)-5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyloxy)phenyl]-2-naphthalenol (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt)	estrogen partial agonist	osteoporosis; cancer
2-methoxyestradiol; 2-ME	Preclinical		estrogen; angiogenesis inhibitor	cancer
estrogen receptor therapy, Ligand/Wyeth Ayerst	Preclinical		estrogen; hormone replacement therapy	hormone deficiency; contraception; cancer; osteoporosis
EMATE	Discontinued	3-[(aminosulfonyloxy)estra-1,3,5(10)trien-17-one	estrene sulfatase inhibitor	cancer

ara-CDP-DL-PTBA; CYTOROS	Preclinical	4-amino-1-[5-O-[1,3-dihydroxy-6-[(1-oxohexyloxy)-2,4-dioxa-8-thia-1,3-diphosphahexacos-1-yl]-beta-D-arabino-furanosyl]-2(1H)-pyrimidinone P,P'-dioxide	ether lipid	cancer
edelfosine; ET 18-OCH ₃ ; ALP	Pre-registration	(+,-)-4-hydroxy-7-methoxy-N,N,N-trimethyl-3,5,9-trioxo-4-phosphahaptacosan-1-aminium hydroxide inner salt, 4-oxide	ether lipid	cancer
EG 6	Preclinical	1-[4-[2-[2-(octadecyloxy)ethoxy]ethoxy]butyl]pyridinium methanesulfonate	ether lipid	cancer
ether lipid, Roswell Park	Preclinical	ara-CDP-rac-1-S-tetradecyl-2-O-palmitoyl-1-thioglycerol	ether lipid	cancer
ether lipid, Vancouver University	Preclinical	4-(hexadecyloxy)-3-(S)-methoxybutyl phosphonylcholine	ether lipid	cancer

ilmofofine; BM 41440; BM 21440	Discontinued	4-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-3,5-dioxo-9-thia-4-phosphapentacosan-1-aminium hydroxide, inner salt, 4-oxide	ether lipid	cancer
miltefosine; hexadecylphonylcholine; HPC; D 18506; MILTEX	Marketed	2-[[[(hexadecyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethylethanaminium, hydroxide, inner salt	ether lipid	cancer; leishmaniasis
perifosine; D 21266; NKA 17	Phase I	4-[[[hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethylpiperidinium inner salt	ether lipid	cancer
SRI 34234	Discontinued	(+,-)-2-[[[hydroxy[[tetrahydro-2-[(octadecyloxy)methyl]-2-furanyl]methoxy]phosphinyl]oxy]-N,N,N-trimethylethanaminium, inner salt	ether lipid	cancer
SRI 62834	Discontinued		ether lipid	cancer; multiple sclerosis
TLC ELL 12; ELL 12	Phase I		ether lipid	cancer

SDZ 62826	Discontinued		ether lipid; immunostimulant	cancer
etoposide phosphate; BMY 40481; ETOPOPHOS	Marketed	(5R,5aR,8aR,9S)-5-[3,5-dimethoxy-4-(phosphonoxy)phenyl]-9-[(4,6-O-(1R)-ethylidene-beta-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one	etoposide analogue	cancer
IGT 13	Preclinical		etoposide analogue	cancer
NK 611; VP 19; 2'-(dimethylamino)etoposide	Phase II	[5R-[5alpha,5a-beta,8a-alpha,9beta(R*)]]-9-[[2-deoxy-2-(dimethylamino)-4,6-O-ethylidene-beta-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one hydrochloride	etoposide analogue	cancer

GL 331	Phase II	[5R-(5alpha,5beta,8alpha,9beta)]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-nitrophenyl)amino]furo[3,4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one	etoposide analogue; DNA topoisomerase inhibitor	cancer
ARGLABIN	Registered		farnesyl protein transferase inhibitor	cancer
B 956	Preclinical	[2S-(2R*,3Z,5R*,6E,8S*)]-N-[8-amino-9-mercapto-5-(1-methylethyl)-1-oxo-2-(phenylmethyl)-3,6-nonadienyl]-L-methionine	farnesyl protein transferase inhibitor	cancer
farnesyl transferase inhibitors	Discontinued		farnesyl protein transferase inhibitor	cancer
L 639749	Preclinical		farnesyl protein transferase inhibitor	cancer

L 744832	Preclinical	[2S- [1[R*(R*),2R*(S),3 R*]]-2-[[2-[[2-amino- 3- mercaptopropyl)amin o]-3- methylpentyl]oxy]-1- oxo-3- phenylpropyl]amino]- 4-(methylsulfonyl)- butanoic acid, 1- methyl ethyl ester	farnesyl protein transferase inhibitor	cancer
L 778123	Phase I		farnesyl protein transferase inhibitor	cancer
PD 169451	Preclinical		farnesyl protein transferase inhibitor	cancer
perillyl alcohol; NSC 641066	Phase II	4-(1-methylethenyl)- 1-cyclohexene-1- methanol	farnesyl protein transferase inhibitor	cancer
ras farnesyl protein transferase inhibitors, Parke Davis	Preclinical		farnesyl protein transferase inhibitor	cancer
ras farnesyl protein transferase inhibitors, University of Pittsburgh	Preclinical		farnesyl protein transferase inhibitor	cancer
RPR 115135	Preclinical		farnesyl protein transferase inhibitor	cancer

SCH 59228	Preclinical	1-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-4-[(1-oxido-4-pyridinyl)acetyl]piperazine	farnesyl protein transferase inhibitor	cancer
L 731734	Discontinued	[3S-[3R*[2R*[2R*(S*),3S*,3R*]]]-2-[(2-amino-3-mercaptopropyl)amino]-3-methylpentyl]amino]-3-methyl-N-(tetrahydro-2-oxo-3-furanyl)pentanamide	farnesyl protein transferase inhibitor; peptide	cancer
L 731735	Discontinued	[2S-[2R*(S*),3S*]]-N-[N-[2-[(2-amino-3-mercaptopropyl)amino]-3-methylpentyl]-L-isoleucyl]-L-homoserine	farnesyl protein transferase inhibitor; peptide	cancer
R 115777	Phase II		farnesyl protein transferase inhibitor; signal transduction inhibitor	cancer
SCH 66336	Phase II		farnesyl protein transferase inhibitor; signal transduction inhibitor	cancer

TOP 53	Phase I	[5R-(5alpha,5beta,8alpha,9beta)]-9-[2-[(2-(dimethylamino)ethyl)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)]-one	DNA topoisomerase inhibitor	cancer
topoisomerase inhibitor, Biota	Preclinical		DNA topoisomerase inhibitor	cancer
topotecan; hycamtamine; SKF 104864; SKF 104864A; HYCAMTIN	Marketed	(S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione	DNA topoisomerase inhibitor	cancer
WTN 63320	Discontinued		DNA topoisomerase inhibitor	cancer
WTN 64593	Discontinued		DNA topoisomerase inhibitor	cancer
XR 5000; NSC 601316; DACA	Phase I	N-[2-(dimethylamino)ethyl]-4-acridinecarboxamide	DNA topoisomerase inhibitor	cancer

BIM 26028	Discontinued		gastrin antagonist; bombesin antagonist	cancer; cachexia; respiratory disease
CDP 845	Discontinued		gelatinase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; angiogenesis inhibitor	cancer
CT 1746	Discontinued		gelatinase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
gelatinase inhibitors, Celltech	Preclinical		gelatinase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
basal cell carcinoma therapy, Ontogeny; patched gene; ptc gene	Preclinical		gene	cancer; skin disease
bcl-6-based non- Hodgkin's lymphoma therapy	Preclinical		gene	cancer
cancer therapy, cancer cell growth genes	Preclinical		gene	cancer
CDK4 based therapy, Axs; melanoma therapy, Axs	Preclinical		gene	cancer
HFE-based therapies, Progenitor	Preclinical		gene	iron overload; cancer

immune system modulators, Chiroscience	Preclinical		gene	autoimmune disease; rheumatoid arthritis; cancer; HIV infection
melanoma differentiation-associated genes	Discontinued		gene	cancer
MMAC1 based therapy, Myriad	Preclinical		gene	cancer
MTS2 based therapy, Myriad	Preclinical		gene	cancer
MTS3 based therapy, Myriad; cancer therapy, Myriad	Preclinical		gene	cancer
mum-1-based cancer therapy	Preclinical		gene	cancer
P-TEN-based cancer therapy, Amplicon	Preclinical		gene	cancer
prostate tumor-inducing genes	Discontinued		gene	cancer; diagnosis
gene therapy, ATase	Preclinical		gene therapy; biotechnology	cancer
gene therapy, C-CAM, Introgen; adenoviral C-CAM, Introgen; INGN 231	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer; SMART GENETIC CONSTRUCTS	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer	Preclinical		gene therapy; biotechnology	cancer

gene therapy, cancer	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer, Cobra Therapeutics; CTL 102; TXS 0202	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer, pulmonary disease	Preclinical		gene therapy; biotechnology	cancer; respiratory disease
gene therapy, hepatocellular carcinoma; HepXia	Preclinical		gene therapy; biotechnology	cancer
gene therapy, ovarian and pancreatic cancer	Preclinical		gene therapy; biotechnology	cancer
gene therapy, ovarian cancer; gene therapy, brca1, MB 700	Preclinical		gene therapy; biotechnology	cancer
gene therapy, p16, p27; gene therapy, restenosis; gene therapy, cancer	Preclinical		gene therapy; biotechnology	restenosis; cancer
gene therapy, p53; gene therapy, cancer	Phase I		gene therapy; biotechnology	cancer
gene therapy, scFV/gamma G250; gene therapy, renal carcinoma	Preclinical		gene therapy; biotechnology	cancer
gene therapy, stress proteins	Preclinical		gene therapy; biotechnology	cancer
gene therapy, thymidine kinase; gene therapy, cancer; gene therapy, HS-tk	Phase I		gene therapy; biotechnology	cancer

SD-144110.1

gene therapy, thymidine kinase; gene therapy, glioma	Preclinical		gene therapy; biotechnology	cancer
gene therapy, tumor antigens; gene therapy, cancer	Preclinical		gene therapy; biotechnology	cancer
gene therapy, ATF BTP1; gene therapy, cancer	Preclinical		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, colorectal cancer, Oxford BioMedica; CoRectoGen	Preclinical		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, glioma, Oxford Biomedica; GlioStat	Preclinical		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, ovarian cancer, Oxford BioMedica; BetOvaC	Preclinical		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, prostate cancer; ProCaStat	Preclinical		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, interleukin-2, Transgene; gene therapy, cancer	Phase I		gene therapy; biotechnology; cytokine; immunostimulant	cancer
gene therapy, wt p53; gene therapy, cancer	Preclinical		gene therapy; biotechnology; radiosensitizer; chemosensitizer	cancer

vaccine, gene-based, colorectal cancer; vaccine, gene-based, CO17-A/GA733; AV GA 7332	Phase I		gene therapy; biotechnology; vaccine	cancer
vaccine, gene-based, human papilloma virus	Preclinical		gene therapy; biotechnology; vaccine	cancer
progression elevated genes	Discontinued		gene; angiogenesis inhibitor	cancer
glutathione inhibitors, Telik	Discontinued		glutathione inhibitor	cancer
AG 2026	Discontinued		glycinamide ribotide formyltransferase inhibitor	cancer
AG 2032	Discontinued		glycinamide ribotide formyltransferase inhibitor	cancer
AG 2034	Phase I	(S)-N-[[5-[2-(2-amino-4,6,7,8-tetrahydro-4-oxo-1H-pyrimido[5,4-b][1,4]thiazin-6-yl)ethyl]-2-thienyl]carbonyl]-L-glutamic acid	glycinamide ribotide formyltransferase inhibitor	cancer
AG 2037	Preclinical		glycinamide ribotide formyltransferase inhibitor	cancer
contortrostatin; CN	Preclinical		glycoprotein IIb/IIIa antagonist; platelet antiaggregant; biotechnology	cancer; thrombosis

mannostatin A	Preclinical	[1R-(1alpha,2alpha,3alpha,4alpha,5beta)]-4-amino-5-(methylthio)-1,2,3-cyclopentanetriol	glycosidase inhibitor	cancer
glycosidase inhibitor, Oxford GlycoSciences	Preclinical		glycosidase inhibitor; NSAID	cancer; rheumatoid arthritis
drug delivery system, ATRIGEL sustained release leuporelin; leuporelin ATRIGEL	Preclinical		gonadorelin agonist	cancer
drug delivery system, microparticle buserelin; buserelin microparticle delivery system	Phase III		gonadorelin agonist	cancer; endometriosis
drug delivery system, sustained release LHRH analogue; LHRH analogue delivery system; ProMaxx, LHRH analogue; ProMaxx 100	Clinicals		gonadorelin agonist	cancer

goserelin; goserelin acetate; ICI 118630; ZOLADEX	Marketed	6-[O-(1,1-dimethylethyl)-D-serine]-1-9-luteinizing hormone-releasing factor (swine) 2-(aminocarbonyl)hydrazide	gonadorelin agonist	cancer; endometriosis; infertility
leuprorelin; leuprorelin acetate; leuprolide; TAP 144; TAP 144SR; ABBOTT 43818; LUPRON; CARCIN; LEUPLIN; LUPRON DEPOT; PROSTAP ST; PROSTAP SR; ENANTONE	Marketed	6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide luteinizing hormone-releasing factor (swine)	gonadorelin agonist	cancer; endometriosis
nafarelin; nafarelin acetate; D-Nal(2)6 LHRH; RS 94991; RS 94991 298; SAMYNAREL; SYNAREL; NASANYL	Marketed	6-[3-(2-naphthalenyl)-D-alanine]-luteinizing hormone-releasing factor (swine)	gonadorelin agonist	cancer; endometriosis; infertility
RL 0903	Phase II		gonadorelin agonist	cancer
triptorelin; BN 52014; BIM 21003; AY 25650; CL 118532; WY 42462; ARVECAP; DECAPEPTYL	Marketed	6-D-tryptophan-luteinizing hormone-releasing factor (swine)	gonadorelin agonist	cancer; precocious puberty; endometriosis

leuprolide + estrogen + progesterone	Phase I			gonadorelin agonist; estrogen; progestogen	contraception; cancer
gonadotropin releasing hormone analogue, conjugated; GnRH analogue copolymer conjugate	Preclinical			gonadorelin agonist; gonadorelin antagonist	cancer
avorelin	Phase II	5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-2-methyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide		gonadorelin agonist; peptide	cancer; precocious puberty; endometriosis
drug delivery system, histrelin hydrogel implant; histrelin hydrogel implant	Phase I			gonadorelin agonist; peptide	precocious puberty; cancer
A 84861	Phase I			gonadorelin antagonist	cancer
abarelix; PPI 149; R 3827	Phase III	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparagyl-L-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide		gonadorelin antagonist	cancer; benign prostate hypertrophy; endometriosis

cetrorelix; SB 75; SB 075; CETROTIDE	Registered	N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N5-(aminocarbonyl)-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide	gonadorelin antagonist	infertility; cancer; endometriosis; benign prostate hypertrophy; contraception
D 20453	Discontinued		gonadorelin antagonist	cancer
D 21775; T 148	Discontinued	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[N-acetyl-3-(acetylamino)-L-alanyl]-D-lysyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide	gonadorelin antagonist	cancer
D 23487	Discontinued	Unspecified	gonadorelin antagonist	cancer
D 26344	Preclinical		gonadorelin antagonist	cancer; infertility

detirelix; RS 68439	Discontinued	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-D-tryptophyl-L-seryl-L-tyrosyl-N6-[bis(ethylamino)methylene]-D-lysyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide	gonadorelin antagonist	contraception; cancer
drug delivery system, ATRIGEL sustained release ganirelix; ganirelix ATRIGEL	Discontinued		gonadorelin antagonist	cancer; endometriosis
drug delivery system, ATRIGEL sustained release GnRH antagonists	Discontinued		gonadorelin antagonist	endometriosis; cancer
drug delivery system, microcapsule SB 75; SB 75 microcapsule	Preclinical		gonadorelin antagonist	cancer; contraception
gonadotropin releasing hormone antagonists, Alanex	Preclinical		gonadorelin antagonist	contraception; cancer
gonadotropin-releasing hormone antagonist, Agouron; GnRH antagonist, Agouron	Preclinical		gonadorelin antagonist	cancer
HOE 2013	Suspended		gonadorelin antagonist	cancer; endometriosis

ramorelix; HOE 013	Phase II	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-D-typtophyl-L-seryl-L-tyrosyl-O-(6-deoxy-alpha-L-mannopyranosyl)-D-seryl-L-leucyl-L-arginyl-L-proline, 2-(aminocarbonyl)hydrazide	gonadorelin antagonist cancer	
A 76154	Preclinical	N-[3-(4-fluorophenyl)-1-oxopropyl]-3-(1-naphthalenyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-N6-(3-pyridinylcarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide	gonadorelin antagonist; peptide	cancer; endometriosis; precocious puberty

teverelix; ANTARELIX	Phase I	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-L-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(aminocarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide	gonadorelin antagonist; peptide	cancer; endometriosis; infertility
deslorelin; BACHEM 9022; SOMAGARD	Marketed	5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide	gonadorelin superagonist	cancer; precocious puberty
drug delivery system, deslorelin implant; deslorelin implant	Preclinical		gonadorelin superagonist	cancer; gynecological; infertility
hematology cytokines, AMRAD; hematology cytokines, Chugai	Discontinued		growth factor	cancer
hematopoietic growth factor mimetics, Ligand	Preclinical		growth factor	cancer; bacterial infection; anemia
GM 1306	Preclinical		growth factor modulator	diabetes; retinopathy; cancer
GM 1474	Preclinical	Unspecified	growth factor modulator	cancer
keratinocyte growth factor antagonist	Preclinical		growth factor modulator; peptide	cancer

hepatocyte growth factor related proteins; HGF-related proteins	Preclinical		growth factor; biotechnology; chemoprotectant; cytoprotectant	cancer
CMI SAF9	Preclinical		growth factor; hematopoietic factor	cancer
thrombopoietin; TPO	Phase II		growth factor; hematopoietic factor; biotechnology	cancer; thrombocytopenia
Tie-2 ligands, Regeneron; angiogenesis ligands, Regeneron	Preclinical		growth factor; hematopoietic factor; cicatrizant; angiogenesis inhibitor; angiogenesis inducer	cancer; restenosis; retinopathy; skin ulcer; atherosclerosis; peripheral vascular disease
SB 251353	Preclinical		growth factor; hematopoietic factor; immunostimulant	cancer
goralptide; seraspemide; BN 52040; BIM 32001	Phase II	1-[N2-[N-(N-acetyl-L-seryl)-L-alpha-aspartyl]-L-lysyl]-L-proline	hematoprotectant; chemoprotectant; peptide	cancer
pentosan polysulfate sodium; SP 54; PZ 68; CARTROPHEN; LASONIL; ELMIRON; LELONG MOUSSE	Marketed	(1-4)-beta-D-xylan 2,3-bis(hydrogen sulfate), sodium salt	heparinoid; vasodilator; NSAID	arthritis; angina; hyperlipidemia; rheumatoid arthritis; cancer; cystitis
MAXAMINE	Phase III		histamine agonist; histamine H2 agonist	cancer; viral infection; hepatitis

MAP 30	Preclinical	N2-[N-[N-[N2-(N-L-threonyl)-L-isoleucyl]-L-lysyl]-L-threonyl]-L-threonyl]-L-lysine	HIV integrase inhibitor	HIV infection; cancer
lovastatin; mevinolin; monakolin K; MK 803; MSD 803; MB 530B; L 154803; MEVACOR; MEVLOR; LOVACOL; HIPOVASTIN; DISLIPIN; LOVASTEROL; LINCIL	Marketed	(S)-2-methylbutyric acid, 8-ester with (4R,6R)-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia; cancer
cancer therapy, Oxis	Preclinical		hormone	cancer
drug delivery system, PEPTITROL	Preclinical		hormone	osteoporosis; Paget disease; cancer
calcitonin; calcitonin PEPTITROL				
drug delivery system, subcutaneous gonadotropin releasing hormone; gonadotropin releasing hormone subcutaneous implant; GnRH subcutaneous implant	Preclinical		hormone	precocious puberty; endometriosis; cancer; contraception
glycoprotein hormone superagonists, NIH	Preclinical		hormone	infertility; cancer

SD-144110.1

human chorionic gonadotropin beta; beta hCG	Preclinical			hormone	cancer
NV 06	Preclinical			hormone; apoptosis inhibitor; antiproliferative agent; differentiation inducer	cancer
gallium nitrate; NSC 15200; CALSTAT; GANITE	Marketed		gallium nitrate nonahydrate	hypocalcemic; nitric oxide synthase inhibitor	hypercalcemia; cancer
AS 101; IVXQ 101; OSSIRENE	Phase II		(SP-5-22)-ammonium trichloro(1,2-ethanedioato(2-)-0,0')-tellurate	immunostimulant	HIV infection; cancer
BCH 1393	Suspended		N2-[[[5-[6-(dimethylamino)-9H-purin-9-yl]pentyl]oxy]carbon yl]-D-arginine	immunostimulant	cancer
beta-alethine; BETATHINE	Phase II		3-amino-N-(2-mercaptoethyl)-propanamide	immunostimulant	cancer
broprimine; ABPP; U 54461; U 54461S; NSC 149027; REMISAR	Pre-registration		2-amino-5-bromo-6-phenyl-4(1H)-pyrimidinone	immunostimulant	cancer; viral infection
CL 246738	Phase II		3,6-bis(2-piperidinoethoxy)acridine trihydrochloride	immunostimulant	viral infection; HIV infection; cancer
CL 870420	Discontinued			immunostimulant	cancer
conagenin	Preclinical		N-(3,5-dideoxy-3-methyl-D-xylonoyl)-2-methyl-L-serine	immunostimulant	cancer

DNA repair enhancers, OXiGENE	Preclinical			immunostimulant	cancer
drug delivery system, liposome muramyl tripeptide-phosphatidylethanolamine; drug delivery system, liposome MTP-PE; MTP-PE liposome	Phase III			immunostimulant	cancer
FCE 24578	Discontinued	alpha-cyano-1,4-dihydro-beta-oxo-N,1-diphenyl[1]benzothio pyrano[4,3-c]pyrazole-3-propanamide		immunostimulant	cancer; bacterial infection
FCE 25276	Suspended			immunostimulant	cancer; bacterial infection
FCE 25648	Suspended			immunostimulant	cancer; bacterial infection
FCE 25651	Suspended			immunostimulant	cancer; bacterial infection
FR 901235	Discontinued	(-)-2,4,9-trihydroxy-6-methoxy-7-methyl-2-(2-oxopropyl)-1H-phenalene-1,3(2H)-dione		immunostimulant	cancer
HAB 439	Discontinued	(4,5-dihydro-3-phenyl-5-isoxazolyl)phosphonic acid		immunostimulant	cancer; bacterial infection

icadamines, Cornell Research Foundation	Preclinical			immunostimulant	viral infection; cancer
idramantone; kemantane	Phase I	5-hydroxytricyclo[3.3.1.1(3,7)]decanone		immunostimulant	cancer
imiquimod; R 837; S 26308; DZ 2636; ALDARA; ZARTRA	Marketed	1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine		immunostimulant	viral infection; cancer
immunostimulant, Repligen; immunostimulant, Pfizer	Preclinical			immunostimulant	cancer; infectious disease
immunostimulants, Massachusetts General Hospital	Preclinical			immunostimulant	cancer; autoimmune disease
IT 3002; CGP 40774	Preclinical			immunostimulant	cancer
KRN 7000	Phase I	[1S-(1R*,2R*,3S*)]-N-[1-[(alpha-D-galactopyranosyloxy)methyl]-2,3-dihydroxyheptadecyl]hexacosanamide		immunostimulant	cancer
large multivalent immunogen; LMI	Preclinical			immunostimulant	cancer
LC 9018; YIT 9018; DP 2202; PS PG; LIMONAL; LEMONAL	Pre-registration			immunostimulant	cancer; HIV infection
lentinan sulfate; lentinan; LENTINAN	Marketed			immunostimulant	HIV infection; cancer
LK 409	Preclinical	N-(1,7-dioxooctyl)-L-alanyl-D-alpha-glutamine		immunostimulant	cancer

loxoribine; RWJ 21757	Discontinued	7-allyl-8-oxoguanosine	immunostimulant	cancer
mirimostim; human urine derived stimulating factor 1 inducer; CSF-HU; P 100; LEUKOPROL; COSTILATE	Marketed	1-214-colony-stimulating factor 1 (human clone p3ACSF-69 protein moiety reduced)	immunostimulant	cancer
MMS 2	Preclinical		immunostimulant	cancer
Nocardia-CWS; N-CWS; rubratine; RUBRATIN	Discontinued		immunostimulant	cancer
OM 163	Preclinical	Unspecified	immunostimulant	cancer
OM 174	Phase I		immunostimulant	cancer
RG 003; RG 136	Discontinued		immunostimulant	HIV infection; cancer
RM 06	Discontinued	N-[N-[[[5-(1,6-dihydro-6-oxo-9H-purin-9-yl)pentyl]oxy]carbon yl]-L-leucyl]-L-methionine	immunostimulant	cancer; transplant rejection
romurtide; MDP-muroctasin; MDP-Lys (L18); MDP-Lys; DJ 7041; NOPIA	Marketed	2-acetamido-3-O-[(R)-1-[[[(S)-1-[(R)-1-carbamoyl-3-[(S)-1-carboxy-5-stearamidopentyl]carbamoyl]propyl]carbamoyl]ethyl]-2-deoxy-D-glucopyranose	immunostimulant	cancer; bacterial infection

RS 0481; S 0481	Discontinued	[R-(R*,R*)]-3-benzoyl-N-(1-phenylethyl)-4-thiazolidinecarboxamide	immunostimulant	cancer
S 27609	Discontinued	4-amino- α , α ,2-trimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol	immunostimulant	cancer
SRL 172	Phase III		immunostimulant	tuberculosis; cancer; asthma; bacterial infection; leprosy; rhinitis
ST 789; PCF 39	Phase I	N-[5-(hypoxanthin-9-yl)pentoxycarbonyl]-L-arginine	immunostimulant	cancer; bacterial infection
thymotrinan; thymopoietin 32-34; RGH 0205; TP3	Suspended	N-(N2-L-arginyl-L-lysyl)-L-aspartic acid	immunostimulant	cancer
vaccine, malignant melanoma; LP 2307	Phase II		immunostimulant	cancer
vaccine, Maruyama; Maruyama vaccine; SSM	Pre-registration		immunostimulant	cancer
vaccine, melanoma, University of Pittsburgh; melanoma vaccine	Phase I		immunostimulant	cancer
tiprotimod; HBW 538	Discontinued	2-[(3-carboxypropyl)thio]-4-methyl-5-thiazoleacetic acid	immunostimulant; antifungal	mycosis; cancer

MGN 3	Phase I	Unspecified	immunostimulant; biological response modifier	cancer
NSC 631570; E 09/029; NSC B238865; UKSR 222; W 122; UKRAIN	Pre- registration	5,5',5"- [phosphinothioylidyn etris(imino-2,1- ethanediyl)tris[5- methylchelidoninium]] trihydroxide	immunostimulant; biological response modifier	cancer
CD40 ligand, Immunex; CD40LT	Phase I		immunostimulant; biotechnology	cancer
prolactin	Preclinical		immunostimulant; biotechnology; hormone; vaccine adjuvant	cancer; infectious disease
pentoxifylline : ciprofloxacin; ciprofloxacin : pentoxifylline; CT 1500	Discontinued		immunostimulant; chemoprotectant; cytoprotectant	cancer
acemannan; CARN 1000; CARN 750; CARRASYN; ALIMINASE; VORALEX; CARRAVEX	Marketed	(1->4),(1->6)-alpha- D-galacto-beta-D- mannan acetate	immunostimulant; cicatrizant	inflammatory bowel disease; skin ulcer; inflammation; cancer
tetrachlorodecaoxide; TCDO; WF 10; OXOFERIN	Marketed		immunostimulant; cicatrizant	skin ulcer; HIV infection; cancer

granulocyte colony stimulating factor mimetic, Ligand/SmithKline Beecham; G-CSF mimetic, Ligand/SmithKline Beecham	Preclinical			immunostimulant; cytokine agonist	cancer; viral infection; bacterial infection
thiathazole	Preclinical	2-[1-(1,1-dioxothiethanyl-3)benzimidazolyl-2-thio] acetic acid		immunostimulant; immunosuppressant; antioxidant	cancer; rheumatoid arthritis; infectious disease; transplant rejection
tabilautide; RP 56142	Discontinued	threo-6-carbamoyl-N2-[N-(N-lauroyl-L-alanyl)-D-gamma-glutamyl]-L-lysine		immunostimulant; lipopeptide	bacterial infection; cancer
hemoregulatory peptide, Nycomed	Preclinical			immunostimulant; peptide	bacterial infection; cancer
immunostimulant peptides, BioChem Pharma	Discontinued			immunostimulant; peptide	cancer; viral infection
interleukin-2 receptor agonist; IL-2R agonist	Preclinical			immunostimulant; peptide	cancer; HIV infection
SUIS-gonadorelin; SUIS-LHRH	Phase I			immunostimulant; peptide	cancer
thymopoietin receptor agonist	Preclinical			immunostimulant; peptide	cancer; HIV infection
ubenimex; bestatin; NK 421; BESTATIN	Marketed	(-)-N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl])-L-leucine		immunostimulant; peptide	cancer

ETHERAMIDE	Suspended			immunostimulant; peptide; oligosaccharide	cancer; infectious disease
monophosphoryl lipid A + myobacterium cell wall sk; myobacterium cell wall skeleton + monophosphoryl I; MPL + CWS; DETOX	Phase III			immunostimulant; vaccine adjuvant	cancer
D5; PM 92114	Discontinued			immunosuppressant	cancer
dehydrodidemnin B; DDB	Preclinical	N-[1-(1,2-dioxopropyl)-L-prolyl]didemnin A		immunosuppressant	viral infection; cancer
dinaline; GOE 1734; NSC 328786; AAPBA	Discontinued	4-amino-N-(2-aminophenyl)benzamide		immunosuppressant	cancer
fluasterone	Phase I			immunosuppressant	cancer; diabetes; systemic lupus erythematosus
gusperimus; gusperimus hydrochloride; deoxyspergualin, 15-; desoxyspergualin; DSG; NKT 01; NSC 356894; BMS 181173; BMY 42215- 1; SPANIDIN; SUPANIDIN	Marketed	(+,-)-7- [(aminoiminomethyl) amino]-N-[2-[[4-[(3- aminopropyl)amino]b uty]amino]-1- hydroxy-2- oxoethyl]heptanamide		immunosuppressant	transplant rejection; multiple sclerosis; cancer
promedulan; TERICIMUS	Discontinued			immunosuppressant	cancer

XENOJECT	Preclinical		immunosuppressant	cancer; autoimmune disease
protein A-based immune modulator	Preclinical		immunosuppressant; immunostimulant	autoimmune disease; cancer
signal transduction modulators, National Jewish Center for Immunology and Respiratory Medicine	Preclinical		immunosuppressant; immunostimulant; NSAID	autoimmune disease; cancer; inflammation
CI 972	Discontinued	2,6-diamino-1,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one monohydrochloride	immunosuppressant; NSAID	rheumatoid arthritis; cancer; psoriasis
cladribine; 2-CdA; NSC 105014F; RWJ 26251; LEUSTATIN; LEUSTAT; MYLINAX	Marketed	2-chloro-2'-deoxyadenosine	immunosuppressant; nucleoside analogue; NSAID	cancer; multiple sclerosis; rheumatoid arthritis
T cell peptide, University of Illinois	Preclinical		immunosuppressant; peptide	autoimmune disease; cancer; bacterial infection
MAb, BR96 sFv-PE40; SGN 10; BMS 191352	Phase I		immunotoxin; biotechnology	cancer
MAb, TES-23-neocarzinostatin; TES-23-NCS	Discontinued		immunotoxin; biotechnology	cancer

MAb, TP3-pokeweed viral protein conjugate; immunotoxin, TP3- pokeweed viral protein conjugate; TP3-PAP	Preclinical		immunotoxin; biotechnology; monoclonal antibody	cancer
MAb, doxorubicin- CEA; DOX-CEA	Preclinical		immunotoxin; biotechnology; monoclonal antibody; anthracycline; antibiotic; DNA intercalator	cancer
drug delivery system, ANCHOR angiostatic agent	Preclinical		integrin antagonist; angiogenesis inhibitor; cell adhesion inhibitor	cancer
S 836	Discontinued		integrin antagonist; angiogenesis inhibitor; cell adhesion inhibitor; alpha5 beta3 integrin antagonist	cancer
CDP 850	Preclinical		integrin antagonist; biotechnology; cell adhesion inhibitor; immunosuppressant; monoclonal antibody; E selectin antagonist	cancer

cytostatin; MJ 654NF4	Preclinical	5,6-dihydro-6-[6-hydroxy-1,5-dimethyl-4-(phosphonoxy)-7,9,11-tridecatrienyl]-5-methyl-2H-pyran-2-one	integrin antagonist; cell adhesion inhibitor	cancer
SB 223245	Preclinical	(S)-7-[[[(1H-benzimidazol-2-ylmethyl)methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid	integrin antagonist; cell adhesion inhibitor	osteoporosis; restenosis; cancer
vitronectin receptor antagonists, DuPont	Preclinical		integrin antagonist; cell adhesion inhibitor; alpha5 beta3 integrin antagonist	osteoporosis; cancer; restenosis

IC 101		Preclinical	(alphaS,2R,5S,6R)-6-ethyltetrahydro-alpha-2-dihydroxy-alpha-methyl-1,5-(3-methylbutyl)-2H-pyran-2-acetyl-(3S)-3-hydroxy-L-leucyl-hexahydro-3-pyridazinecarbonyl-N-hydroxy-L-alanyl-glycyl-(3S)-hexahydro-3-pyridazinecarbonyl-N-hydroxy-D-Alanine (7->2)-lactone	integrin antagonist; cell adhesion inhibitor; immunostimulant; peptide; antibiotic	cancer; bacterial infection
	anti-inflammatory agents, Chiroscience/Trega	Preclinical		integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; cancer
	cell adhesion inhibitor, GlycoTech/Novartis	Preclinical		integrin antagonist; cell adhesion inhibitor; NSAID	cancer; inflammation
	drug delivery system, STEALTH cell adhesion inhibitors	Preclinical		integrin antagonist; cell adhesion inhibitor; NSAID	cancer; inflammation
	GM 7050	Discontinued		integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; cancer
	RGD-based angiogenesis antagonists	Preclinical		integrin antagonist; NSAID; cell adhesion inhibitor	cancer; rheumatoid arthritis; eye disease

drug delivery system, interferon alfa; interferon alfa depot delivery; MPI 7057	Discontinued		interferon	cancer
drug delivery system, transdermal BIPHASIX interferon alfa; interferon alfa transdermal	Preclinical		interferon	cancer; viral infection
interferon alfa; BALL-1; MR 22; BALL 1; OIF; IFN ALPHA MOCHIDA	Marketed		interferon	cancer; viral infection; mucositis; musculoskeletal disorder
interferon alfa; Interferon Alfaflavine	Marketed		interferon	cancer; viral infection
interferon alfa-n3; KEMRON; ALFERON; ALFERON N; ALFERON LDO; ALTEMOL; REFERON	Marketed		interferon	viral infection; cancer
interferon beta; FRONE	Marketed		interferon	multiple sclerosis; cancer; eye disease
interferon gamma, natural; IFN gamma, natural; OH 6000; OGAMMA 100	Marketed		interferon	cancer
interferon-alpha; IFN-alpha	Preclinical		interferon; biotechnology	cancer; viral infection
interferon, modified, Tanox	Preclinical		interferon; biotechnology; immunosuppressant	cancer

leukocyte alpha interferon; ALFAFERONE; CILIFERON	Marketed		interferon; immunostimulant	viral infection; cancer
doretinel; BASF 47011; RWJ 20257; ORF 20257	Discontinued	(E)-1,2,3,4- tetrahydro-7-[2-[4- (hydroxymethyl)phen yl]-1-methylethenyl]- 1,1,4,4- tetramethylnaphthalen ol	keratolytic	cancer
U 74389	Preclinical	Unspecified	lazaroid	cancer
U 74500A	Preclinical	21-[4-[3,6- bis(diethylamino)-2- pyridinyl]-1- piperazinyl]-16- methylpregna- 1,4,9(11)-triene-3,20- dione hydrochloride	lazaroid	cerebrovascular disease; cancer
lysofylline; lisofylline; CT 1501R; ProTec	Phase III	(R)-1-(5- hydroxyhexyl)-3,7- dimethylxanthine	lysophosphatidate acyltransferase inhibitor; xanthine	cancer; cardiovascular disease; respiratory disease; mucositis
breflate; NSC 656202; NAS 656202	Preclinical	N,N-dimethyl- glycine, [1R- (1R*,2E,6S*,10E,11a S*,13S*,14aR*)]- 1,6,7,8,11a,12,13,14,1 4a-decahydro-1- hydroxy-6-methyl-4- oxo-4H- cyclopent[floxacyclot ridecin-13-yl ester	macrolide; antibiotic	cancer

duocarmycin SA; DC 113	Discontinued	(7bR)-1,2,4,5,8,8a-hexahydro-4-oxo-2-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl]cyclopropa[c]pyrrolo[3,2-e]indole-6-carboxylic acid methyl ester	macrolide; antibiotic	bacterial infection; cancer
rhizoxin; lizoxine	Phase II		macrolide; antibiotic	cancer
drug delivery system, liposome CGP 31362; CGP 31362 liposome; MLV-CGP 31362	Discontinued		macrophage stimulator; immunostimulant	cancer
GPX 325	Preclinical		MAO inhibitor; chemoprotectant; cytoprotectant; radioprotectant	cancer
matrilysin inhibitors, Affymax	Preclinical		matrilysin inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
matrix metalloproteinase inhibitors, OsteoArthritis; cartilage degrading enzyme inhibitors, OsteoArthritis; CHONDROPROTECTOR	Discontinued		matrix metalloproteinase inhibitor; cicatrizant; proteinase inhibitor; NSAID	arthritis; periodontal disease; skin ulcer; cancer

anticancer matrix metalloproteinase inhibitors	Preclinical		matrix metalloproteinase inhibitor	cancer
CMT 3; COL 3; NSC 683551; METASTAT	Phase I	(4aS,5aR,12aS)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-1-carboxamide	matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
ID 1927	Preclinical		matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
ID 2163	Phase I		matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
ilomastat; GM 6001; CS 610; GALARDIN; GALARDIN MPI	Phase III	N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methoxymethyl)-2-(methoxymethyl)-2-(2-methylpropyl)-butanediyl]butanediylamide	matrix metalloproteinase inhibitor; proteinase inhibitor	retinopathy; diabetes; cancer

marimastat; BB 2516; Phase III TA 2516		(2S,3R)-N4-[(1R)-2,2-dimethyl-1-[(methylamino)carbonyl]propyl]-N1,,2-dihydroxy-3-(2-methylpropyl)butanamide	matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
matrix metalloproteinase inhibitors, Agouron	Preclinical		matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
S 3304	Phase I		matrix metalloproteinase inhibitor; proteinase inhibitor	cancer; inflammation
prinomastat; AG 3340	Phase III	Unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; angiogenesis inhibitor	cancer; retinopathy
CH 104	Discontinued		matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; inflammation
CH 715	Discontinued		matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; inflammation
matrix metalloproteinase inhibitor, State University of New York	Preclinical		matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	periodontal disease; kidney disease; cancer; arthritis; osteoporosis

matrix metalloproteinase inhibitors, ProScript	Preclinical		matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; arthritis
PI 88	Phase I		matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	inflammation; cancer
solimastat; BB 3644	Phase I	(2S,3R)-3-[(1S)-2,2-dimethyl-1-(2-pyridylcarbamoyl)propyl]carbamoyl]-2-methoxy-5-methylhexanoic acid	matrix metalloproteinase inhibitor; TNF inhibitor; proteinase inhibitor	multiple sclerosis; rheumatoid arthritis; inflammatory bowel disease; cancer
BIBW 22; BIBW 22BS	Discontinued		MDR inhibitor	cancer
biricodar dicitrate; VX 710; INCEL	Phase II	(S)-1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-2-piperidinecarboxylic acid 4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester	MDR inhibitor	cancer
buthionine sulfoximine; BSO; NSC 326231	Phase I	(2S)-2-amino-4-(S-butylsulfonimidoyl)butanoic acid	MDR inhibitor	cancer

dexniguldipine; (+)-niguldipine; (R)-niguldipine; niguldipine, (R)-; B 8509035; B Y 935	Discontinued	(R)-1,4-dihydro-2,6-dimethyl-4-(3-mitrophenyl)-3,5-pyridinecarboxylic acid 3-(4,4-diphenyl-1-piperidiny)propyl methyl ester	MDR inhibitor	cancer
drug delivery system, liposome ciclosporin; ciclosporin liposome; CYCLOXOME	Discontinued		MDR inhibitor	cancer
flezolastine; D 18024	Preclinical	4-((4-fluorophenyl)methyl)-2-(hexahydro-1-(phenylethyl)-1H-azepin-4-yl)-1(2H)-phthalazinone monohydrochloride	MDR inhibitor	cancer
H 85	Preclinical	N-[2-[[3-(4-chlorophenyl)-2-propenyl]formylaminomethyl]-5-isoquinolinesulfonylamide	MDR inhibitor	cancer
LU 49667	Discontinued		MDR inhibitor	cancer
LU 51903	Discontinued		MDR inhibitor	cancer
MDR inhibitor, BioNumerik	Preclinical		MDR inhibitor	cancer
MDR inhibitor, Xenova	Preclinical		MDR inhibitor	cancer
MDR inhibitors, Fox Chase Cancer Center	Preclinical		MDR inhibitor	cancer

MS 209	Phase II	4-(diphenylacetyl)- alpha-[(5- quinolinyl)oxy)methyl]-1-piperazineethanol, (E)-2-butenedioate (2:3)	MDR inhibitor	cancer
NA 382	Preclinical	N-(ethoxycarbonyl)- 7-oxostaurosporine	MDR inhibitor	cancer
PAK 104P	Preclinical	trans-5-(4,6-dimethyl- 2-oxido-1,3,2- dioxaphosphorinan-2- yl)-2,6-dimethyl-4-(3- nitrophenyl)-3- pyridinecarboxylic acid 2-[4- (diphenylmethyl)-1- piperazinyl]ethyl ester trihydrochloride	MDR inhibitor	cancer
propyl bis-acridone	Preclinical	1,3-bis(9-oxoacridin- 10-yl)propane	MDR inhibitor	cancer
R 101933	Phase I		MDR inhibitor	cancer
Ro 112933	Discontinued	N-[2-(3,4- dimethoxyphenyl)eth yl]-N-methyl-2-(2- naphthalenyl)-1,3- dithiane-2- propanamine hydrochloride	MDR inhibitor	cancer

S 16209	Preclinical	(+)-4-(2,3-dichlorophenyl)-1,4-dihydro-2-methyl-6-[[2-[2-[(4-nitrophenyl)methyl]amino]ethoxy]ethoxy]methyl]-3,5-pyridinedicarboxylic acid 5-ethyl 3-methyl ester	MDR inhibitor	cancer
S 16317	Preclinical	(+)-4-(2,3-dichlorophenyl)-1,4-dihydro-2-methyl-6-[[2-[2-[(4-pyridinyl)methyl]amino]ethoxy]ethoxy]methyl]-3,5-pyridinedicarboxylic acid 5-ethyl 3-methyl ester	MDR inhibitor	cancer
S 16324	Preclinical	(+)-4-(2,3-dichlorophenyl)-1,4-dihydro-2-methyl-6-[[2-[2-[(3-thienyl)methyl]amino]ethoxy]ethoxy]methyl]-3,5-pyridinedicarboxylic acid 5-ethyl 3-methyl ester	MDR inhibitor	cancer

S 9788	Discontinued	6-[4-[[2,2-bis(4-fluorophenyl)ethyl]amino]-1-piperidinyl]-N,N'-di-2-propenyl-1,3,5-triazine-2,4-diamine	MDR inhibitor	cancer
SB RA 31012	Preclinical		MDR inhibitor	cancer
SDZ 214103	Discontinued	2-(3-methyl-D-2-hydroxybutanoic acid)-4-L-leucine-7-L-threonine-10-L-leucine cyclosporin A	MDR inhibitor	cancer
XR 1500	Suspended		MDR inhibitor	cancer
CRL 1336	Discontinued		MDR inhibitor; chemosensitizer	cancer
valsopodar; SDZ PSC833; PSC 833; SDZ PSC 833; AMDRAY	Phase III	6-[[R-(E)]-6,7-didehydro-N,4-dimethyl-3-oxo-L-2-aminooctanoic acid]-7-L-valine-cyclosporin A	MDR inhibitor; chemosensitizer; P glycoprotein inhibitor	cancer
elacridar; GF 120918; GG 918	Suspended	N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]p-phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide	MDR inhibitor; P glycoprotein inhibitor	cancer

timcodar dimesylate; VX 853	Phase II	(alphaS)-4-chloro- alpha- [methyl[oxo(3,4,5- trimethoxyphenyl)ace- tyl lamino]-N- (phenylmethyl)-N-[3- (4-pyridinyl)-1-[2-(4- pyridinyl)eth- yl]propyl]benzenepro- panamide	MDR inhibitor; P glycoprotein inhibitor	cancer; neuropathy
XR 9051	Suspended	(Z,Z)-N-[4-[2-(3,4- dihydro-6,7- dimethoxy-2(1H)- isoquinolinyl)ethyl]p- henyl]-4-[[4-methyl- 3,6-dioxo-5- (phenylmethylene)pip- erazinylidene]methyl] benzamide	MDR inhibitor; P glycoprotein inhibitor	cancer
SDZ 280446	Discontinued	cyclo[N-methyl-L- alpha-Asp-N-methyl- L-Ile-N-methyl-L-Ile- Gly-N-methyl-L-Val- O-methyl-L-Tyr-(2S)- 2-hydroxypropanoyl- (2S)-2- piperidinecarbonyl-N- methyl-L-Val-L-Val], 1,1-dimethylethyl ester	MDR inhibitor; peptide	cancer

melanostatin; BMY 28566; BU 3619E	Discontinued	(S)-3-[[1-carboxy-2-(1H-imidazol-4-yl)ethyl]amino]-N-(N-methyl-L-phenylalanyl)-L-alanine	melanin synthesis inhibitor	cancer
lithium gamma-linolenate; EF 13; GLAMOLEC	Discontinued		metalloproteinase inhibitor; proteinase inhibitor	cancer; HIV infection
PGE 2946979	Preclinical	3-[[[(hydroxyamino)carbonyl]-4-[(4-methoxyphenyl)sulfonyl]-1-piperazinecarboxylic acid phenylmethyl ester	metalloproteinase inhibitor; proteinase inhibitor	inflammation; cancer
metalloproteinase inhibitors, Syntem	Preclinical		metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; arthritis
BW 1069C85	Suspended		microtubule assembly inhibitor	cancer
cryptophycin 52; LY 355703	Phase I	(2S)-3-chloro-N-[(2E,5S,6S)-5-hydroxy-1-oxo-6-[(2R,3R)-3-phenyloxiranyl]-2-heptenyl]-O-methyl-tyrosyl-2,2-dimethyl-beta-alanyl-2-hydroxy-4-methyl-pentanoic acid (3fvdarw1)-lactone	microtubule assembly inhibitor	cancer

cryptophycin 8	Preclinical	(2S)-3-chloro-N- [(2E,5S,6R,7R,8S)-8- chloro-5,7-dihydroxy- 6-methyl-1-oxo-8- phenyl-2-octenyl]-O- methyl-D-tyrosyl- (2R)-2-methyl-beta- alanyl-2-hydroxy-4- methylpentanoic acid (3->15)-lactone	microtubule assembly inhibitor	cancer
cryptophycin A derivatives, Wayne State University ID 24851	Preclinical		microtubule assembly inhibitor	cancer
	Preclinical	1-[(4- chlorophenyl)methyl]- -alpha-oxo-N-4- pyridinyl-1H-indole- 3-acetamide	microtubule assembly inhibitor	cancer
epothilone	Preclinical		microtubule assembly inhibitor	cancer

maitansine; maytansine; NSC 153858	Preclinical	N-acetyl-L-N-methyl-L- alanine [1S- (1R*,2S*,3R*,5R*,6R*,16E,18E,20S*,21R*)]-11-chloro-21- hydroxy-12,20- dimethoxy-2,5,9,16- tetramethyl-8,23- dioxo-4,24-dioxo- 9,22- diazatetracyclo[19.3.1 .110.14.03.5]hexacos a-10,12,14(26),16,18- pentaen-6-yl ester	microtubule assembly inhibitor	cancer
T 138067	Phase I	2-fluoro-1-methyl-4- pentafluorophenylsulfonamide	microtubule assembly inhibitor	cancer
T 900607	Preclinical	onamidobenzene	microtubule assembly inhibitor	cancer
AC 7700	Preclinical		microtubule assembly inhibitor; angiogenesis inhibitor	cancer
epothilones, Society for Biotechnology Research	Preclinical		microtubule assembly inhibitor; antibiotic	cancer
cemadotin; LU 103793	Phase II	N,N-dimethyl-L- valyl-L-valyl-N- methyl-L-valyl-L- prolyl-N- (phenylmethyl)-L- prolinamide	microtubule assembly inhibitor; peptide	cancer

LU 223651	Preclinical	N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-prolin-Tert-butylamide	microtubule assembly inhibitor; peptide	cancer
epothilones	Preclinical	[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione (B is [1S-, 16-methyl])	microtubule assembly promoter	cancer
antimitotics, Nanodesign TZT 1027	Preclinical		mitosis inhibitor	cancer
	Phase I	[2S-N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]propyl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-L-valinamide	mitosis inhibitor	cancer
vinorelbine; CI 980; NSC 613862(-)	Phase II	(S)-(5-amino-1,2-dihydro-2-methyl-3-phenylpyrido(3,4-b)pyrazin-7-yl)carbamate ethyl ester	mitosis inhibitor; tubulin polymerase inhibitor	cancer